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Ab s t r a c t
This study evaluated existing In Vitro educational 
materials in qualitative and quantitative parameters that 
currently exist to educate potential clinicians of 
nationally accredited Nuclear Medicine programs.
A review of over 3 00 articles, texts, and manuals 
pertaining to In Vitro Nuclear Medicine procedures clearly 
demonstrated that no In Vitro laboratory manual for 
undergraduate students presently existed.
Every Nuclear Medicine program director in the United 
States was surveyed. They were asked for their overall 
philosophy in terms of developing an In Vitro manual and 
requested to evaluate the significance of 22 general 
principles/concepts and 34 specific laboratory testing 
procedures.
From the responses to the survey, an In Vitro Nuclear 
Medicine manual was created and appended to the study. The 
manual consists of lecture and study material, chapter 
reviews, and laboratory assignments and exercises.
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Chapter 1
THE PROBLEM
Introduction to the Problem
Health care, with all its interrelated manifestations, 
is America's second largest industry, and it promises to 
soon become number one. Many diverse allied health 
professionals, including those trained in Nuclear Medicine 
technology, are needed to meet the every-changing needs of 
this complex and rapidly developing segment of our economy.
To demonstrate this transition, the evolvement of all 
allied health professions in this century has been nothing 
short of phenomenal. Around 1900, one of every three people 
engaged in health care was a physician. By 1967 the ratio 
was reported to have changed to approximately one physician 
to ten allied health personnel. The ratio now is closer to 
one in twenty (Kirby, p. 88). The education of health 
professionals has become a major concern to physicians, 
administrators, and to the general public.
Historically, the education of nuclear medicine 
education professionals took place in a hospital or in the 
office of a doctor and was devoted primarily to the 
practical aspects of patient care; theoretical or background 
subjects were taught only as they were directly pertinent to 
practice. Under this arrangement, the cost was borne by
2hospitals or physicians. In some cases, students received 
pay or stipends (Master Plan for Radiologic Technology 
Programs).
As complexity of health care increased and as nuclear 
medicine technologists became responsible for more 
sophisticated duties, hospitals and physicians recognized 
that colleges and universities were the appropriate sites to 
provide the background in science, mathematics, and 
communications needed for new responsibilities, frequently 
demanding new knowledge, inferential thinking, and decision­
making. Clinical education with its patient-contact 
emphasis continued to be offered in hospitals and 
practitioners' offices. However, it has been found that 
many subjects directly related to professional goals of the 
students could often be more appropriately taught in 
colleges and university classrooms or laboratories as in the 
clinical facilities. Thus the trend in Nuclear Medicine 
education has moved toward universities and community 
colleges from the hospital setting.
Over the past 2 5 years development of new 
radiopharmaceuticals, gamma-ray cameras, advanced laboratory 
techniques and equipment have dramatically changed the field 
of nuclear medicine. Consequently, the educational 
requirements of those students training in the field have 
constantly been revised to keep pace.
3Nuclear medicine technology applies the uses of tracer 
amounts of radioactive materials to visualize and measure 
regional function in living biologic systems. This non- 
invasive procedure has in the last two decades brought about 
significant improvements in basic understanding of disease 
processes as well as in medical diagnoses.
Throughout this tremendous growth in Nuclear Medicine, 
two major areas have developed within the field: In Vitro 
and In Vivo Nuclear Medicine.
In Vitro Nuclear Medicine may be define as that area of 
nuclear medicine in which the results may be expressed in a 
quantitative fashion. These testing procedures are 
performed in test tubes utilizing tracer amounts of 
radioactive material. In vitro laboratory procedures have 
made possible direct assays of many physiologic substances 
present in minuscule concentrations including hormonal, 
blood, and drug levels.
In Vivo Nuclear Medicine has become a more dominant 
component in the educational process of students. This 
aspect involves the use of gamma-ray cameras and scanners to 
make interpretations on a qualitative (subjective) basis.
Though all educational Nuclear Medicine programs 
require both In Vitro and In Vivo studies, most students do 
not acquire adequate training in the In Vitro laboratory 
areas. A recent survey by the Joint Review Committee on 
Accreditation of Nuclear Medicine Programs cites the need
for more emphasis on the in-vitro aspects of Nuclear 
Medicine Technology (Nuclear Medicine Technology Essentials 
Questionnaire).
They are approximately 7 0 accredited Nuclear Medicine 
Technology Programs, either at the Associate of Science, or 
Bachelor of Science level. Many of these programs have had 
problems in their recent accreditation applications due to 
their lack' of In Vitro laboratory education.
Statement of the Problem
Although In Vitro Nuclear Medicine has been an integral 
part of the education of students in the field, there is at 
this time NO educational In Vitro laboratory manual for 
training students. This has been detrimental to the proper 
training and understanding of Nuclear Medicine's graduating 
students in regard to becoming qualified technologists.
There is a need to develop an In Vitro Nuclear Medicine 
laboratory manual for the training of students in these 
programs. The purpose of this research was to identify 
through documentation this need through a nationwide survey 
of Nuclear Medicine program directors and review of the 
literature in the field. The research resulted in the 
development and writing of an In Vitro laboratory manual to 
meet the deficiencies cited.
5Questions
This research resulted in answers to the following 
questions:
1. Was there a need for an In Vitro laboratory 
manual for students in Nuclear Medicine 
Technology?
2. What general principles/concepts of In Vitro 
studies must be included in this student 
manual?
3. What were the types of testing methodologies 
and procedures that must be included in a 
comprehensive student In Vitro manual.
4. What aspects of In Vitro Nuclear Medicine are 
most commonly overlooked that need to be 
taught to graduating Nuclear Medicine 
students?
Significance of Study
Fundamentals of In Vitro Nuclear Medicine. Prior to 
I960, substances present in small amounts in blood and other 
body fluids were exceedingly difficult to measure. Until 
then, chemical and bioassays of these substances, usually 
hormones, were somewhat crude. This led to considerable 
inaccuracy in the measurement of such small amounts, and 
results were difficult to reproduce in other laboratories.
In addition, rather large samples were usually needed for
6the determinations. In 1960, Yalow and Berson reported a 
method for the quantitative measurement of insulin based on 
a new technique of competitive binding assay (Rothfeld,
1985, p. 91). This was the beginning of numerous 
breakthroughs in the use of In Vitro laboratory techniques 
today.
Through the use of In Vitro Nuclear Medicine laboratory 
procedures, biologically active molecules present in the 
blood in concentrations as low as 1 part in 50 million can 
be accurately measured. Until recent years, the problem of 
measuring these proteins and sorting them out as specific 
entities from numerous basically similar molecules seemed 
virtually impossible (Chard, p. 43-45). Now the capability 
for measuring clinically significant substances such as 
hormones, drug levels, and blood components at levels of 
picograms or nanograms per milliliter is available to almost 
any In Vitro laboratory that has the appropriate equipment.
There have been numerous books, journals, and articles 
written describing Nuclear Medicine In Vitro's capability 
for precise and accurate measurement of tracers in clinical 
diagnosis, pharmacology, and biochemistry, and in estimable 
values in hematology and hormonal, metabolic, infectious, 
and inflammatory disorders. The impact of these Nuclear 
Medicine methodologies on progress in medicine should not be 
underestimated. In Vitro laboratory advances have greatly 
enhanced the field of Nuclear Medicine and its ability to
7diagnose minute amount of substances in the human blood 
system.
Even though there is a sufficient quantity of material 
on In Vitro laboratory procedures in the literature, there 
is no definitive laboratory manual, text, or guide written 
to meet the needs of Nuclear Medicine Technology students. 
Many texts discussed in the literature review pertain to 
theoretical constructs, while others devoted to practical 
applications are written at a highly sophisticated level not 
intended for undergraduate students.
On October 19, 1987, letters were written to a number 
of highly regarded professionals in the field, requesting 
their professional assessment of the need for a student In 
Vitro laboratory manual.
One of these professionals, Sheila Rosenfeld (1987), a 
member of the Joint Review Committee on Accreditation of 
Nuclear Medicine Programs and Program Director of Nuclear 
Medicine at St. Louis University, replied to this letter. 
After discussing texts commonly used to teach In Vitro 
studies in Nuclear Medicine programs, Rosenfeld states, "I 
personally feel that there is a definite need for a student 
laboratory manual1" (Ltr. , Nov., 1987).
Wynn Harrison, Director of the Nuclear Medicine Program 
at Weber State University in Utah writes, "I have taught In 
Vitro procedures for the past four years in the Weber State 
College Nuclear Medicine Program, there has been no suitable
8textbook or laboratory material in this area. It would be a 
service to the profession to have such materials" (Ltr.,
Dec., 1987).
Allen West, Director of the Nuclear Medicine Program at 
the University of Alabama Birmingham writes, "It is a shame 
that most programs cannot provide the necessary In Vitro 
laboratory procedure due to the lack of quality text or 
manuals to train students properly" (Ltr., Dec., 1987).
Anthony Snow, Director of a San Francisco Hospital's 
Nuclear Medicine Department writes, "Most students enter the 
work force not sufficiently trained in In Vitro Nuclear 
Medicine procedures, due to the lack of materials written at 
the undergraduate level" (Ltr., Sept., 1988).
Further telephone conversations with Henry Ernstal, 
Director of the Society of Nuclear Medicine,; Virginia 
Pappas, President of Technologist Section of the Society of 
Nuclear Medicine; Craig Harris, Nuclear Medicine Program 
Director at Duke University; and Marsha Boyd, Director of 
Baptist Memorial Hospital and President of the Technologist 
Section of the American Registry of Radiologist 
Technologists; all reiterated the need for a student In 
Vitro Nuclear Medicine laboratory manual.
A recent questionnaire sent to 1,122 registered Nuclear 
Medicine technologists by the Joint Review Committee on 
Nuclear Medicine Technology identified the fact that 
graduating technologists were not receiving the proper
9educational requirements and did not receive sufficient 
experiences in In Vitro laboratory procedures.
Therefore, the purpose of this research was to survey 
all Accredited Nuclear Medicine Program Directors in order 
to gather information pertinent to:
1. Identifying the need for a student Nuclear
Medicine In Vitro laboratory manual,
2. Identifying those aspects or concepts that
must be included in a student manual, and
3. Identifying the types of testing
methodologies and procedures that must be 
included in a comprehensive student In Vitro 
manual.
From the information gathered in the research and the 
content analysis of the literature, a Student Nuclear 
Medicine In Vitro Laboratory Manual to meet this need was 
developed.
Premises
The first premise is that developing an In Vitro 
student laboratory manual is desireable and in the best 
interest of Nuclear Medicine Technology education. In 
support of this premise, the majority of Nuclear Medicine 
program directors believe that a student manual is needed.
10
The second premise is that a student manual can be 
developed to meet the overall In Vitro needs of many diverse 
educational Nuclear Medicine programs.
The third premise is that constructing a laboratory 
manual was possible based on data collected. Furthermore, 
there was enough congruence between the directors of 
accredited programs in their responses that an overall 
consensus can be derived.
The fourth premise is that directors of accredited 
programs are expert enough in the field of In Vitro 
laboratory procedures to make intelligent decisions
pertaining to its future needs.
The last premise is that a review of the literature and
a content analysis of In Vitro material reveal a gap or a
need for a student In Vitro manual for prospective 
graduating Nuclear Medicine Students.
Delimitations
The survey itself was delimited by the relatively small 
number of accredited Nuclear Medicine programs in the United 
States (approximately 70). This researcher made extensive 
efforts to elicit responses from all universities/colleges 
surveyed.
Another possible delimitation pertaining to the small 
number of existing Nuclear Medicine Programs is that 
extraneous variables may enter into the evaluation process.
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These include restrictions in different universities 
pertaining to core requirements for graduation and the 
attempt of some program directors to protect their existing 
program and set In Vitro curriculum. There may also be an 
attempt by certain directors to hide their program's In 
Vitro laboratory weaknesses and possibly deny the need for a 
student manual.
Many Nuclear Medicine Program Directors may themselves 
have limited backgrounds and work experiences in In Vitro 
laboratory procedures. Others may be removed from the 
clinical setting by their current administrative duties and 
have not kept pace with the changing In Vitro laboratory 
field.
Finally, some universities may not employ a Nuclear 
Medicine program director. The dean or administrative head 
of that sector were asked to assume the responsibility of 
completing the survey. This delimitation might impact the 
number of questionnaires received and interpretations 
expressed.
Method of Research
The first step in the study was to develop a 
questionnaire based on content analysis of current 
literature which provides information the researcher 
desires. Secondly, the field test of the questionnaire was 
distributed to a small group of authorities in Nuclear
12
Medicine. Once the field test questionnaire was received, 
the survey was revised accordingly.
The final questionnaire was distributed to all 
accredited Nuclear Medicine Program Directors or their 
representatives. Follow-up contact was made until a 
representative sample of the survey is attained. Due to the 
limited numbers in the study (70), every effort was made to 
obtain a 100 percent response rate.
Next the questionnaire was categorized and the data 
analyzed based on the respondent's answers. Another content 
analysis was developed based on the questionnaire. This 
information was then utilized to:
1. Compare the assessments of Nuclear Medicine 
program directors with the content analysis 
of the current literature,
2. Categorize through general principles 
concepts and specific types of In Vitro 
testing procedures seemed most essential to 
students entering the field of Nuclear 
Medicine, and
3. Develop a student In Vitro laboratory manual 
based on the overall needs indicated by the 
review of the literature and the national 
survey.
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Definition of Terms
AART. The American Registry of Radiologic 
Technologists. This association develops policies and sets 
standards for radiologic technologists. It also provides a 
written test of competence in the field of radiologist 
technology. This examination is nationally accepted.
Accreditation of Nuclear Medicine Program. A formal 
process in which a school applies for and has a site 
visitation of their program by an Agency that has the 
authority to evaluate the appropriateness of their studies.
Accuracy. Closeness to true or real value.
Advanced Radiologic Technology. Generally considered 
more sophisticated forms of radiology, such as nuclear 
medicine, C.T. scanning, nuclear magnetic resonance.
Affinity. Strength (energy) of binding to the 
receptor.
Analvte. The patient sample.
Antigen fAb). A protein formed as part of an 
immunologic response to foreign substance.
Antigen fAg). A substance capable of including 
formation of antibodies.
Antiserum. Measure of the strength of the bound Ag.
Avidity. Measure of the strength of the bound Ag.
B.S.R.T. Program. Bachelor of Science, Radiologic 
Technology. Usually upper-level curriculum only.
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CAHEA. Committee of Allied Health Education and 
Accreditation.
Competencies. Specialized area in which individuals 
are trained in radiological sciences.
Competitive Binding Assay. A type of In Vitro testing 
procedure that is commonly used to analyze blood components.
Controls. May be a standard or any known concentration 
c-f testing material that serves as a comparison between 
successive test runs.
Cross Reactivity. Similar structured Ag that interfere 
with analysis of a given assay.
Equilibrium Saturation. Competition between labeled 
and unlabeled ligand is allowed to occur simultaneously 
until equilibrium is reached between the ligand and the 
binder.
Freud's Adjuvant. An emulsifier that enhances the 
immune response and allows for slow absorption into an 
animal's system when producing antiserum.
Hapten. A substance that is not immunogenic in itself 
but becomes immunogenic when complexed with another 
compound.
Hematocrit. Formed elements divided by whole blood.
Immunogen. A substance capable of inducing an immune 
response.
Immunoqlobulins. A group of serum proteins 
(antibodies) that specifically bind the antigens.
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Inflammatory Disorders. Reaction of the tissues to 
injury; the essential process, regardless of causative 
agent.
In Vitro Nuclear Medicine. Testing procedures 
performed in test tubes utilizing tracer amounts of 
radioactive material. Usually involves direct diagnostic 
assays of physiologic substances present in minuscule 
concentrations including hormonal, blood, and drug levels.
In Vivo Nuclear Medicine. The use of gamma-ray cameras 
and scanners to make interpretations on a qualitative basis. 
Commonly referred to as scans such as bone, liver, brain 
scans, etc.
JCAH. Joint Commission on Accreditation of Hospitals. 
This is the accrediting agency for all U.S. hospitals.
Joint Review Committee on Accreditation of Nuclear 
Medicine Programs. A committee that is granted its 
authority by the Committee of Allied Health Education and 
Accreditation, which grants accreditation to all Allied 
Health programs.
Laboratory Manual. A working guide to help an 
individual understand the application of theory into a 
practical nature.
Ligand. The substance that is bound.
Milliliters. 10‘3 liters.
Modalities. Various types of technical areas in 
radiological sciences such as radiation therapy,
16
radiography, nuclear medicine, ultrasound, and C.T. 
scanning.
Nanoarams. 10'9 grams.
Non-invasive Procedures. Diagnostic procedures that do 
not cause harm or pain to the patient receiving it.
Non-Specific Binding. When labeled Ag and Ag free 
serum (without Ab's) are put into the same test tubes.
Nuclear Medicine Program Director. The individual who 
directs, supervises, and administrates the individual 
Nuclear Medicine program.
Nuclear Medicine Technologist. An individual who 
performs diagnostic and therapeutic procedures utilizing 
radiopharmaceuticals.
Picoarams. 10’12 grams.
Precision. Degree of agreement of repeated measurement 
of a quantity (usually expressed as coefficient of 
variance).
Prototype Curriculum. Course work designed to be 
implemented in any radiological sciences program.
Quality Control. Ensure that the results of assays are 
reliable and representative of true concentration.
Radioimmunoassay. Radioligand assay in which the 
receptor is an antibody. The use of radioactive tracers to 
evaluate blood components, hormonal levels, or drug levels.
Radiographer. One who is responsible for actually 
performing the x-ray procedure on the patent.
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Radiologic Technologist. A generic term to describe 
any technologist that works in the field of radiology, 
including radiographer, nuclear medicine, ultrasound, 
radiation therapy, and C.T. scanning.
Rank Order. A chronological listing from top to bottom 
of certain items based on an assessed value.
Receptor. A substance (protein) that specifically 
binds a certain compound (ligand).
Sensitivity. Minimum quantity detectable.
Society of Nuclear Medicine. A national society of 
physicians, scientists, and technologists whose desire is to 
promote the field of Nuclear Medicine and maintain up-to- 
date material.
uciSpecific Activity. Activity, usually expressed as
mass.
Specific Gravity. Materials’ weights are being 
compared to that of water.
Specificity. Capacity to discriminate antigens of 
similar structure.
Standard. A substance that is added to certain 
reference tubes to serve as a yardstick for quantitation of 
the contents.
Standard Curve. A curve of dilutions of known amounts 
of substance to which the unknown may be compared.
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Technical Education. Those aspects of training 
involving hands-on experience and less emphasis on 
theoretical thought-provoking ideas.
Technologist Sections. A group designed to meet the 
group needs of technologists of a specific discipline.
Titer. Measurement of antibody concentration— the 
dilution of antiserum that will bind 50 percent of added 
radioligand.
Organization of Study
In order to develop a strategy which ultimately results 
in adding to the body of knowledge in Nuclear Medicine 
Technology education, this study must first seriously 
examine the literature pertinent to the field. Secondly, 
develop a method of collecting relevant information related 
to the researcher's stated problem. Thirdly, analyze data 
and synthesize results in order to bring about meaningful 
change in Nuclear Medicine In Vitro Laboratory education.
A thorough review of the literature includes historical 
perspective of Nuclear Medicine education, its growth, 
development, recent trends, and all literature pertinent to 
the development of a Nuclear Medicine In Vitro Laboratory 
manual. It was vitally important to establish the need for 
this study by discussing previously related endeavors and 
other research which may be peripheral or corroborated to 
this study's eventual findings. Based on the supportive
19
literature findings, a well-conceived questionnaire was 
developed which provided research information desired.
This survey questionnaire was field-tested for 
reliability and validity by sending it to five established 
experts in the field of Nuclear Medicine, identified by the 
Society of Nuclear Medicine, for their input and 
evaluations. When returned to the researcher, questions 
were reconstructed to conform with the group's criticisms. 
Those who do not respond were contacted by follow-up.
The results were analyzed and the data used to develop 
an In Vitro Laboratory Manual identified as being needed in 
Nuclear Medicine Technology education. This laboratory 
manual was based on the information gathered in the national 
survey and currently lacking in the literature.
20
Chapter 2
REVIEW OF THE LITERATURE
Development of Nuclear Medicine Technology Education
This chapter provides a literature review of many 
important aspects within the field of Nuclear Medicine. In 
order to develop an appreciation for Nuclear Medicine, three 
major areas are discussed and analyzed. These include: 
Nuclear Medicine Technology Education, an overview of 
historical changes in Nuclear Medicine, and a content 
analysis of In Vitro Nuclear Medicine literature.
The first section concentrates on the development of 
Nuclear Medicine education. This discipline emerged through 
Allied Health concept which emphasizes the training, 
certification, and how professional practices of specialized 
fields developed. Other aspects contributing to Nuclear 
Medicine education including task analysis, credentializing, 
movement toward baccalaureate-level curriculums, Nuclear 
Medicine Associations, and advancement in technology.
The chapter continues with a fairly in-depth look at 
the historical development of the field of Nuclear Medicine. 
The discoveries and inventions that revolutionized our 
society's concept of diagnostic and therapeutic treatment of 
people using radioactive material beginning in the early
21
1920s to the late 1980s. Special emphasis is given to the 
development of In Vitro Nuclear Medicine, including 
radioimmunoassay principles.
The final thrust of the review of the literature 
centers on the content analysis of over 300 texts, articles, 
and manuals written on the subject of In Vitro Laboratory 
Procedures. The tables that were developed characterize 
these written works into the level of material, type of 
material, and whether they provide laboratory exercises.
Development of the Allied Health Concept.
For hundreds of years, medicine was practiced in 
conjunction with religion. During this time, many health- 
related decisions were based upon faith and superstition. 
With the Twentieth Century, there began a new era in 
medicine. The turn of the century marked the science age. 
Soon, the superstitions which served as the basis for 
medicine were replaced by scientifically founded facts.
The advent of new technological discoveries led to a 
rapid increase in the demands for health care services. 
One-to-one doctor-patient care became a thing of the past. 
These new technologies became so complex that their proper 
operation required specially trained personnel. As these 
health technologies began to develop individual autonomies, 
the people within the specific fields began to form their 
own professional societies.
22
The establishment of technological societies resulted 
in the identification of specific education requirements for 
each technology. This led to the process of accrediting 
educational institutions for each respective health field by 
the American Medical Association (AMA). Currently AMA has 
defined 23 allied health fields or professions based 
principally on technology (Amer. Society of Radiologic 
Technologists, 1972, p. 1). These include the following: 
Assistant to the Primary Care Physician 
Cytotechnologist
Electroencephalographic Technician 
Electroencephalographic Technologist 
Histologic Technician 
Medical Assistant 
Medical Assistant in Pediatrics
Medical Laboratory Technician (Associate Degree) 
Medical Laboratory Technician (Certificate)
Medical Records Administration 
Medical Records Technician 
Nuclear Medicine Technologist 
Occupational Therapist 
Operating Room Technician 
Ophthalmic Medical Assistant 
Physical Therapist 
Radiation Therapy Technologist 
Radiologic Technologist
23
Respiratory Therapist 
Respiratory Therapy Technician 
Specialist in Blood Bank Technology 
Surgeon's Assistant 
Each profession is autonomous in matters of training, 
certifying, and setting standards of professional practice.
Although the arrival of the scientific age played an 
important role in the development of allied health 
professions, there were also other factors which assisted in 
its development. These factors include the Allied Health 
Act of 1966; pressures from professional societies; 
increases in the number of community colleges, and their 
attempt to meet the needs of the community; and the 
establishment of schools of health-related sciences (Amer. 
Society of Technologists, 1972, p. 1).
Use of Task Analysis for Program Development in Allied 
Health, such as Nuclear Medicine Technology
Professional allied health societies evolved for a 
number of reasons. Some of the reasons were to prevent 
incompetent people from practicing, to standardize the 
training of personnel, to reduce the competition in the job 
market, and to protect technologists' positions. One major 
outcome of the professional societies was the establishment 
of registries and/or certification.
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Originally, professional societies were responsible for 
the development and implementation of registries and/or 
standards of certification. As time progressed, the 
American Medical Association (AMA) became involved in 
accrediting allied health education programs. Eventually, 
in order for an individual to become eligible to write a 
specific registry or qualify for certification, allied 
health personnel had to graduate from a school accredited by 
the AMA. Currently, school accreditation is contingent upon 
the institution complying with the "essentials" or 
guidelines established by the AMA for allied health (AMA, 
1978). As technology continues to advance, the list 
"essentials" continues to increase.
In 1970-71, the Association of Schools of Allied Health 
Professions and the AMA sponsored a "Study of Accreditation 
of Selected Health Education Programs" (JAMA, 1971, 218, p. 
238-240). The objective of the study was to evaluate the 
current accreditation process for various allied health 
fields. The results of the study demonstrated that 
accrediting agencies, including the AMA, require a multitude 
of accreditation criteria. The criteria include a variety 
of specific courses, course credits in terms of credit 
hours, and hours of supervised clinical practice.
In essence, the committee defined many of these 
criteria as meaningless. As a result, the theory of 
"essentials" has been scrutinized by Ruhe and Kuhli, staff
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members of the AMA. They perceive that the future criteria 
of allied health was stated in meaningful and measurable 
behavioral terms.
The World Health Organization supports the concept of 
defining behavioral objectives and has gone on record as 
stating tat the failure to define goals is one reason which 
has prevented significant advances in the quality of health 
care (McBride, 1977, p. 14).
One method of defining goals is through task analysis. 
Task analysis involves the identification of tasks 
associated with a specific job. There are several 
approaches that may be employed to identify tasks. One 
approach is to have a group of "experts" in a particular 
field list the tasks associated with a job. A second method 
is to survey the population involved in performing the 
tasks, and allow the population to identify the relevant 
tasks. Probably the best method of task identification is 
to allow the "experts" to identify the tasks, they survey 
the population that performs the tasks to confirm or alter 
the task list established by the "experts".
The process of task analysis should include the 
identification of the frequency the task is performed, the 
amount of knowledge required to perform the task, and the 
importance of the task. Identification of tasks in 
accordance with their frequency, knowledge, and importance 
enables the development of an educational program. For
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example, the tasks identified as requiring basic knowledge 
would represent the basic or elementary program course work 
and the tasks identified as requiring advanced knowledge 
would represent the advanced program course work.
The development of specific course content and unit 
objectives would require a further analysis of the task.
The further analysis of the task would serve to identify the 
"steps" or "work activities" which would result in producing 
the identifiable task output (Bosissoneau, 1983, p. 155).
Because of the current public concern over quality 
health care, the state and federal governments have begun to 
mandate that goals and objectives be established for allied 
health. Some states require that allied health personnel 
obtain licenses in order to practice their respective 
specialty. This is of particular importance in Nuclear 
Medicine in which technologists prepare and administer 
radioactive materials to patients. Proponents of mandating 
minimum educational standards at the federal level are 
Senator Edward Kennedy (National Health Insurance Bill), the 
National Advisory Commission of Health Manpower, and the 
Secretary's Commission of Medical Practice.
The actions of these proponents indicate that in order 
for allied health personnel to have a voice in their own 
futures, it is important that the members of the allied 
health professions actively pursue the defining of their
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goals and purposes in educating future individuals in their 
fields.
Credentialina in Nuclear Medicine Technology
Credentialing is a term used to describe how graduates 
of accredited Nuclear Medicine Programs become eligible to 
take a national registry in their chosen fields. A number 
of national organizations and committees helped to develop, 
coordinate, and implement what is today a national 
credentialing examination accepted throughout the country. 
Its brief history began only 25 years ago.
In the early 1960s, the growing importance of 
radioisotopes as diagnostic and therapeutic tools of 
radiology and a correspondent need to develop and identify 
individuals with the specialized skills necessary to assist 
physicians in the practice of Nuclear Medicine became 
apparent to the Board of Trustees of The American Registry 
of Radiologic Technologists (ARRT). Consequently, in 1962, 
the Board moved to begin the examination and certification 
of radioisotope technologists the following year.
Recognizing the need for standardization of education in the 
new allied health specialty, the ARRT also proposed to the 
Board of Chancellors of the American College of Radiology 
(ACR) that the Council on Education of the American Medical 
Association be requested to consider the establishment of 
minimal educational standards for a one-year program for
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radioisotope technologists. An interim curriculum was 
provided by the American Society of Radiologic Technologists 
(ASRT) as a basis for the first examination which was held 
on November 2, 1963. The 148 technologists who passed that 
examination were certified on December 1, 1963, to become 
this country's first credentialed Nuclear Medicine 
Technology Specialists (Lam, 1980, p.52).
The following year, the American Society of Clinical 
Pathologists (ASCP) in collaboration with the American 
Society of Medical Technologists (ASMT) implemented a 
program to examine and certify medical technologists in its 
nuclear medicine subspecialty. Subsequently, both the 
ASCP/ASMT and the ARRT organizations continued to separately 
examine and certify nuclear medicine technologists.
Although there was some overlap, the ARRT generally 
attracted candidates who had worked and trained under 
radiology with emphasis on imaging procedures, whereas the 
ASCP/ASMT operated on a smaller scale primarily serving 
candidates with medical laboratory training and experience 
emphasizing wet laboratory procedures. However, with the 
advent of formalized education in Nuclear Medicine 
technology, these differences gradually became less 
pronounced.
In 1977, the ARRT and ASCP/ASMT registries cooperated 
as members of an ad hoc committee to draft essentials for 
educational programs in Nuclear Medicine technology. The
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work of that committee led to the approval of the first 
"Essentials of an Accredited Education Program for the 
Nuclear Medicine Technologists" by the AMA House of 
Delegates in 1979. Included in the "Essentials" was a 
provision for a "Board of Schools" to serve as a review body 
for educational programs in Nuclear Medicine technology.
The "Board of Schools" later became the Joint Review 
Committee on Educational Programs in Nuclear Medicine 
Technology.
As a step toward further cooperation between 
organizations in 1979, the ASRT Board of Directors proposed 
that the ARRT establish reciprocity of certification with 
ASCP/ASMT Board of Registry. Subsequently, the ARRT Board 
of Trustees authorized correspondence with other parties 
affected by the ASRT proposal and appointed representatives 
to develop a mutual exchange of information with the ASCP, 
ASMT, and the Society of Nuclear Medicine (Seibert, 1981, p. 
346) .
In March, 1981, the president of the ARRT met in 
Washington, DC, with representatives of the Registry of 
Medical Technologists (ASCP), the American Society of 
Medical Technologists and the Technologist Section of the 
Society of Nuclear Medicine to explore the possibility of 
forming a conjoint registry for Nuclear Medicine technology. 
A task group was formed "to prepare a draft of guidelines 
for training and certification in nuclear medicine
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technology" to be considered at the annual meeting of the 
Society of Nuclear Medicine (Seibert, 1981, p. 52).
Later in 1981, representatives of the Joint Review 
Committee on Educational Programs in Nuclear Medicine 
Technology met with ARRT representatives at the Registry 
office in Minneapolis over a mutual concern with 
fragmentation of certification in nuclear medicine 
technology. Eligibility requirements, examination 
questions, and administrative procedures of the ARRT and 
ASCP/ASMT examinations were compared and discussed at 
length. It was agreed that it would be desirable to have a 
common examination in Nuclear Medicine technology. It was 
the consensus of those present that a conjoint committee 
should be established to make up future examinations using a 
common pool of questions.
Finally, it was concluded that the organizations should 
work toward a single certificate of registration in nuclear 
medicine technology with appropriate notations of interested 
parties to the certification (Seibert, 1981, p. 52).
Today, through the combined efforts of these 
organizations, the examination and credentialing of 
certified nuclear medicine technologists is accepted as 
proof of qualifications in all 50 states and many countries 
abroad.
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Recent Trends in Nuclear Medicine Technology Education
The Movement Toward Baccalaureate Level Curriculum for 
Nuclear Medicine Programs. Nuclear medicine is generally 
credited with being the second largest radiological science. 
It has significantly changed its curricula from two-year 
programs to four-year baccalaureate-level degrees.
There is a little doubt that the baccalaureate degree 
is valuable both to an individual and to the profession to 
which he belongs. In a study of allied health graduates, 
Broski and Ballinger found that those from baccalaureate 
programs enjoyed higher levels of professional 
responsibilities, higher salaries, better geographic 
mobility, and greater job satisfaction than their associate 
degree counterparts (Broski, 1980, p. 51-485) .
In that study, it was also demonstrated that 
baccalaureate decreed Nuclear Medicine graduates are 
assuming responsible positions with relatively high 
frequency. The positions assumed most frequently by 
graduates in that survey were in educational settings, 
administration, and in advanced or alternate imaging 
modalities. These findings confirm what has been revealed 
by a survey of Nuclear Medicine technology program directors 
in 1975, that there was a need for advanced training in 
specialized areas, administration, and educational 
techniques.
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Growth in advanced Nuclear Medicine technology 
education has been affected to a large extent by the 
preponderance of the 24-month curriculum. In 1966, programs 
of two years in duration proliferated as a result of the 
ARRT policy requiring 24 months of formal education for 
examination eligibility. However, in recent years, 
educators have questioned whether the two-year curriculum 
can be the primary mode of meeting traditional as well as 
specialty personnel requirements in Nuclear Medicine 
technology. For example, in 1977, as a result of an 
international survey that analyzed the length of educational 
programs in Nuclear Medicine technology in 25 countries, 
Ohnysty (1978) found that basic curricula of two years in 
duration were in the minority, and he observed that "Based 
on the development of new imaging procedures, laboratory 
tests, variations in equipment in Nuclear Medicine and 
increased responsibilities of the technologists, two-year 
programs have proven to be inadequate to train the caliber 
of technologist necessary in current practice" (p, 448).
Many factors have influenced the education of Nuclear 
Medicine technologists to higher levels of education. In 
the past ten years, the shift in accredited Nuclear Medicine 
programs nationwide has been toward increased higher levels 
of educational qualifications and a reduction in the overall 
number of programs that provide training. Some of this 
reduction has been due in part to lack of adequate In Vitro
33
laboratory education. In 1974, the total number of 
accredited Nuclear Medicine programs in the United States 
was 177 with only 28 of those requiring two years or more to 
complete. In 1984, a marked reduction in the number of 
overall programs is noted at 110, with 70 of these programs 
now providing at least two years or more to complete. The 
trend has definitely evolved toward a higher level of 
education, requiring background courses that allow for a 
more sophisticated, career-minded Nuclear Medicine graduate. 
The three most important phenomena that have helped to 
advance educational levels higher are: Nuclear Medicine 
technologist associations, advancement in technology, and 
national accreditation agencies. It is important to examine 
each individually to see how they have influenced Nuclear 
Medicine education.
Nuclear Medicine Associations
The development of strong state Nuclear Medicine 
associations have helped foster higher levels of 
qualifications for employment in radiology and have mandated 
higher levels of education in certain states. Such 
associations have been highly correlated to states that 
provide highly qualified technologists, the highest level of 
education and generally demand the highest salaries 
nationwide. States such as California and Florida are 
excellent examples. Florida has laws regarding personnel
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licensure employees that use radioactive materials and 
equipment. Furthermore, it has state competency 
examinations in many different specialty classifications—  
such as radioassay, technician, technologist, and 
radiological administrator. The prerequisites for taking 
examinations include educational requirements that enhance 
the movement toward higher levels of sophistication of 
knowledge and understanding of new modalities in theoretical 
terms in order to be employed at that respective position.
Strong, unified state organizations have used their 
political clout to muster the energy to convince lawmakers 
that only specially-trained individuals should be allowed to 
use radioactive materials for diagnostic and therapeutic 
means. This has had the effect of elevating radiological 
education requirements and fostering higher levels of 
training and specialization.
Advances in Technology
No one can deny the massive and impressive advances in 
health care technology over the past few decades.
Individuals that enter the medical field need to be trained 
on highly sophisticated, diverse computerized systems of 
diagnostic and therapeutic medicine. Students of Nuclear 
Medicine sciences are entering a dynamically growing 
increased specialized field including digital subtraction 
imaging, nuclear cardiology, radioimmunoassay, and nuclear
medicine resonance. Each of these testing procedures need 
specific didactic and clinical educational experiences 
associated with them. further these students must possess 
basic understanding in chemistry, biology, physics, and 
computers. These advances in Nuclear Medicine technology 
have pushed the emphasis of education to higher levels in 
which individuals would be required to have many preliminary 
courses in order to fully comprehend these new modalities.
National Accreditation Agencies
The Joint Commission on Accreditation for Allied Health 
programs has helped foster standards of educational 
proficiency. JCAH has placed great emphasis on updating 
educational curricula and providing students with 
theoretical and practical experiences that assure quality in 
job performance.
Ficken, a medical physician with over 15 years as a 
member of Nuclear Medicine programs joint review inspection 
teams, believes that such programs need to be placed at 
four-year level universities. He reasons that there is 
increased intellectual demands on technologists and that a 
university setting can provide overall better facilities, 
more qualified teachers, and prerequisite courses needed in 
order for students to fully comprehend new advances in 
Nuclear Medicine technology (1985). These comments and 
actions by JCAH have helped push the education pendulum back
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toward higher educational levels for potential Nuclear 
Medicine technologists.
History of the Field of Nuclear Medicine
Before the Early 1920s, discoveries of Roentgen, 
Betquerel, Curie, and Rutherford began to revolutionize the 
concept of radioactivity and its biological effects and 
potential usefulness. But not until 1923, when Hevesy 
employed a natural radioisotope of lead to investigate the 
metabolism of lead in plants was the field of Nuclear 
Medicine born.
When Hevesy and Paneth used radioactive "indicators," 
they relied mainly on the gold-leaf electroscope.
Measurement of the tracer's radioactivity provided 
thousandfold increases of sensitivity and accuracy over 
existing chemical assays, which Hevesy exploited 10 years 
later in following the movement of a tracer in living 
systems. By measuring the radiolead accumulated in various 
portions of the plant, he was able to quantify the uptake of 
lead in them. So sensitive was his gold-leaf electroscope 
that he could use the radiolead in quantities so minuscule 
as to avoid the toxic effect of lead, an important basic 
principle in tracer methodology. This first use of a 
"radioindicator" in biomedicine presaged things to come 
(Aebersold, 1956, p. 1027).
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The foundation and basic rationale of much of nuclear 
medicine stem from Hevesy's realization that the state of 
radioactivity of radioelements in no way affects their 
biochemical properties. More than anyone, Hevesy deserves 
the designation "grandfather of Nuclear Medicine." He 
visualized that a radioactive atom might be used as a 
"representative" tracer of stable atoms of the same element 
whenever and wherever it accompanied in biologic systems.
His studies in this "classical period" were limited, of 
course, to the few available naturally radioactive 
materials. These were comprised of radioisotopes of 
uranium, thorium, radium, polonium, bismuth, and lead- 
elements that were not of great biologic importance.
Radium, in its transmutations into radioactive isotopes of 
bismuth and lead, he found most feasible for developing his 
tracer method of analysis (Aebersold, 1956, 1027).
Blumgart and co-workers conducted the first clinical 
studies with radioactive tracers in the '20s in Boston.
They injected solutions of radium C(214Bi) into one arm and, 
with a cloud chamber, detected the appearance of highly 
penetrating gamma rays in the other. Their aim was to study 
the "velocity of the circulation." In these pioneering 
studies, the mean normal arm-to-arm circulation time was 18 
seconds, which was prolonged in patients with heart disease. 
Using a forerunner of the Geiger counter with platinum 
needle electrodes over the right atrium and left elbow, they
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were able subsequently to calculate pulmonary circulation 
time and pulmonary blood volume and to study effects on them 
of various heart and lung lesions, thyroid disorders, 
anemia, polycythemia, and drugs. Such classical studies 
illustrate that minds and method were fully prepared to 
exploit the eventual appearance of radioactive isotopes of 
physiologic elements (Moss, Dalrymple, & Boyd, 1976, p. 48).
The growing understanding of the nature of the atom and 
of the behavior of its radiations made it a practical 
certainty that there would soon emerge a means to produce 
radioactive tracers of many elements. Among the most 
important was the discovery by Rutherford, in 1919, that the 
structure of matter could be changed by bombarding elements 
with alpha particles from radium.
In the 193 0s, the development by Lawrence of the 
cyclotron made it possible to produce radioactive materials. 
This was the beginning of the first uses of artificial 
radioisotopes employed for therapeutic and diagnostic value 
in man.
The metabolism of phosphorus in animals and in man 
quickly was delineated further in a series of studies made 
possible by the availability of large amounts of the 
cyclotron-produced tracer 32P. Hevesy, Chiewitz, Aten, 
Chaikoff, Cohn, Cook, Greenberg, Hahn, Jones, Lawrence, 
Perlman, and Scott were among the investigators pursuing 
this trail. The great efficiency with which the body
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absorbed inorganic phosphorus and preferentially utilized it 
in hematopoietic tissues and in rapidly multiplying cells, 
such as those associated with malignancies, was observed. 
John Lawrence was the first to seize upon the therapeutic 
implications of these findings, and on Christmas Eve of 
1936, he first used 32P as phosphate in the treatment of 
leukemia, thus inaugurating the therapeutic employment of 
artificial radioisotopes (Chiewitz & Hevesy, 1935, p. 754).
In the 1940s, relative uptake of radioiodine in the
thyroid and in distant metastases was being portrayed by a
prototype "scanner" consisting of a shielded directionalized 
Geiger counter used for manual "point-by-point counting" 
over areas of interest. With careful and laborious 
charting, a map could be constructed of the distribution of
uptake, and isocount lines drawn. It first occurred to
Benedict Cassen, a physicist, that the scanning pattern 
could be refined mechanically by means of a motorized dector 
moving in a raster fashion over the area to be charted. The 
output of the detector then could be used to activate a 
moving pen, which could thus depict with ink dots an "image" 
of the relative numbers of gamma rays emanating from the 
area so scanned.
In the development of this important approach, several 
problems had to be solved. At the dector end, the Geiger 
counter had serious deficiencies. It was notoriously 
inefficient in its reactions with the penetrating gamma
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photons used for external detection, and this shortcoming 
necessitated large doses of 131I. It was necessary to find a 
detector more sensitive to gamma radiation to make it 
possible to use smaller doses of this radioisotope for 
diagnostic purposes (Hamilton, 1942, p. 541).
The answer came from the field of crystallography. 
Certain crystals of high density and transparency have the 
power to absorb the gamma photon and produce a flash of 
light called a scintillation. Fluorescent phenomena had 
been known for some time, and indeed, Rutherford had relied 
on fluorescence in many of his early studies of particles.
In 1947, Kallmann devised a scintillation detector by 
utilizing organic crystals of naphthalene attached to the 
face of multiplier phototube, which had the capacity to 
transduce the flashes of light into amplified surges of 
electricity. Kallmann's first detector, crude by present 
standards, still was much more efficient for gamma rays than 
the Geiger counter tube (Anger, 1958, p. 27).
In the 1950s, Cassen developed the Gamma Scanner. 
Cassen's first rectilinear scanner in 1951 used inorganic 
calcium tungstate detector crystals, which were even much 
more efficient than naphthalene. Detector efficiency was 
improved further by Hofstadter when he activated high- 
density sodium iodide crystals by adding small amounts qf 
thallium. An especial advantage of these crystals is that 
they may be grown from molten salt into the enormous sizes
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currently being used in Nuclear Medicine. Not only do they 
interact highly efficiently with gamma rays to give large 
scintillations but the sizes of many of these light flashes 
are proportional to the energy of the absorbed gamma photon. 
Consequently, the voltage pulses triggered by the multiplier 
phototube may be sorted electronically to discriminate among 
gamma ray emissions of various energies to select only the 
ones of primary interest. This facilitates the localization 
of sources of direct emissions because one may "turn out" 
irrelevant off-axis, low-energy secondary photons resulting 
from degrading scatter of some of the primary gamma rays 
within the patient, improved images of the spatial 
distribution are the result (Anger, 1958, p. 27).
Cassen's scanning machine displayed the results as a 
picture by applying the amplified detector's pulse to a pen 
that contacted the paper by a carrying arm that moved in 
parallel with the directionalized scintillation detector. 
Response of the pen involved considerable mechanical inertia 
and the writing process was subject to jamming.
In the early 1960s, Hal Anger, embodying in a single 
person a "convergence" of nuclear physics, electronics, 
optics, and information handling, pursued a completely 
different path at the Donner Laboratory of Medical Physics 
of the Lawrence Berkeley Laboratory. He sought a means of 
utilizing gamma rays to build an image rapidly, camera-wise, 
in contrast with one built up over long intervals of time
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with a moving scanner based on a raster principle. Gamma 
rays cannot be refracted with lenses, like light, or bent in 
magnetic fields, like charged particles and thereby 
"focused" (Anger, 1963, p. 56).
Besides Cassen and Anger, many other developers and 
manufacturers added to the body of knowledge and improved 
the scintillation camera.
When the camera finally caught on, and it became 
readily available commercially in 19 64, it fairly 
"revolutionized the practice of clinical Nuclear Medicine." 
It accentuated the significance of such radioisotopes as 123I 
and 99mTc, whose low-particulate and gamma-ray emissions are 
so appropriate for camera use (Wagner, 1978, p. 121).
The development of the gamma-ray camera included 
multihole collimators, ever larger sodium iodide crystals, 
the use of larger banks of improved detector phototubes, 
tomographic applications, and highly sophisticated linkages 
with computers that has resulted in an explosion in new 
measurement technology.
Through this technology of gamma cameras and scanners 
developed in to what is referred to as In Vivo Nuclear 
Medicine. In the 1970s and 1980s, the ability to detect and 
accurately diagnose different diseases in man continued 
through the improvement of gamma camera.
Increases crystal diameter in gamma cameras has 
permitted a larger field of view in camera application; it
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has also improved some aspects of scanning by allowing the 
geometric efficiency of the detector to be increases. With 
focused collimators, more emissions from a source of 
radioactivity can be collected on a broader crystal surface. 
In effect, this raises sensitivity to nuclear emissions much 
as a widened lens aperture increases the sensitivity to 
light in a camera. More emissions are collected per unit of 
time; thus, shorter exposures are required for detecting and 
recording enough events to form a statistically significant 
image, and the speed with which the scanning head can move 
on its path may be increased significantly. A crystal with 
a diameter of 5 inches provides roughly a threefold gain, 
and an 8-inch crystal an electric circuit can be made that 
will accept only desired pulse amplitudes— those 
characteristic of direct, unscattered gamma rays from the 
specific radioisotope used. This process is called pulse- 
height selection.
The result is a scintillation counter with energy 
specificity, or, in other words, a counter that 
discriminates against gamma rays from radioactive isotopes 
of different energy. It produces electrical pulses that can 
be quantified in terms of counts per second, which is 
important in estimating the amount of the radioactive tracer 
at different sites within the body (Wagner, 1978, p. 121).
Two other factors need to be discussed in relate to the 
growth of both In Vivo and In Vitro Nuclear Medicine in the
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1970s and 1980s. They are computers and 
radiopharmaceuticals.
The technology of Nuclear Medicine permits direct 
measurements to be made of body processes in man that in the 
past could only be examined in experimental animals. Such 
study often produces large amounts of data, often in the 
form of quantities of radioactivity distributed in specific 
sites within the body, often changing over a period of time. 
The instrumentation utilized presents the data either as 
quantities that can be plotted and analyzed or as image 
analogues that allow the clinician to visualize the 
distribution of radioactive tracer materials within an organ 
or lesion (Natarajan, 1969, p. 823). the full diagnostic 
potential of nuclear data cannot be realized without 
computer assistance.
Today, throughout the nation there are very few Nuclear 
Medicine departments that do not fully utilize a dedicated 
Nuclear Medicine computer system. A highly trained 
technologist must set up the computer with proper perimeters 
and carefully analyze the image received in order to 
evaluate the lesion correctly.
In order to study the intrinsic contrast between the 
amount of radioactivity within a lesion as compared with 
that in the surrounding tissue, it is frequently necessary 
to use contrast enhancement to make the lesion readily 
visible. The technologist adjust the contrast in much the
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same manner as he would with a television set. Should he 
adjust for high contrast, he achieves a dramatic gross 
differentiation between area of activity, but possible 
important subtleties in the blacked-out or bleached-out 
areas are lost to him. In short, he makes a deliberate 
decision to exclude certain data that the machine is capable 
of providing. Should he adjust for low contrast over a wide 
range of values, he runs the risk of overlooking 
diagnostically important variations that greater contrast in 
narrower ranges would show him. Although remarkable in 
capacity for spatial resolution, the human eye and brain are 
notoriously poor in memory and ability to quantify, 
precisely those attributes in which computers excel (Anger, 
1983).
The second major factor in the development of Nuclear 
Medicine is radiopharmaceuticals. During the past 2 5 years, 
clinical applications of radioactive materials have become a 
major branch of medicine. The growth rate of such 
applications is still progressing exponentially and is now 
estimated at from 2 5 to 4 0 percent annually, as measured in 
terms of persons involved in these applications and of the 
industry developed to support them. Already, most hospitals 
contain or are developing a Nuclear Medicine facility.
While nuclear procedures may never be available in every 
physician's office, there is scarcely a practitioner in any 
field whose understanding of physiology and pathophysiology
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is not increases through the application of radioisotopes to 
the study of man (Anger, 1983).
The development of both the nuclear reactor and the 
cyclotron has allowed for the inexpensive production of 
radiopharmaceuticals for medical use.
The nuclear reactor generates power through controlled 
nuclear fission which introduced a new dimension into the 
production of artificial radioisotopes. It was appreciated 
that the nuclear reactions occurring in a nuclear reactor 
result in a high flux of neutrons that could be used for the 
generation of radioisotopes. Almost any material could be 
lowered into the reactor and subjected to neuron 
bombardment, producing "neutron-excess" radioisotopes 
(MacRae, 1974, p. 497)).
The cyclotron utilized the concepts developed at 
Lawrence Laboratories of particle acceleration to provide 
radionuclides. In cyclotron, the particles are repeatedly 
accelerated through intermediate voltages to achieve high 
energy. Protons are commonly used as a bombarding material. 
It has the advantage over a nuclear reactor in providing a 
wide variety of radionuclides. Another advantage is that it 
is capable of producing certain useful radionuclides, 
preliminary short lived, that are not produced in 
significant quantities in nuclear reactors.
Development of In Vitro Nuclear Medicine
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Nuclear Medicine's capacity for precise and accurate 
measurement of tracers has made possible a variety of 
laboratory assays of great importance in clinical diagnosis, 
pharmacology, biochemistry, and many other fields. The 
studies of blood ferrokinetics, volume determinations, and 
vitamin B-12 absorption have been of inestimable value in 
hematology. Other radioassays have sharpened diagnosis in a 
host of hormonal, metabolic, infectious and inflammatory 
disorders. All of these testing procedures that utilize 
tracer amount of radioactive material in test tube sampling 
analysis have become commonly referred to as either In Vitro 
Nuclear Medicine or Radioimmunoassay.
Radioimmunoassay is a term that describes the use of 
radioactive tracers to assay or analysis of an unknown 
quantity. Radioimmunoassay (RIA) came into being not by 
directed design but as a fallout from what might be 
considered an unrelated study. Prompted by the suggestion 
of I. Arthur Mirsky that maturity-onset diabetes might not 
be due to an absolute deficiency of insulin secretion but 
rather to its abnormally rapid degradation by an enzyme 
which Mirsky called insulinase (Thorell, 1984, p. 4),
Solomon A. Berson attempted to study the metabolism of 131i- 
insulin following intravenous administration to diabetic and 
non-diabetic subjects (Thorell, 1984, p. 4). He observed a 
slower rate of disappearance of the 131I-insulin from the 
plasma of insulin-treated subjects than from the plasma of
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untreated subjects. He postulated that the slower 
disappearance was a consequence of the binding of labeled 
insulin to antibodies that had developed in response to 
treatment with foreign proteins— i.e., animal insulins.
The use of radioisotopic techniques for studying the 
primary reaction of antigen with antibody and analyzing 
soluble antigen-antibody complexes initiated a revolution in 
theoretical immunology, and it is now generally appreciated 
that peptides as small as vasopressin and oxytocin are 
antigenic in some species and the equilibrium constants for 
the antigen-antibody reaction can be as great as 10uL/mol. 
(Rothfeld, 1985, p. 14).
Radioimmunoassay Principle
The principle of RIA is quite simple. The 
concentration of the unknown, unlabeled antigen is obtained 
by comparing its inhibitory effect on the binding of 
radioactively labeled antigen to specific antibody with the 
inhibitory effect of known standards. It should be 
appreciated that there is no requirement for standards and 
unknowns to be identical chemically or to have identical 
biologic behavior. A properly validated assay is one in 
which the concentration in the unknown sample is independent 
of the dilution at which it is assayed. As described later, 
some assays have proven to be properly validated due to lack
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of immunologic identity between standards and the sample 
whose concentration is to be determined.
The RIA principle need not be limited to immune systems 
but has been extended to other systems in which, in place of 
the specific antibody, there is a specific reactor of 
binding substance. Herbert and associates (Herbert, et al, 
1959, p. 433; 1960, p. 160) first demonstrated the 
applicability of competitive radioassay to the measurement 
of vitamin B12 in a liver receptor assay using 60Co-vitamin 
B12 and intrinsic factor as the binding substance. However, 
it remained for Rothenberg (1961, p. 45) laboratory and 
Ekins (1960, p. 453) to develop assays for serum vitamin B12 
using this principle. Ekins and later Murphy (1964, p. 679) 
employed thyroxine binding globulin as the specific reactor 
for the measurement of serum thyroxine.
In the 1950s, when bioassay procedures were in the 
forefront, the first presentation of the potential of 
hormonal measurements by RIA went virtually unnoticed (Yalow 
& Berson, 1960, p. 1157). Somewhat more interest was 
generated by the demonstration of the practical application 
of RIA to the measurement of plasma insulin in man. It 
became evident that the sensitivity and simplicity of RIA 
permitted ready assay of hundreds of plasma samples, each as 
small as a fraction of a milliliter. It made possible 
measurement not only of single blood samples (as had been 
performed on occasion with In Vivo bioassay) but also of
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multiple samples, thus permitting study of dynamic 
alterations in circulating insulin levels in response to 
physiologic stimuli.
In the 1960s, results of numerous studies were 
consistent with the assumption that immunologic activity 
reflected biologic activity and that the behavior of 
endogenous hormone in plasma resembled that of exogenous 
purified hormone added to plasma. Thus, plasma ACTH 
paralleled plasma cortisol throughout the day, responded 
appropriately to a variety of stressful stimuli, was 
elevated in patients with adrenal insufficiency not 
receiving steroids and was suppressed by steroid therapy, 
etc (Yalow & Berson, 1960, p. 1157). There were many 
similar studies with other peptide hormones measured by RIA.
RIA was initially employed primarily for the assay of 
peptide hormones since its exquisite sensitivity was 
required to permit their measurement in plasma in the 
unstimulated state in which the concentrations may range 
from 10 13M to 10'1°M. However, the specificity and 
simplicity of RIA methodology soon led to its application to 
the measurement of non-peptidal hormones as well. Chopra 
(1972) first described RIAs for tyrosine (p. 938) and 
triiodothyronine (T3). The sensitivity and specificity of 
the RIA for the thronines and the ability to measure 
thyrotropin (TSH) (Chopra, p. 938) have made possible a 
nationwide screening program for neonatal hypothyroidism, a
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disease that must be treated shortly after birth to avoid 
irreversible mental retardation (Chopra, p. 938).
By 1969, a sensitive solid-phase RIA for plasma 
estradiol-17 beta had been described. Soon thereafter the 
number of applications of RIA to the measurement of steroid 
hormones grow very rapidly. Within five years, in a review 
of the field, Abraham (1969) indicated that RIA had been 
applied to the measurement of every known hormonal steroid 
and to many other steroids without known biological activity
(p. 866).
RIA in Pharmacology
Although RIA appeared to belong almost exclusively to 
endocrinology during the first decade after its description, 
the rediscovery of the work of Landsteiner (1945) on 
production of antibodies by low molecular weight haptens 
coupled to proteins led to the realization that RIA could be 
adapted to the measurement of drugs. At the end of that 
decade Oliver, et al (1968), published a classic paper 
describing the measurement of digitoxin in human serum by 
RIA (p. 1035). At present, commercial kits for the 
measurement of the cardiac glycosides are routinely employed 
in hundreds of laboratories. A particularly important 
application in toxicology is the assay in plasma of the 
concentration of antibiotics for which there is a very 
narrow range between efficacy and toxicity. Microbiological
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essays for these drugs are time consuming and expensive.
The introduction of the RIA for gentamicin (Oliver, 1958, p. 
1035). led the way, and commercial kits soon became 
available for assay of many antibiotics. RIAs for the host 
of other drugs are now available; many are in simple kit 
form.
RIA in Infectious Diseases
The first application of RIA to the field of infectious 
disease began with the development of an assay for hepatitis 
B antigen, then known as Australia antigen (Purcell,
Holland, Walsh, et al, 1969, p. 383).
Over the past few years the incidence of acquired 
immunodeficiency syndrome (AIDS) due to infection with a 
tretovirus has skyrocketed, and the incidence rate is 
increasing yearly. Although an enzyme-linked immunoassay 
for detection of antibody to this virus contributes to the 
safety of blood used for transfusion, a test for the virus 
itself is urgently required. It is evident that there are 
infected persons without antibody, either because it is too 
early in the course of infection for antibody to have 
developed or because compromise of the immune system may 
decrease antibody production. It is not unreasonable to 
hope that an RIA for the virus will be developed that will 
permit improved safety of bank blood.
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It can be predicted that RIA and related techniques 
will be applied increasingly to the detection of active 
infectious disease. Straus, et al (1981), have reported an 
RIA for a tuberculoprotein that can make the diagnosis of 
active tuberculosis more rapidly and in a much less 
expensive, simpler, and far safer fashion than with the use 
of classic microbacteriologic methodology (p. 3 214). Even 
were this technology applicable only to the diagnosis of 
tuberculosis, it would remain a major breakthrough.
However, it should serve as a model for the development of 
assays for proteins associated with other slow-growing 
organisms, the diagnosis of which may be difficult with 
standard microbiologic methodology.
Future of RIA
This review of the development of a small sampling of 
applications of RIA emphasizes the fact that in science new 
truths become evident when new tools become available. For 
more than a quarter century, RIA has been an important tool, 
fruitfully employed in diverse areas of biomedical 
investigation and clinical medicine. Can we predict what 
the relative usage of radioactive and non-radioactive labels 
in immunologic methods for diagnosis (immunodiagnostics) 
will be in the future?. A Wall Street investment concern has 
attempted such a prediction (Dunne, 1981). They have 
estimated that in 1980 the market segment for RIA in
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immunodiagnostics was $332 million, for non-radioisotopic 
therapeutic drug monitoring $43 million, and for all other 
non-radioisotopic immunoassays $28 million; in 1990, they 
predict markets of $785 million, $625 million, and $838 
million respectively for these three methodologies. Thus, 
from a commercial point of view RIA usage is expected to 
more than double during the decade of the 1980s, but its 
fraction of the total immunodiagnostics market is expected 
to drop from over 80 percent to about 35 percent. Why?
First of all, many of the new applications simply do not 
require the exquisite sensitivity of RIA. For instance, in 
therapeutic drug monitoring the concentrations being 
determined are generally a million-fold higher than the 
concentrations of peptide hormones. Furthermore, assays for 
drugs generally need not be quantitative over a multiple 
hundredfold range. It is often necessary only to determine 
whether the concentration is high enough to be efficacious 
and not so high as to be toxic. In the field of infectious 
diseases, where immunodiagnosis will play a major role, the 
choice between radioisotopic and non-radioisotopic 
methodology again would depend on the sensitivity required; 
in the presence of massive infection, the massive infection 
the sensitivity of RIA is not likely to be necessary. 
However, in a number of instances, those promoting non- 
radioisotopic labels are not necessarily suggesting that 
these have any technical advantage, but rather that
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regulatory procedures and fear of radiation at any level 
would make radioisotopic label less desirable. Nonetheless, 
RIA is likely to remain the method of choice for what has 
been its first application, the measurement of peptide 
hormones in plasma and other body fluids, since their 
concentrations are well below 10*1°M, and the sensitivity of 
RIA is essential (Dunne, 1981).
RIA and related methodologies have opened new vistas in 
science and medicine. RIA is now used in thousands of 
laboratories around the world to measure hundreds of 
substances of biologic interest. Even now, a quarter 
century after the introduction of RIA, there remain many 
additional fields that can be explored with its help.
Review of In Vitro Literature
A selective review of the nuclear medicine In Vitro 
literature was performed on over 300 articles, text books, 
and manuals. This researcher examined the literature and 
categorized the materials into a content analysis chart.
The five areas were: Level of Material, Type of Material, 
Possibility of Providing Laboratory Exercises, General 
Principles, Concepts Discussed, and Specific Testing 
Procedures Mentioned.
The following is presented as a content analysis chart 
and a summary of resultant values obtained.
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Content Analysis of In Vitro Nuclear Medicine 
Literature. Column indexes and abbreviation conventions: 
Column 1, Bibliography 
Column 2, Level of Material 
under = undergraduate 
grad = graduate 
tech = technical 
Column 3, Form of Material 
Column 4, Laboratory Exercises Provided 
Column 5, Concepts Discussed 
Column 6, Specific Testing Procedures
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Summary of Resultant
Level of Material. In order to evaluate the need for a 
student laboratory In Vitro manual, it was necessary to 
examine the literature content and categorize in terms of 
(NOTE: The numbers following each section relate to the 
total frequency of occurrence for that topic mentioned 
within the literature:
Undergraduate Level: Understandable to beginning 
students in field or general public (13).
Technical Level: Written for individual in field
(206).
Graduate Level: Highly sophisticated; for advanced 
educational-level individuals (91).
Tvne of Material. This is the form the material was 
written in, either an article, text, or manual.
Article: Categorized as in a journal or presented 
as a paper in a symposium (262).
Textbooks: Larger volumes covering numerous area 
and topics of In Vitro material (48).
Manuals: Written as a guide to students to work 
through problems and exercises (4).
Providing Laboratory Exercises. Of the over 300 types 
of In Vitro literatures examined only seven times were any 
exercises included. The types of exercises were: basic RIA, 
concepts, separation techniques, calculation of results,
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labeling, basic reactions, basic immunology, and blood 
components sampling procedures.
General Principles and Concepts Discussed. The 
literature was categorized in 11 overall principles and 
concepts, each different type were placed into one of these 
areas:
Basic Principles/Concepts: This included materials 
that discussed elements, standards, structures, basic TIA 
properties and methodologies and typical RIA examples (62).
Basic Reactions: Concepts included concentrations, 
components of RIA, equations, chemical properties, 
physiology, interfering substances (65).
Radiolabelinq: Labeling of radioactive materials, 
production and purification of labeled isotopes (29).
Basic Procedures: Techniques, evaluation of 
techniques, applications, calibrations (13).
Kit Evaluation: Assessment of basic manufacturer 
RIA testing kits (12).
Separation Techniques: Separation of bond-free
(26) .
Calculations of Results: Measurement, assessment, 
evaluations (54).
Preparation; Patient sampling, binding properties, 
receptors, Ag-Ab preparation (18).
Quality Control: RIA laboratories, equipment, kits
(19) .
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Alternative Immuno Blood Testing; Enzyme, 
luminescence, fluorescent excitation testing (24).
Specific Testing Procedures. A review of the In Vitro 
literature reveals numerous types of testing procedures 
discussed. The following is a list in descending order of 
the most commonly mentioned testing procedures (NOTE:
Numbers correspond to frequency distribution of test 
procedures mentioned within literature): 
thyroid T3, T4 - (56) 
blood volumes - (18) 
schilling testing - (15) 
vitamin B12 - (13) 
red blood cell survival - (11)
WBC labeling - (10)
peptide (protein hormones) - (10)
insulin - (9)
iron (Fe) recovery - (8)
drug testing - (8)
TSH - (7) 
thyrotropin - (7)
CEA - (7)
estradiol, estrone - (7) 
folic acid - (6) 
alpha-feto protein - (6)
3 — 5
corticol
testosterone
FSH
HCG
LSH
PTH
creatine kinase 
renin, aldosterone 
aminoglycoside 
ACTH
gonadotropin 
steroid testing 
IGE
angiotension
monoclonal antibodies
norepinephrine
TBG
LH
digoxin
In summary, this chapter attempts to review those 
aspects most influencial on the development of In Vitro 
Nuclear Medicine education. This review of the literature 
exposes the reader to many reasons for the development of 
Nuclear Medicare Technology education, the historical 
changes influencing the field of Nuclear Medicine and 
finally the tabulated content analysis of over 3 00 articles, 
texts, and manuals written within In Vitro Nuclear Medicine.
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This content analysis of the review of In Vitro 
literature is used as the basis for the development of the 
nationwide survey sent to all Nuclear Medicine program 
directors. The general principles/concepts, testing 
procedures and laboratory exercises cited in the literature 
are evaluated by the program director as to their relative 
importance in the educational process of nuclear medicine 
students.
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Chapter 3 
METHODOLOGY
Introduction
Chapter III is concerned with the methods and 
procedures that were used in this study. Information was 
provided regarding the selection and description of the 
subjects, and description of the development and 
administration of the instruments.
Settincr and Subjects
Based on the content analysis of the Nuclear Medicine 
In Vitro Laboratory literature a questionnaire was 
developed. Before any nationally accepted survey could be 
sent out to all Nuclear Medicine program directors the 
validity and reliability of the questionnaire had to be 
established.
Five authorities in the field of Nuclear Medicine 
technology were identified to evaluate the initial surveys 
contents. A letter was sent to the Joint Review Committee 
on Accreditation of Nuclear Medicine Program and the Society 
of Nuclear Medicine asking these groups to choose 
individuals they deem as experts in the field. From the 
suggested list of individuals, five were selected at random 
and received by mail the researcher's initial survey.
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The final sampling population consisted of all 
Accredited Nuclear Medicine Technology Program Directors in 
the United States (approximately 7 0). A list of accredited 
programs were supplied by the Joint Committee on Education 
in Radiologic Technology (1988 listings).
Directors of each accredited degree program were 
selected not so much for their educational and professional 
experience, but because they may have the most dominant 
voice in the actual implementation and future use of this In 
Vitro Student Manual into their curriculums.
Since there may not be a Nuclear Medicine program 
director for a given university, the person directly 
responsible for the program (dean, chairman, etc.) were 
asked to complete the questionnaire. Their title was 
designated on the form. No differences were analyzed 
between various titles as long as they have direct 
responsibility for the Nuclear Medicine technology program.
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The following Procedural Chart outlines the basic 
sequencial steps undertaken that ultimately lead to the 
development of an In Vitro laboratory manual.
PROCEDURAL CHART
Content analysis of literature is used to develop basic 
questionnaire on the needs of In vitro Nuclear Medicine 
procedures.
i i i i
V
Letter to Joint Review Committee on Accreditation of 
Nuclear Medicine Program and Society of Nuclear Medicine 
asking them to choose individuals they deem as experts in In 
Vitro Laboratory procedures to evaluate questionnaire.
i i 
i i
V
Five experts randomly selected from list provided.
t t 
i i
V
Questionnaire was revised and necessary changes made 
based on criticisms of experts.
i i 
i i
V
Survey is sent to all Nuclear Medicine Programs 
Directors nationwide (approximately 70 schools).
i i
i i
V
Data is collected and analyzed.
i i
i i
V
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In Vitro Laboratory Manual is written to meet education 
needs cited.
i i i i
V
Manual is sent to experts for their critique and 
comments about how well manual will meet needs in Nuclear 
Medicine In Vitro Laboratory.
Procedure
A letter was developed and sent to the Joint Review 
Committee on Accreditation of Nuclear Medicine Programs and 
the Society of Nuclear Medicine asking them to identify 
experts in the field of Nuclear Medicine education. A 
random selection of five names were used to validate the 
researcher's initial questionnaire.
The five individuals chosen randomly were: Wynn
Harrison, Director of Nuclear Medicine, Weber State 
University, Utah; John Hamlett, Director of Nuclear 
Medicine, Temple University; K. McEnerney, Director of 
Nuclear Medicine, California State University, Berkeley; 
Sheila Rosenfield, Director of Nuclear Medicine, St. Louis 
University; John Rollins, Director of Nuclear Medicine, 
University of Alabama, Birmingham.
A cover letter and questionnaire was mailed to these 
Nuclear Medicine Technology authorities in the field of 
Nuclear Medicine technology. The cover letter explained the
89
purpose of the study and the importance of their input.
They were requested to respond by a certain date. Telephone 
calls followed to three experts who did not return a 
questionnaire asking or reminding them for their response.
A second letter and questionnaire was sent with appropriate 
follow-up contact made until all five authorities did in 
fact complete and return the questionnaire.
From the five authorities responses an overall review 
and necessary changes were made to adjust to the criticisms 
of these individuals. The final survey was sent to all 
Nuclear Medicine Program Directors from the University of 
Nevada, Las Vegas with a self-addressed, stamped envelope 
for easy return. In hopes of increasing participation the 
participants were asked whether they wished to have the 
results of the research sent to them.
Again, due to the relatively small number of accredited 
Nuclear Medicine programs, any director that did not respond 
was contacted by phone and reminded to please make every 
effort to respond to the survey. A second cover letter and 
questionnaire was sent to those who had not responded.
Every attempt was made to receive an overall response rate 
of 70 percent or better.
From all Nuclear Medicine Program Directors that did 
respond the data was analyzed and a In Vitro Laboratory 
Manual was developed by this researcher.
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Finally a cover letter and the In Vitro Laboratory 
Manual developed was sent to two of the original five 
experts for their overall evaluation and commentary.
Instrumentation
Each Nuclear Medicine program director (or person 
responsible for program) throughout the United States was 
asked to complete a questionnaire for this survey research. 
This instrument was designed to develop a nationally 
accepted In Vitro Student Laboratory Manual based on data 
collected.
The survey was first field tested by five authorities 
in the field of Nuclear Medicine education, identified by 
either the CAHEA or the Society of Nuclear Medicine. The 
surveys were returned to this researcher and questions were 
reconstructed to conform with the overall groups' 
criticisms.
The follow-up questionnaire was designed to have 
program directors evaluate the appropriateness of general 
principles, concepts and specific testing procedures 
essential to a quality Nuclear Medicine Student In Vitro 
Laboratory Manual. A cover letter sent to all those 
surveyed explaining the purpose of developing an In Vitro 
Laboratory Manual for their curricula.
The survey first asked the respondent to identify the 
school's name, their name and their title. Initially four
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yes/no type questions are asked of the respondent. These 
relate to the individuals philosophical perspective of the 
projected In Vitro Laboratory Manual.
The questionnaire is then broken down into two major 
sections. The first section includes a series of statements 
dealing with components of basic principles and theories to 
be discussed within the laboratory manual. A list of 
twenty-two (22) general principles and concepts are provided 
to be evaluated for their relative importance in In Vitro 
Nuclear Medicine education.
The second section relates the testing procedures which 
need to be part of a successful Nuclear Medicine In Vitro 
Laboratory Manual. A list of 34 specific testing procedures 
associated with In Vitro testing were supplied. These lists 
for both sections were derived from the content analysis in 
the In Vitro literature review.
In both section I and section II the participants were 
asked to evaluate the significance or importance of general 
principles, concepts and specific tests listed by each 
selecting the appropriate option described.
1. Must be part of: should be thoroughly discussed
or reviewed.
2. Must be part of: does not need thorough
discussion.
3. Should be part of: some aspects are vital to In
Vitro education.
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4. Could be part of: nice to know.
5. Is irrelevant.
The survey respondents are then asked to please add 
general principles, concepts or specific testing procedures 
they feel have been omitted that are essential to an In 
Vitro Laboratory Manual of prescribed lists.
This chapter examined the overall methodology and 
process which was undertaken for this research. Discussion 
included the setting for the investigation and the subjects 
utilized. A procedural chart attempted to simplify the 
sequencial steps. An indepth look at procedure followed, 
along with a comprehensive analysis of the questionnaire 
utilized in the national survey.
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Chapter 4 
COLLECTION AND ANALYSIS OF DATA
Introduction
This chapter will discuss how the research was 
collected and analyzed. The entire population of accredited 
Nuclear Medicine programs in the United States were surveyed 
for this study. The questionnaire was sent from the 
Univcersity of Nevada, Las Vegas, with return envelopes. 
Based opn the 74 percent response rate, the average values 
for all questions and statements were tabulated and 
analyzed.
The sampled population consisted of all Nuclear 
Medicine Program Directors in the United States 
(approximately 70). This group was selected because they 
have the strongest influence on the development and future 
implementation of an In vitro Student Manual into their 
curricula. Therefore, any valid study of future changes 
regarding In vitro education must include the perceptions of 
these individuals.
The survey was designed to have the Program Directors 
assess the need in the development of an In vitro Student 
Manual. Then if such a need exists, evaluate the 
appropriateness of particular general principles, concepts 
or specific type of tests in an In vitro Student Manual.
The questionnaire was mailed out from the University of
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Nevada at Las Vegas with a cover letter explaining the 
purpose of the survey. Telephone calls followed, and 
follow-up surveys to those directors that did not initially 
respond, asking or reminding them of the importance of their 
input of the 70 Nuclear Medicine programs surveyed 
nationwide. Fifty-Two responded to the questionnaire. One 
of the schools reported back that they had dropped their 
Nuclear Medicine program. Therefore, the actual number of 
completed surveys were 51 out of a possible population of 
69; this represents 74% of the total Nuclear Medicine 
programs in existence in the United States. The study 
achieved its goal of at least seventy percent (70%) response 
rate.
The large overall collection of questionnaires clearly 
demonstrates the meaningfulness and importance to the 
Nuclear Medicine educational community the need for an In 
vitro Laboratory Manual to be developed.
The Nuclear Medicine Program Directors surveyed were 
first presented with four (4) yes/no type questions and 
asked to please circle the answer that best represents their 
philosophy in terms of the projected In vitro Laboratory 
Manual. The overall raw data results follow each question.
1. Do current texts, workbooks or laboratory manuals meet 
the needs of your nuclear medicine students with 
respect to In vitro procedures? '
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Yes No
9 41
Eighty-two percent (82%) of these surveyed felt that 
the current literature do not meet the needs of the Nuclear 
Medicine students. This fact seems to support the review of 
the literature which reveals no laboratory manual was 
currently available to educators that provided a thorough 
examination of In vitro procedures in Nuclear Medicine.
2. Do you believe an In vitro Nuclear Medicine 
Undergraduate Level Manual is needed to properly train 
your students?
Yes No 
43 6
In response to this question eighty-eight percent (88%) 
of the Nuclear Medicine educators felt that a manual was 
needed.
3. Does a laboratory In vitro Manual need to be written to 
meet this need?
Yes No
40 8
The overwhelming response was affirmative by the 
various educators surveyed. Eighty-three percent (83%) felt 
strongly enough to indicate that a laboratory manual needed 
to be written.
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4. Should such a manual provide both a discussion of
theoretical constructs and laboratory exercises for
students?
Yes No
41 9
In this question the surveyor was attempting to see if 
the Nuclear Medicine educators felt that a manual needed to 
in fact integrate the theory and practical work concepts. 
Again, the overwhelming number of participants were 
convinced, with a response rate of 85 percent that an In 
vitro Manual was needed both theoretical constructs and 
laboratory exercises.
The next two sections of the survey asked the Nuclear 
Medicine experts to evaluate the importance of various basic 
principles, theories and testing procedures which need to be 
a part of any successful In vitro Nuclear Medicine 
Educational Manual. Each respondent was asked to place a 
numerical value on each item listed in both sections.
The numerical values were as follows:
1. Must be part of: should be thoroughly discussed 
or reviewed.
2. Must be part of: does not need thorough
discussion.
3. Should be part of: some aspects are vital to In
vitro education.
4. Could be part of: nice to know.
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5. Is irrelevant.
Section I included statements dealing with components 
of basic principles and theories. The average results of
all participants follows each item.
Elements of R.I.A. antibody-antigen reaction. 1.3
Growth development, historical changes in In vitro 3.2
Laboratory Technology.
Properties and methodologies of typical R.I.A. tests. 1.4
Components of R.I.A. equations of equilibrium, 1.2
chemical properties, physiology.
Basic blood components and interfering substances. 1.3
Separation of free from bound techniques. l .6
Calculations of results, assessment and evaluation of 1.6 
resultant values.
Evaluation of different techniques and kits. 2.8
Quality control on instrumentations, equipment in 1.5
laboratory.
Typical R.I.A. testing procedures. 1.3
Labeling of radioactive material. 2.6
Production and purification of labeled isotopes. 2.7
Preparation of patient samples, blood and urine. 2.2
Gamma well counters and liquid scintillation. l.3
Alternative immune testing procedures, enzyme, l.7
luminescence, gas spectroscopy.
Proper intravenous injection techniques. l.9
Statistics and computer data. l.5
Presentations in R.I.A.
Blood volumes. l.9
W.B.C. labeling. 2 .1
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R.B.C. labeling. 1.4
B-12 absorption testing, Schilling testing. 1.7
Iron recovery. 2.8
All basic principles and concepts described were 
classified by evaluators as (3.2) or numerically lower.
This would seem to indicate that every principle and theory 
listed needed to be at least some part of the In vitro 
Manual.
Of the 22 statements and numerical values that followed 
three (3) categories were developed to evaluate the extent 
that these items would appear in the Nuclear Medicine 
Laboratory Manual.
1.6 or lower - thoroughly discussed and reviewed.
2.2 - 1.7 - discussed, but not in great detail.
3.5 - 2.3 - needs to be part of, briefly analyzed and 
discussed.
This scale was developed and utilized because almost 
all general principles/concepts listed were considered by 
educators as at least in the range of should be part of In 
Vitro education. The educators were asked to please add any 
principle or theory not included in this list. Only one (1) 
item was listed on more than 5 returned surveys. This was 
the concept of dilution principles listed 12 separate times. 
It was therefore included into the laboratory manual overall 
concepts discussion and analysis.
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Section II of the survey asks the Nuclear Medicine 
Program Directors to evaluate the appropriateness of 
different types of testing procedures. Using the same scale 
utilized in section If the experts selected numerical values 
(1-5) for each item on the list of 34 testing procedures 
provided.
The final total averaged results for the national 
survey for section II was as follows:
Thyroid 1.2 Angiotensin 3 . 4
Blood Volume 1.4 Drug Testing 1.4
Iron Recovery 1.8 I.G.E. 2.8
Cortisol 3.0 Monoclonal Antibodies 2.1
Testosterone 2.1 Norepinephrine 4 . 5
Estradiol, estrogen 2.1 Digoxin 2.6
CEA 1.6 LH 2.2
Peptide 4.2 TBG's 1.4
RBC Survival 1.6 Folic Acid 1.6
LSH 1.9 Alpha-feto Protein 1.9
Insulin 3.8 HCG 2.6
TSH 1.4 Vitamin B-12 1.5
PTH 2.9 Schilling Test 1.6
WBC Labeling 1.5 Thyrotropin 4.2
Renin, aldosterone 2.7 Creatinine 3.4
ACTH 3 . 6 Aminoglycoside 4.2
Gonadotropin 3.4
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Again, the respondents were asked to add any other 
testing procedures that could enhance Nuclear Medicine In 
vitro education.
The following testing procedures were named as 
important enough to be part of the developed laboratory 
manual.
Hepatitis Testing
Gastrin
Myoglobin
Calcitonin
Gentamicin
Phenytoin
Theophylline
Of these responses only hepatitis testing appeared on 
more than three (3) separate surveys. It was added to seven 
different survey responses. This the researcher felt was 
significant and is thoroughly discussed in the laboratory 
manual. The other tests are only briefly reviewed.
Summary of Resultant Values of 51 Nuclear Programs 
Nationwide The following basic principles, concept or
testing procedures were ranked (1.6 or lower) and are 
thoroughly discussed and reviewed in the developed Nuclear 
Medicine In vitro Manual.
Elements of R.I.A., antibody-antigen reaction.
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Components of R.I.A. equations of equilibrium, chemical 
properties, physiology.
Basic blood components and interfering substances. 
Separation of free from bond techniques.
Calculations of results, assessment and evaluation of 
resultant values.
Quality control on instrumentations, equipment in 
laboratory.
Typical R.I.A. testing procedures.
Properties and methodologies of typical R.I.A. tests. 
Proper intravenous injection techniques.
Statistics and computer data presentation in R.I.A. 
Blood volumes.
W.B.C. labeling.
R.B.C. survival.
Gamma well counters and liquid scintillation.
Vitamin B-12.
Schillings.
CEA.
Thyroid.
Blood volumes.
TSH.
Drug Testing.
RBC survival.
TBG's .
Folic Acid.
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WBC labeling.
* Hepatitis testing.
* Dilution principles.
(* Added to list by respondents.)
The following basic principles, concepts or testing 
procedures were ranked between (2.2 - 1.7) and are 
discussed, but not in great detail:
Evaluation of different techniques and kits.
Labeling of radioactive material.
Production and purification of labeled isotopes. 
Preparation of patient samples - blood or urine. 
Alternative immune testing procedures, enzyme, 
luminescence, gas spectroscopy.
Monoclonal antibodies.
LH.
Alpha-feto protein.
Iron recovery.
Estradiol, estrogen.
Testosterone.
FSH.
LSH.
The following basic principles, concepts or testing 
procedures were ranked between (2.3 - 3.5) and are briefly 
discussed and analyzed in the In vitro Laboratory Manual. 
Growth, development, historical changes in In vitro 
Laboratory Technology.
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I.G.E.
Digoxin.
Cortisol.
HCG.
PTH.
Creatinine.
Ren in, Aldosterone.
Angiotensin.
* Gastrin.
* Myoglobin.
* Calcitonin.
* Gentamicin.
* Phenytoin.
* Theophylline.
(*These testing procedures were added by the Nuclear 
Medicine Program Directors surveyed. None of these tests 
appeared on more than three (3) separate respondent 
surveys.)
Three categories were developed based on the overall 
average values assessed to each general principle/concept or 
testing procedure by the Nuclear Medicine program directors. 
Items ranked (1.6 or lower) are thoroughly discussed and 
reviewed the the Nuclear Medicine student In Vitro manual. 
This section included 27 properties. The next category 
included principles/concepts or tests which ranked between
1.7 to 2.2 and were discussed in the In Vitro manual, but
not in great detail. This section encompassed 13 
principles/concepts or testing procedures. The final 
category incorporated basic principles/concepts or testing 
procedures ranked 2.3 to 3.5 and was briefly analyzed in the 
In Vitro manual. This group included 14 such items. Items 
with a numerical value greater than 3.6 was not included in 
the manual.
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Chapter 5
SUMMARY, CONCLUSIONS, RECOMMENDATIONS,
AND RECOMMENDATIONS FOR FURTHER STUDY
This chapter briefly reviews the problem, summarize the 
results, and identify the conclusion based on the research. 
The major emphasis focuses on examining how well the four 
initial questions raised in Chapter 1 were answered by the 
research data. Then suggest alternative ways of solving the 
problems raised and provide recommendations for further 
research.
Restatement of the Problem
The purpose of this study was to examine the necessity 
for development of an In Vitro student laboratory manual to 
be used by accredited nuclear medicine technology programs.
A review of the literature reveals through a content 
analysis that such a manual is not in existence.
A questionnaire was developed and distributed to all 
accredited nuclear medicine program directors nationwide.
The survey elicited responses pertaining to general 
principles, concepts, and specific testing procedures they 
deemed essential to an educationally sound In Vitro 
laboratory manual for graduating students.
106
Summary
Based on the responses from the questionnaire, this 
section discusses the overall findings of the study. The 
initial questions posed which the basis of all the research 
was formulated is discussed, and analyzed.
The research attempted to answer four initial questions 
posed by the researcher.
1. Is there a need for an In Vitro laboratory manual 
for students in nuclear medicine technology?
First, through an extensive content analysis of In 
Vitro nuclear medicine literature it was clear that no such 
manual existed. There is no undergraduate level of material 
that provides laboratory exercises, conceptual discussion, 
and analysis of specific testing procedures vital to 
educating successful nuclear medicine technology students.
Secondly, 82 percent of the nuclear medicine program 
directors responding to the national survey felt that 
current texts, workbooks, or laboratory manuals did not meet 
the needs of their nuclear medicine students with respect to 
In Vitro procedures. Furthermore, 88 percent of the nuclear 
medicine educators felt that a manual was needed.
2. What general principles/concepts of In Vitro 
studies must be included in this student manual?
Through the extensive content analysis of the In Vitro 
literature, 22 general principles/concepts were cited. From 
these lists the national survey asked nuclear medicine
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program directors to assess the importance of each item and 
add to this list whatever was in their view missing.
3. Identify the types of testing methodologies and 
procedures that must be included in a comprehensive student 
In Vitro manual.
Again, through the content analysis of the literature 
and the national survey 34 predominant testing procedures 
merged as important enough to be part of a comprehensive 
nuclear medicine In Vitro laboratory manual.
4. What aspects of In Vitro nuclear medicine are most 
commonly overlooked that need to be taught to graduating 
nuclear medicine students?
This question, though not specifically asked of the 
national survey respondents, can be deduced from the data 
collected. A number of general principles, concepts and 
testing methodologies not mentioned in the literature were 
sighted by nuclear medicine program directors as essential 
to this developed manual.
Conclusion
All of the data collected from both the review of the 
nuclear medicine literature and the national survey clearly 
indicates a need for development and future implementation 
of an In Vitro laboratory manual in nuclear medicine 
programs nationwide. This researcher has analyzed this data 
by developing and writing a student In Vitro manual at the
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undergraduate level to meet this need. This laboratory In 
Vitro manual consists of nine chapters discussing general 
principles, concepts and specific testing procedures 
performed in nuclear medicine. The manual also provides 12 
laboratory exercises for students to have hands-on 
experiences.
This laboratory manual will be made available to CAHEA, 
the Society of Nuclear Medicine, and nuclear medicine 
programs nationwide. The information gathered from this 
study can also be used by program directors in assessing 
their current In Vitro curricula and identify deficiencies.
One limitation that must be cited, is that due to time 
constraints and a tremendous amount of nuclear medicine 
materials, certain aspects may not have received the full 
extent of discussion they warranted.
Based on the data collected from this study further 
research in this area and other such texts, manuals need to 
be developed. Clearly there is a tremendous need not being 
met by the current writings in the field of nuclear medicine 
education. Future research may wish to utilize this 
research data and emphasis in greater detail general 
principles/concepts or specific testing procedures. Others 
may desire to devote their energies on laboratory exercises 
for students. It is quite obvious that much more can be 
researched and developed to foster nuclear medicine In Vitro 
education to a higher level.
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QUESTIONNAIRE FOR 
UPDATE OF THE NMT 
ESSENTIALS
The JRCNMT would appreciate a moment of your time to respond 
to the enclosed questionnaire, relevant to the education and 
practice of Nuclear Medicine Technology. The information 
derived from this and future assessemtns will guide us in 
our review of education programs and future revisions of the 
Essentials and Guidelines.
Please indicate in the space provided, your answers to the 
following questions.
Demographic Data
1. Present Position(s), Check all which apply to you 
Staff Technologist Physician
Senior Technologist Scientist
Chief Technologist Radiation Safety Officer
Administrator Clinical Instructor
Educator Radiopharmacy Technologist
Student Other
2. Training and education in nuclear medicine
OJT CAHEA ADV. DEGREE
RT BS/BA M.S.
MT AS/AA M.D.
RN Certificate Ph.D.
HS Certificate
2a. Years in Practice:
3. Type(s) of institution where presently employed: Check 
all which apply
Private Hospital 
University Hospital 
Community Hospital 
Government (Federal or State)
Private Practice 
Mobile Service
4. What is the size of your principal institution:
Over 100 beds 
101-200 beds 
201-500 beds 
over 800 beds 
Does not apply
5. Location: Large City
Suburb 
Small City
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6. Zip Code:
7. Where is nuclear medicine practiced in your 
institution?
Nuclear Medicine is separate department
Nuclear Medicine is part of Radiology
Nuclear Medicine is part of Pathology
Nuclear Medicine is part of Internal Medicine
Other ____________ Specify ____________
8. Does the Nuclear Medicine Department at your 
institution perform: Check all that apply
Imaging procedures
In Vitro procedures
In vivo non-imaging procedures
9. How many nuclear imaging procedures does your 
institution perform each month:
Under 100 
101-200 
201-400 
401-600 
601-800 
801-1000 
Over 1000
10. How many immunoassays does your institution perform 
each month:
Under 100
100-500
501-1000
1001-5000
5001-10,000
Greater than 10,000
11. How many nuclear medicine technologists are currently 
employed at your institution?
Nuclear Medicine Practice
RADIOPHARMACY
12. Where are radiopharmaceuticals prepared?
in your institution's Nuclear Medicine Department 
in your institution's Pharmacy Department 
outside commercial centralized pharmacy
other_____  Specify ________
Do you anticipate any changes?  yes  no
Comment:
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13. What is the professional background of the principal 
individual responsible for radiopharmaceutical 
preparation?
nuclear medicine technologist 
radiographer 
medical technologist 
other Specify ________
14. Who is responsible for radiopharmaceutical quality 
control procedures?
nuclear medicine technologist
radiographer
medical technologist
radiopharmacist
radiochemist
other Specify _______
IMMUNOASSAY
15. Have you performed immunoassay prcedures in the last 
two years?
_____  yes ______  no
16. Where are radioassays performed at your institution?
nuclear medicine 
pathology
outside commercial lab 
do not do
17. Which of the following methods are used for 
immunoassay? (indicate % of tests done by each method)
RIA _____ %
EIA _____ %
Fluorescent _____ %
18. Do you anticipate any changes in the involvement of 
Nuclear Medicine Technologists in Immunoassays at your 
institution?
_____  yes _____  no
If yes, please comment:
APPENDIX B
NUCLEAR MEDICINE PROGRAM DIRECTOR NATIONAL SURVEY
School's Name____
Individual's Name
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Title________________________________
Please Circle the answer that best represents your philosophy in
terms of the projected In vitro laboratory manual.
Yes/No 1. Do current teHts, workbooks or laboratory manuals meet
the needs of your nuclear medicine students with 
respect to In Vitro procedures?
Yes/No 2. Do you believe an In Vitro nuclear medicine under­
graduate level laboratory manual is needed to properly 
train your students?
Yes/No 3. Does a laboratory In Vitro manual need to be written 
to meet this need?
Yes/No 4. Should such a manual provide both a discussion of 
theorical constructs and laboratory exercises for 
students?
Section 1: The following series of statements deal with components
of basic principle and theories to be discussed within 
laboratory manual. (Please write the appropriate 
numerical value in the space provided for each item 
mentioned.)
1. Must be part of: should be thoroughly discussed or reviewed
2. Must be part of: does not need thorough discussion
3. Should be part of: some aspects are vital to In Vitro education
4. Could be part of: nice to know
5. Is irrelevant
______ Elements of R.I.A., antibody - antigen reaction.
______ Growth, development, historical changes in In Vitro
laboratory technology.
______  Properties and methodologies of typical R.I.A. tests.
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______ Components of R.I.A. equations of equalibrium, chemical
properties, physiology.
______ Basic blood components and interferring substances.
______ Separation of free from bond techniques.
______ Calculations of results, assessment and evaluation of
resultant values
______ Evaluation of different techniques and kits.
______ Quality control on instrumentations, equipment in
laboratory.
______ Typical R.I.A. testing procedures.
______ Labeling of radioactive material.
______ Production and purification of labeled isotopes.
______ Preparation of patent samples - blood or urine.
______ Gamma well counters and liquid scintillation.
______ Alternative immune testing procedures, enzyme,
liminescency, gas spectroscopy.
______ Proper intravenous injection techniques.
______ Statistics and computer data presentations in R.I.A.
______ Blood volumes.
______ W.B.C. labeling.
______ R.B.C. survival.
______ B-12 absorption testing, schilling testing.
______ Iron recovery.
Please add any principle or theory not included in this list:
Section II: The rest of the data collection relates to the testing
procedures which need to be part of a successful 
nuclear medicine In Vitro laboratory manual. (Please 
write the appropriate numerical value in the space 
provided for each item mentioned.)
1. Must be part of: significant, thoroughly discussed or reviewed
2. Must be part of: but not have to be thoroughly discussed
144
2 . Should be part of: some aspects are vital to In Vitro educatio
4. Could be part of: but not vital to In Vitro education
5. Can be excluded from: In Vitro nuclear medicine manual
Thyroid
Blood volume
Iron recovery
Corticol
Testosterone
Estrodiol, estrone
CEA
Peptide
RBC survival
FSH
LSH
Insulin
TSH
PtH
WBC labeling 
(Fe) recovery 
Renin, aldosterone 
ACtH
Drug testing 
CEA 
I . G . E .
Monoclonal antibodies 
Norepinephrine 
Digoxin 
LH
TBG' S
Folic acid
Alpha feto protein
HCG
Vit. B -12 
Insulin
Schilling test 
Thyrotropin 
Creatine 
Aminoglycoside 
Gohadotropin
Angiostensin
Please add any other testing procedure that could enhance nuclear 
medicine In Vitro education.
I wish to have results reported to me.
nn
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Chapter 1
INTRODUCTION TO 
RADIOIMMUNOASSAY
Objectives
The student should
•  be able to understand the basic advantages of 
radioimmunoassay over other tests;
•  comprehend basic antigen-antibody reactions;
•  be able to identify the 4 basic steps in a R.I.A. reaction;
•  understand the purpose of RIA, including percent 
bound antigen concentration relationship;
•  define and describe standards, labeled antigen, ligands, 
cross-reactivity, haptens, antigen production;
•  describe a typical RIA exam, including controls;
•  be familiar with isotopes used, binders (Ab), titer, 
affinity, iodination;
•  give an example of basic RIA procedure;
•  understand the concept of non-competitive assay.
Introduction
Prior to 1960, certain substances in the blood and other body 
fluids were extremely difficult to measure. This was to soon 
change and a new world of medicine would soon flourish. Two 
researchers, Yalow and Berson, reported a method for the
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quantitative measurement of insulin in the bloodstream. The 
technique was known as “competitive binding assay”.
The technique they developed made use of an insulin binding 
protein using 1-131 and guinea pig antibodies.
Before “RIA”, substances in biological fluids were measured 
by chemical analysis or bioassay. These methods, however, 
lacked sensitivity, specificity, and accuracy. The methods 
were laborious, expensive and time consuming. Radioim­
munoassay techniques became widely used for measuring 
many substances, particularly hormones. Much of the 
progress in endocrinology during the past decade has oc­
curred because of the availability of RIA techniques.
In the 1970’s and 1980’s, much of the invitro laboratory pro­
cedures’ rapid growth and development were due to:
•  production of more and better antibodies;
•  different labeling techniques;
•  solid phase techniques;
•  new methodologies;
•  new instrumentation;
•  and more accurate data reduction protocols.
The advantages of RIA over other systems include greater 
sensitivity, accuracy, specificity, and precision. RIA is 
synonymous with these other terms in principle: “saturation 
analysis”, “competitive radioassay”, “competitive binding 
assay”, “displacement analysis”, and “radiosteroassay”.
RIA is based on the principle that antibodies are produced to 
specifically interact with foreign substances which enter the 
body. They are the main basis of the body’s immune system. 
RIA is based on the concept that certain substances to be 
measured, antigens, will react with these specific antibodies. 
This reaction is outlined as follows:
ki
Ag + Ab *' AgAb
k2
where ki represents the rate constant or association con­
stant, k2 represents the rate constant or dissociation con­
stant. At the start of the reaction with free Ag and free Ab,
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the rate of association is high (ki). Until the rate is equal in 
both directions, the reaction will continue until equilibrium 
is reached and no further changes in concentration will result. 
K can be demonstrated as follows:
AgAb = k (equilibrium or affinity concentration) 
[Ag][Ab]
Low concentrations of an antigen can be detected by deter­
mining the ability of these antigens to be bound by a specific 
antibody. Competition of a non-labeled hormone or antigen 
(Ag) with a radio-labeled antigens for the same binding sites 
on an antibody (Ab) causes a depression of the amount of 
bound, labeled material in the final solution.
(* radioactive Ag)
Ag *Ab
By studying a series of labeled antigens as standards, known 
amounts of unlabeled hormone (in unknown patient serum) 
can be measured because it offers similar competition with 
labeled hormone molecules for the antibody. In other words, 
the labeled and unlabeled antigens will compete equally.
The antigen to be measured is known as a “ligand”. The 
antibody is a gamma-globulin protein with receptor sites for 
the antigens. The radioactive tracer is known as a 
“radioligand”.
THE STEPS IN THE REACTION ARE AS FOLLOWS:
(*)labeled antigen
unlabeled antigen
antibodies
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[Stepi]
where both labeled and unlabeled antigens, again, are al­
lowed to interact with the antibody in solution. The result is 
two more substances, namely bound labeled antigen and 
bound unlabeled antigen.
[Step 2j
Incubation period - this time allows the process to reach 
equilibrium (the constants are equal).
[Step 3j
The separation of bound and free or unbound antigens.
[Step 4!
Determining the amount of radioactivity present using the 
appropriate instrumentation.
Adding4arger amounts of known quantities of the original 
antigen will result in the formation of less of the labeled 
bound. The excess unlabeled form competes successfully 
against the small amount of labeled antigen for the binding 
sites on the antibody.
After the free and bound substances are separated, the 
amount bound can be measured.
100
% bound 60
400 800 1200 1600
antigen or ligand 
concentration
This chart demonstrates the reaction principle that the greater 
the amount of ligand or patient antigen present, the lower the 
percent bound of the added radioactive antigen or ligand.
Antigens, in more detail, are specific types of ligands. Ligands 
may be purified from natural or synthetic materials and an 
ample supply of these purified ligands must be used to gain
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the desired reaction. One of the most important qualities of 
a ligand is that it be identical to the endogenous ligand being 
measured (the patient sample). If they are dissimilar, the 
assay’s specificity, sensitivity, and accuracy will be affected. 
The ligand is capable of stimulating an antibody response and 
must consist of the following properties:
© it must be foreign to the host;
® must have a molecular weight of 5000 or greater;
•  must be pure;
e and again, must be identical to the endogenous ligand.
Elements used in RIA reaction are incubated to allow the 
reaction to occur. The competition between labeled and 
unlabeled ligands is allowed to occur simultaneously until 
equilibrium is reached the ligands and the binder. This is 
known as “equilibrium saturation”. The sensitivity obtained 
by the RIA reactions as a whole depend somewhat on the 
specificity of the antibody as well as the antigenicity of the 
antigen, but depends primarily on the equilibrium constant or 
affinity constant. The higher the affinity, the greater the 
sensitivity of the antibody and the more rapid the attainment 
of equilibrium. The greater the affinity, the greater the con­
centration of antigen-antibody complex formed and the 
smaller the dissociation constant.
Separation of bound from free reactants once equilibrium is 
reached is determined by making use of the procedure which 
will give the greatest amount of separation with the least 
amount of effort, but in the meanwhile not sacrificing sen­
sitivity. Procedures such as gel filtration, chromatography, 
precipitation of the bound form (double antibody technique) 
and absorption of the free phase by charcoal are a few of the 
methods used. Regardless of the technique used, there 
should be no effect on the antigen-antibody reaction.
Determining the amount of radioactivity present is done by 
using gamma counters for traces of 1-125 and 1-131, for ex­
ample, and liquid scintillation is used for H-3 and C-14 and 
other beta emitting radionuclides. The radioactivity 
measured reflects the relative amount of radioactive bound 
fraction and radioactive unbound fraction. The results are 
usually reported as a dose-response curve.
The dilution of antiserum binding in a predetermined percent 
of tracer which is usually equal to the concentration to be used 
on the assay is called titer. The dilution is that amount which 
will bind 50% if the antigen.
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The term immunogen is used synonymously with the ligand. 
Also, the patient sample (antigen or ligand) can also be 
termed analyte.
Certain characteristics of the labeled antigen must also be 
present. It must be highly purified, it must be able to be 
radiolabeled without loss of immunoreactivity. Many an­
tigens are polypeptides which contain tyrosine residues that 
are fairly easy to label with iodine. Often 1-125 is used as the 
tracer, since a higher specific activity (act/mass) can be 
gained.
Antigens are produced from an antiserum. This antiserum is 
usually from guinea pigs or rabbits in sufficient amounts for 
RIA purposes. The actual antibody used in testing usually 
represents a high dilution of the original sera; the final dilu­
tion may be 1:1,000,000 and 1ml of the antiserum will suffice 
for 2,000,000 assays.
The labeled antigen can be labeled with not only 1-125, but 
also 1-131, C-14, H-3, P-32, Se-75, Fe-59, Co-57. These 
isotopes are several of the more historical substances. More 
widely used today is 1-125, though Co-57, Fe-59, Se-75, and 
H-3 may be used. The ideal radionuclide must conform to the 
following characteristics:
•  high abundance;
•  high counting efficiency;
•  moderately long half-life;
•  be bound easily to the antigen;
•  and consist of a low or negative radioactive risk.
The shorter the half-life and the greater the specific activity, 
the greater the sensitivity.
The tagging process as performed by the manufacturers of the 
“kits,, are done by several methods. When labeling with H-3, 
this process is completed via invivo or invitro H-3-lab precur­
sors, neutron activation, chemical synthesis, and the Wilzbach 
technique (an exchange reaction where H-3 is substituted for 
stable H on the molecule).
The iodination of an antigen is accomplished directly or in­
directly by conjugation of a prelabeled tyrosine molecule to 
an antigen. The 1-125 is substituted for H in the aromatic 
chain of tyrosine residues by conversion of unreactive I- to a 
highly reactive I + state.
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For large protein molecules, direct labeling is usually not a 
problem since they contain a tyrosine residue. The amount 
of labeling depends on the specific activity of iodine or the 
number and location of tyrosine residues.
The most popular method of iodination is called the 
“chloramine-T” method. It is useful in the iodination of 
peptides and proteins. Chloramine-T is found to oxidize I- 
125-labeled Nal for reactions with tyrosine residues.
Conjugation labeling makes use of haptens or bridges. First 
coupling of iodine to a carrier molecule is followed by con­
jugation to an antigen by the hapten. Conjugation labeling is 
successful for several reasons:
•  it does not expose the ligand to chemical damage;
•  it can be applied to ligand without tyrosine residues;
•  and it is a simple procedure.
Quality assurance regarding these radiolabeled ligands or 
antigens include:
•  radiochemical purity—chromatography is used to 
check the maximum binding or nonspecific binding;
•  immunoreactivity—checked by the use of excess 
antibody and a small amount of labeled ligand (if a 
significant amount of label does not bind it denotes 
nonimmunoreactivity);
•  specific activity—measurement of the curves 
containing radioactive isotope/weight of both labeled 
and unlabeled ligand—the degree of specific activity 
can affect assay sensitivity;
•  stability—this category includes half-life, storage, 
chemical breakdown, and loss of immunoreactivity.
The stability of the antigen used as the standard is particularly 
important because they are used in assays over a long period 
of time. Of importance in the maintenance of stability is an 
awareness of interfering substances. These substances may 
prevent nonidentity of the standard and include urea, heparin, 
bilirubin, buffers, and the effects of temperature and pH.
There are three types of binders common in RIA. They are 
the antibody, circulating binding protein, and cell receptors.
The most important characteristics of binders include affinity 
capabilities, specificity, and availability.
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The antibody, again, is an immunoglobulin produced in 
response to an antigen or immunogen. The proteins are 
categorized as albumin, alpha, beta, or gamma globulin. 
There are five distinct classes of globulins, all of which have a 
common structure but a different function. They are known 
as IgG, IgA, IgD, and IgE. The IgE, for example, is respon­
sible for allergic reactions, while IgM is present at the onset 
and eventually disappears. Specificity of the antibody for an 
antigen interaction is influenced by the heterogeneity of an­
tibodies for the same antigen; that is, the cross-reactivity for 
similar substances. The RIA system depends on the Ag-Ab 
reaction and not upon the biological activity of the antigen or 
ligand. A specific concentration of the antibody must be used, 
and the dilutionis often chosen which will be sufficient to bind 
50% of the labeled antigen, with the resultant bound to free 
ration (B/F) being 1:1.
Certain substances, called haptens, are used in the production 
of antibodies for use in RIA. They are relatively small 
molecules unable to initiate an antibody response by themsel­
ves, but which can combine with larger molecules to produce 
an antibody response.
Polyclonal antibodies are produced in response to a variety of 
antigenic determinants on an immugen which is injected into 
an animal. Each antigenic determinate produces an antibody 
with its own affinity and specificity. This is the antiserum. 
Small amounts of immunogen are used at regular intervals 
and booster shots are given. The immunogen must be as pure 
as possible and given in a combination of mycobacteria, 
minerals, and emulsifiers that enhance the immune response 
and allows for slow absorption into the system, known as 
Freud’s adjuvant. The route of administration is usually 
subcutaneous and the selection of host animal depends on a 
variety of variables: volume of antisera needed, foreignness 
of the immunogen and the availability of the animal. After 
the booster injections are given, usually every 6-8 weeks, the 
antiserum gained is purified.
The antibody gained is a fairly specific three dimensional 
configuration. Certain portions of the molecule are exposed 
or are available to react with other molecules, known as the 
lock and key phenomenon. Cross-reactivity becomes impor­
tant at this point; the antibody may have a low avidity for the 
antigen resulting in the inability to discriminate different 
antigens because of their structural similarities. The greater
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the specificity of an antibody, the less likely the chances of 
cross-reactivity.
Binding proteins, the second type of binder mentioned, are 
used in assays for thyroid hormones, cortisol, estrogens, and 
progesterone. The disadvantages of binding proteins are:
•  a low affinity constant (less sensitive);
•  poor specificity;
•  temperature dependency;
•  and high concentration of binder.
Cell receptors, the third type of binder, are important when 
dealing with protein hormones. The effects of many protein 
hormones are exerted by first coupling specific receptor sites 
on cell membranes. The receptor activity measured ultimate­
ly becomes a measurement of biologic activity. Difficulties 
arise due to:
•  diverse tissue;
•  low concentration present;
•  unstableness;
•  and can be easily damaged.
Because of the reasons stated above, antibodies remain the 
major choice of binders available.
The ideal competitive radioassay should consist of the follow­
ing criteria:
•  nonradioactive and radioactive ligands or antigens 
should be chemically and immunologically 
indistinguishable;
•  the reaction should continue until equilibrium is 
reached (ki=k2);
•  antigen and antibody binding sites should react in a 1:1 
ratio;
® the antibody should be specific for a single antigen;
•  the amount of antigen should be in excess of the 
antibody;
•  and antibody binding sites should be independent of 
one another.
In review, the purpose of binding assays is to determine the 
concentration of the antigen in patient serum or plasma or 
other body fluids. Tb perform this function, a dose response
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curve must be constructed using serial dilutions of a known 
standard, known as a standard curve.
For an example of a typical RIA procedure see laboratory 
exercise section.
In non-competitive assays, the antibody is usually labeled 
instead of the ligand. This method is particular useful when 
the ligand cannot be easily labeled, as is the case with 
hepatitis-associated antigen or other viruses.
The receptor preparation is incubated with the sample con­
taining the ligand to be assayed until all ligand present is 
bound to the receptor. Now, a second set of receptors is 
added, which are soluble but have a radioactive tracer labeled 
to their outer end. The radioreceptor adheres to any bound 
ligand present in the sample.
The ligand must be sufficiently large to have two or more 
molecular regions that can act as combining sites (divalent or 
polyvalent). Following the incubation with radioactive recep­
tors, the matrix is washed and all non-bound radioactivity is 
removed.
The radioactivity remaining bound to the matrix is now 
measured. The activity bound to the solid phase is propor­
tional to the amount of non-radioactive ligand present:
% bound
ligand
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REVIEW
Section 1
1-10 Matching
__  1. pt. sample a.
__ 2. antigen b.
__  3. affinity c.
__  4. accuracy d.
__  5. ligand e.
__  6. precision f
__ 7. sensitivity 8•
__  8. specificity h.
__  9. standard i.
  10. equilibrium /
in RIA it is considered the incuba­
tion period
minimum quantity detectable 
capacity to discriminate (Ag)
reference tubes that react withAb 
similarly to patient sample 
the substance that is bound 
the substance capable of inducing 
formation of (Ab) 
repeatability of measured quantity
closeness to true or real value 
substance that is interpolated into 
standard curve 
k. substance that is not immugenic it­
self
Section 2
VERY briefly describe or explain the following questions:
1. List and describe the 4 basic procedural steps in any RIA 
test.
a.
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C .
d.
Section 3
Multiple Choice
1. RIA has become a widely used technique for measuring 
many substances because .
a. high specific activity
b. wide range of isotopes available
c. ability to detect small quantities
d. very fast process (less than 15 min.)
e. all of the above
2. Antibodies are .
a. receptor sites
b. usually gamma-globulin protein
c. bivalent or polyvalent molecules
d. all of the above
3. Competitive protein binding is inversely related to ligand 
present, why?
a. the titer is at 75% dilution
b. Ab receptor sites are saturated
c. *Ag, Ag (pt. sample) compete for binding sites on 
Ab
d. only the Ag (pt.) is labeled and can be measured
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4. The principle of radioimmunoassay is based upon the fact 
that .
a. both labeled and unlabeled antigens will combine to 
form a measurable entity
b. only labeled antibody and labeled antigen will com­
bine to form a measurable entity
c. only unlabeled antigen will compete with the 
labeled antibody to form a measurable entity
d. both labeled and unlabeled antigen will compete 
with a known amount of antibody to form a 
measurable entity
5. The term radioimmunoassay is synonymous with .
a. saturation analysis
b. competitive-binding analysis
c. displacement analysis
d. all of the above
e. a and c only
6. In general, the basic components of an RIA reaction are_
a. labeled antibody, unlabeled antigen
b. antibody, labeled antigen
c. antibody, labeled antigen, unlabeled antigen
d. labeled antibody, unlabeled antibody, antigen
7. Which one doesn’t belong: haptens are substances
a. foreign in origin
b. sm. molecules
c. can induce Ab formation
d. linked to larger molecule
8. The isotope most commonly used in RIA procedures is
a. 1-131
b. C-14
c. H-3
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d. 1-125
9. Antiserum used to produce (Ab) in RIA .
a. come from sm. animals such as guinea pigs and rab­
bits
b. used in a final dilution of 1:1,000,000
c. used in a final dilution of 1:500
d. a and b
e. a and c
10. The titer of the antibody is a term which refers most 
specifically to  .
a. avidity
b. affinity
c. concentration
d. stability
11. An example of non-competitive assays is_____ .
a. digoxin
b. T-7
c. HCG-B
d. hepatitis (virus)
e. a and b only
12. Non-competitive binding is different than competitive 
because .
a. radioactivity is labeled to Ab
b. radioactivity to bound ratio is 1/2
c. radioactivity labeling is to Ag
d. a and b
13. In non-competitive binding the ligand is  .
a. directly related to % bound
b. indirectly related to bound
c. inversely related to amt. of counts recorded
d. dependent if its solid phase
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14. In order for (Ag) to induce (Ab) it must be of foreign 
origin and relatively high molecular weight.
a. true
b. false
K 1
15. Ligand + Ab ----- ► LI + Ab - K1 is
K2
a. overall rate of reaction
b. association constant
c. dissociation constant
d. dependent on amount of tyrosol residues
16. In a competitive binding radioassay, competition exists 
between .
a. a ligand and an antigen
b. an antigen and an antibody
c. a ligand and a radiolabeled ligand
d. a ligand and an analyte
17. After the ligand, radioligand, and binder are given time 
to equilibrate .
a. the radiolabeled ligand must be separated from the 
binder
b. the radiolabeled ligand must be separated from the 
nonbinder
c. the bound ligands must be separated from the free 
ligands
d. all of the above
Section 4
T o r F
  1. A hapten is defined as the substance to be bound.
  2  In a competitive assay between Ag and Ab the
greater the amount of ligand or patient antigen 
present, the lower the percent bound.
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  3. Patient (Ag) or ligand must be identical to other
(Ag) and have a molecular weight o f500.
  4. The measure of the strength of the bound antigen is
called affinity.
  5. In non-competitive assays such as hepatitis-as­
sociated antigen or other virus, the labeled molecule 
could be either theAg or Ab.
  6. Inproducing antiserum, freud’s adjuvant is used to
enhance the immune response and allow for slow ab­
sorption into the animal’s system.
  7. In non-competitive assays, the antibody or the an­
tigen are labeled as count rates increase and con­
centration decreases.
Chapter 2
ASSAY CHARACTERISTICS AND 
PROCEDURAL EVALUATION
Objectives
•  Understand the uses and meanings of: total counts 
tubes, blank tubes, standards and controls.
•  Be able to describe the differences between pooled and 
commercial serum sources of controls.
•  Develop a working knowledge and purpose of the 
College of American Pathologists, American College 
of Nuclear Physicians, and the ‘Center for Disease 
Control.
•  Be able to define accuracy, sensitivity and specificity 
and how they are measured in RIA testing procedures.
•  Describe other considerations to be considered when 
evaluating testing procedures.
Assay Characteristics
The following is a discussion of the components of a typical 
RIA test and their function in determining final resultant 
values.
Total Activity or Total Counts TUbes
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Usually the first tubes utilized in any test. These tubes contain 
only the radioactive tracer and are used as a comparison to all 
other tubes.
Blank TUbes - 2 Types:
•  Standard “O” Tubes
•  NSB-Non-Specific Binding Tubes
Blanks: Blanks, or solutions containing only portions of the 
assay system, are often necessary in the assay. An antibody 
blank contains labeled ligand (Ag*), antibody, and antigen- 
free serum. Its use allows assessment of the antibody - labeled 
antigen interaction as well as the efficiency of the separation 
step. A second blank consisting of labeled ligand and antigen- 
free serum (without antibody or unlabeled ligand) gives infor­
mation about the non-specific precipitation of labeled 
hormone and the trapping of “free” ligand in the bound 
fraction.
Standards or Calibrators
Known amounts of different concentrations used to analyze 
and compare with pt. unknowns and controls.
The purposes of standards are 1) to establish a curve of 
dilutions on known amounts of substances to which the un­
knowns may be compared, 2) to ensure a stable interassay 
comparison, and 3) to compare the results obtained with other 
laboratories or established quantities in other assay systems.
Controls
A control may be a standard or any known concentration of 
test material that serves as a comparison between successive 
runs (inter-assay), whereas the usual standard involves vary­
ing concentration used to evaluate individual samples within 
a single run (intra-assay). Controls may vary in concentration 
ranges so that high, medium, and low ranges are covered. 
Controls and standards are solutions that contain known 
amounts of material, but their end uses may differ.
The manufacturers recommend levels of control Sera for each 
different type of RIA assay. This is commonly referred to as 
target values.
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These controls are used as a means of setting individual 
precision limits of reproducibility from day to day on specific 
tests being performed.
Sources of Control 
•  Pooled Serum—Manufacturers may send a laboratory 
a serum containing many different Ag (Antigen) which 
are to be used for numerous RIA assay procedures, 
e Commercial—A serum containing only one specific 
type of control assay.
External Surveys used as control measures for laboratory 
assay quality control.
College of American Pathologists and the American College 
of Nuclear Physicians help laboratories establish and main­
tain quality control. JCAH of hospital may waive a formal 
evaluation of an RIA if they are accredited by either organiza­
tion.
The laboratory receives monthly unknown control serum 
from these bodies and reported their results quarterly. A 
composite answer from all reference labs that comply will 
provide verifiable information pertaining to controls used.
If the laboratory is significantly off composite control answer, 
they will have to document corrective actions to alleviate the 
problem.
Center for Disease Control
can be utilized as stop-gap for new procedures or new kits. 
Example: Can provide positive (negative) serum samples for 
new AIDS tests on the market.
Pt. Unknown Sample
These are the serum from the patient. One wants to find their 
actual value of antigen in body. These values are determined 
by interpolating counts from patient test tubes and comparing 
them with counts of known standard values of concentration.
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Procedure Evaluation and Validation
Accuracy
Closeness to true or real value
In our RIA tests the true values are the standards or calibrators 
provided to labs by the manufacturer of these kits.
These reference standards are weighted and measured by the 
National Board of Standards which defines what calibrators 
are acceptable and will be allowed to be used.
The National Institutes of Health and the World Health Or­
ganization manufactures some standards that are used as 
reference standards. Kits produced by RIA manufacturers 
need to meet the criteria and specifications set up by one of 
these bodies.
Recovery Studies
When a manufacturer sends a laboratory a known amount of 
an antigen or reagent. The RIA lab does not know the true 
value and must test for the amount of antigen and recover the 
quantity. They then send in their analysis to the manufacturer 
to see how close they were to the “true value.”
Precision
Degree of agreement of repeated measurement of a quantity 
or “reproducibility.” Two types:
•  Within Assay R un-In any particular RIA test, all 
reagents are run in duplicate tubes. A coefficient of 
variance value of less than 10% is acceptable.
•  Between Assay Runs—A comparison of standard curve 
from one assay run to another. Secondly, a cumulative 
data collection of all high, medium and low controls run 
on that type of assay.
Sensitivity
Minimum quantity detectable
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The manufacturer in his packet insert will describe and 
analyze the smallest value that can be accurately interpreted 
and reported out for a particular assay. This is usually 
described in terms of some value (B) compared to the stand­
ard “O” value (Bo) - B/Bo.
Specificity
Capacity to discriminate antigens of similar structure Can be 
described and analyzed in terms of:
•  Dilutional Parallelism—when a laboratory dilutes the 
pt. samples and attempts to see if and/or where the ratio 
of resultant values changes significantly.
Cts
Example: Dilution 1:1 - 10,000
1:2 -will cts be cut in half?
1:3 - will cts be cut by one-third?
1:4 - will cts be reduced by one-fourth?
•  Cross Reactivity—asks the question: What other 
similarly structured antigens will interfer with analysis 
of a given assay?
•  Non-Specific Binding—NSB tubes when labeled 
ligand (Ag*) and antigen-free serum (without antibody 
or unlabeled ligand) are put together in the same test 
tubes. The lab is looking for information about the 
non-specific precipitation of labeled hormone and the 
trapping of “free” ligand in the bound fraction.
Other Considerations when evaluating procedures include:
•  Cost—Is it too expensive to run this kit in your 
laboratory?
•  Personnel Time—Do you have the workers that have 
sufficient time to run this testing procedure?
•  Equipment Required—Do you have all the necessary 
materials available?
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•  Manufacturers—Are they reliable, established, 
reputable?
•  Service—Can they supply the kits and materials 
needed?
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REVIEW
Section 1
1. Discuss the purpose of:
a. Recovery study -
b. Dilutional parallelism -
c. Cross-reactivity -
2. Explain why these components are utilized in an RIA test.
a. Tbtal counts tubes____________________________
b. Blanks______________________________________
c. Standards___________________________________
d. Controls____________________________________
e. Pt. unknown________________________________
Section 2
1. The property of antisera whereby antibodies react with two 
or more antigens of similar structure and which reduces the 
specificity of the assay is known as
a. sensitivity
b. cross-reactivity
c. avidity
d. antigenicity
2. Controls need to
a. be part of standard curves
b. set laboratory acceptable levels of reproducibility
c. be able to induce formation of (Ab) or (Ag)
d. all of the above
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3. Cross-reactivity results from some (Ab) molecules low 
avidity for (Ag) and being unable to discriminate between 
different (Ag) because of their structural similarities.
a. True
b. False
4. Cross-reactivity is
a. not desirable in RIA
b. similar to haptens
c. used as reference standards
d. all of the above
5. When running a standard RIA test, what goes into the 
total count tubes?
a. standard O only
b. tracer and Ag-free serum
c. tracer and standard O
d. tracer only
Section 3
SftrSSSSSSS&SS
TorF
  1. The total cts tubes are the second blank tubes con­
sisting of labeled ligand and antigen-free serum.
  2. Calibrators can be used to ensure a stable inter­
assay comparison and compare results obtained with 
other laboratories.
  3. Two sources for control are the pooled serum and
the Center for Disease Control.
  4. The College of American Pathologists work as a
stop-gap for new procedures or new kits. (Example: 
provide positives for new AIDS tests)
  5. A  precision test within assay run is a comparison of
standard curves from one assay run to another.
  6. Sensitivity can be analyzed by comparing some
valve (b) to the standard “O” valve.
  7. Non-specific binding is analyzed by using dilutional
parallelism.
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8. Cross-reactivity is when similar structures interfere 
with analysis of a given assay.
9. Non-specific binding are test tubes that have only 
labeled Ag and antibody.
10. Most hospitals using RIA procedures send their 
results to the National Institute of Health for evalua­
tion.
.11. Precision is the capacity ofAg to discriminate.
.12. Affinity is closeness to true value.
13. In most testing procedures, the order of analysis of 
test tubes is unimportant as long as the technologist 
knows which is which.
.14. Controls are used to establish a curve of dilutions 
on known amounts of substances to which the un­
knowns may be compared.
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Chapters
SEPARATION TECHNIQUES IN RIA
Objectives
•  Understand the overall purpose and usefulness of any 
separation technique.
•  Demonstrate a knowledge and understanding of the 
purpose and methodology of:
° the absorption technique
° non-specific precipitation
° immunoabsorbent technique
° sandwich technique
° double antibody technique
0 magnetic separation method
•  Be able to recall the uses of electrophoretic method 
and gel filtration separation techniques.
Separation Methods in Radioimmunoassay
There are two basic methods of isotopic dilution performed 
in the presence of specific binding agents. Radioimmunoas­
say utilizes techniques that employ the principle of isotopic 
dilution of labeled antigens and unlabeled antigens in the 
presence of specific antibodies, with the desired end being the 
separation of bound, labeled ligand (Ag) from the unbound, 
free, labeled ligan (Ag). Radioassay utilizes specific binding 
proteins instead of specific antibodies.
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The selection of a suitable separation procedure is based upon 
the properties of the antigen and nature of the biological 
material to be assayed. Successful separation techniques 
should be rapid, inexpensive and simple. Also, common 
available reagents should be used and there should be a 
minimal margin for error in the procedure.
There are a number of separation techniques available, each 
of which is discussed in the following paragraphs:
Absorption Techniques are based on the removal of the un­
bound, labeled ligand (Ag) from the system after the con­
clusion of the reaction. Many physical and chemical factors 
determining the absorption, including size, charge of antigen, 
cimposition and concentration of other proteins present pH 
and ionic strength of the solution. The advantage of this 
technique is the reduction of the concentration of free an­
tigens to zero very quickly, thus eliminating kinetic influences 
that would cause dissociation of the complex.
Some common absorbents are charcoal, talc, and silicates. A  
common characteristic shared by all of the absorbents is rapid 
binding of unbound Ag/*Ag. Silicates specifically are of value 
because of their ability to absorb peptide hormones. Silicates 
with high silica content are added to the incubation period or 
phase. The absorption is rapid and centrifugation is simple, 
the end result of centrifugation being the packing of silica on 
the bottom of the test tube.
(add
silica supern­
atant+ Ag
Ab fuge) counted
bound Ag is absorbedSample Incubate
to the surface of the
added silica
Ab
Ab
Ag Ag* Ag
Ag*—Ab
Ag — Ab
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Separation of bound from free labeled Ag is the process 
known as the Electrophoretic Method. This method uses 
differential migration in an electric field to accomplish the 
separation of labeled Ag from the Ag-Ab complex.
Chromatoelectrophoresis depends initially on placing a 
sample containing 1) undamaged, free hormone, 2) bound 
hormone, and 3) damaged hormone on a paper strip that 
demonstrates selective preference for the absorbent of the 
labeled, undamaged hormone.
The labeled, undamaged hormone is returned at the origin, 
while other components migrate under the influence of buffer 
flow of evaporation and the electric field on the strip. The 
entire process, though, has some major disadvantages: it is 
too complex and time consuming, needs a high voltage, and 
must be performed under cold temperatures.
Non-Specific Precipitation is based on the principle that at 
critical concentration of inorganic salt or organic liquid, the 
Ab (globulins) become insoluble, while free Ag remains in 
solution. The procedure precipitates all Ab present including 
labeled Ag and Ab attached.
Separation of both free fraction of labeled Ag and bound can 
be achieved by filtration or centrifugation.
Ag*
Ag
A g-A b  
Ag*—Ab
either
(^NK.feSa,
ethanol
centrifuge
Ag*—Ab
unboundA g-A b
Patient/
Standard Incubation 
(or equilibrium)
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What does precipitated mean? It means to cause a substance 
to settle (heavier particles) in solid particles.
Gel Filtration, another separation technique, separates 
materials according to size by the elution of these materials 
through beds of porous beads. The adjustment of various 
sizes and types of molecules can be done by correcting the 
pore size distribution of the beads.
The incubated mixture can pass through the column in such a 
way that the bound portion of the Ag-Ab complex is eluted, 
leaving the unbound Ag in the resin.
The immunoabsorbent technique is similar to the solid phase 
technique; the test tubes are manufactured labeled with Ab. 
In the immunoabsorbent technique, an insoluble polymer is 
coupled to an Ag binding agent. A polymer is a compound of 
high molecular weight derived either by a combination of 
smaller molecules or by condensation of small molecules 
(eliminating the OH- molecule).
x =
un labeled 
antigen
coated
disc
tube
Longer
Incubation
/  "X Ag*
Ag
X Incubate Ag
Ag ---- ►X Ag*
Ag
X AbAb
add Ig *
* Ag*Ag
Ag*Ab
4 disc is 
removed 
& counted
% bound
Ag ligand concentration 
(High count rates reflect low unlabeled Ag concentration.)
The Ab is absorbed on polyethylene or polypropylene tubes.
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Another useful method is known as the Sandwich Technique 
and is used for the detection of hepatitis B and viruses. A 
plastic tube is pre-coated with a specific antibody. A standard 
or unknown sample is added to the Ab coated tubes and 
allowed to incubate. If the antigen is present, it will react with 
the specific antibody sites. After incubation, the labeled Ag 
is added and is followed by a second incubation. The tubes 
are then washed and counted and any unbound radioactivity 
is washed away. This is an example of a noncompetitive 
binding assay.
Ab
Ab
+ Ab*incubate A b-A g
Ab
A b-A g
add
radioacti'
antibodi
Ab
A b-A g
Ab
Ab-coated
tube standard 
& patient A b-A g-A b*
Ag concentration 
increases, final count 
rate will increase. A b-A g-A b*
Ab
% bound
Ag
(Direct relationship in the noncompetitive binding assay)
The Double Antibody Technique utilizes a second Ab to 
precipitate the initially formed Ag-Ab complex.
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Ag Ab-Ag Ag-Abi-Ab2
Abi + Ag* Ab-Ag Ab2 Ag*-Abi-Ab2
Ag A g-A g
specific Ab
competitive 
binding assay
double antibody 
separation
The second antibody is capable of recognizing the antigenic 
sites on the first antibody molecule (Abi).
Abi-from a small animal such as a guinea pig or rabbit
Ab2-from a large animal; uses preparation of immuno-globulin 
against those of the small animals
The advantage of the double antibody technique is in its 
effective separation of free from bound hormone. This tech­
nique differs from non-specific separation in that there is little 
precipitation of the free, unbound, labeled Ag in the Ag-Abi- 
Ab2 complex.
The Magnetic Separation Method also utilizes two an­
tibodies, as well as polymer beads with the capability of being 
magnetized. When a magnetic field is introduced, separation 
can begin. Antibody A is bound to the Antibody B (which is 
attached to the beads), and it is this process which allows the 
separation of free and bound Ag to take place. The beads 
move to the bottom when the magnetic field is applied.
The advantages of this process are reduced incubation 
periods, centrifugation is not longer needed, and it is simple.
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REVIEW
Section 1
1. Briefly describe these RIA separation techniques 
(choose only 3 out of 5):
a. Absorption technique:
b. Non-specific precipitation:
c. Immunoabsorbent:
d. Double antibody technique:
e. Magnetic separation technique:
2. From one (1) of the above, draw out the process and dis 
cuss each aspect. Is this technique competitive or non-com­
petitive and why?
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Section 2
wsmmms
TorF
_  1. During non-specific precipitation, the bound por­
tion is on the bottom of the tubes.
_  2. In non-specific precipitation, the principle that at
critical concentrations of inorganic salt or organic liq­
uid the (Ab) concentration becomes insoluble while 
(Ag) remains in solution.
  3. The absorption technique utilizes a paper strip that
demonstrates selective preference for the absorbent of 
the labeled.
  4. In non-specific precipitation the unbound Ag is on
the bottom of the test tube after separation.
  5. The magnetic separation method utilizes a double
antibody technique.
Section 3
mmmmsmsmimmma
Multiple Choice
1. When the final product after separation is Ab-Ag-Ab* 
and there is a direct relationship between counts and an­
tigen, the separation technique used was
a. double antibody
b. immunoabsorbent
c. sandwich
d. magnetic
2. A technique that utilizes a polymer, removes a disc to 
count, and is an indirect measurement of antigen is
a. sandwich
b. absorbent
c. double antibody
d. immunoabsorbent
3. In the absorption technique, the most common 
material used is
a. polypropylene
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b. (NH4)2S04
c. silicates
d. peptide proteins
4. Which does not belong? Selection of suitable separa­
tion procedure is based upon
a. being rapid
b. inexpensive
c. fairly simple
d. commonly available reagents
e. none of the above
5 .  is absorbed to the surface of the added silica
material.
a. Unbound Ab
b. Radioactive Ag
c. Radioactive Ab
d. Unbound Ag
6. The sandwich technique is used for
a. detection of hepatitis B antigens
b. non-competitive binding
c. Ab coated tubes
d. all of the above
7. Chromatoelectrophoresis, solid-phase, double-antibody 
immunoprecipitation, filtration, and centrifugation are all 
methods used to
a. iodinate the labeled antigen
b. separate bound from free antigen
c. purify the labeled antigen
d. produce antibodies for use in the assay
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Chapter 4
STATISTICS IN IN VITRO 
LABORATORY TESTING
Objectives
Know the meaning and uses of:
•  the mean
•  frequency distribution
•  normal distribution
•  median
•  mode
•  range
•  standard deviation
•  percent error
•  confidence intervals
•  normal ranges
•  fitting the standard curve
Statistics Needed
Invitro RIA tests depend upon statistics principles very heavi­
ly. Some important questions that need to be considered are:
•  How long should a sample be counted?
•  What do you do with a sample with low count rates and 
high background counts?
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•  When is the quality of results compromised?
•  How do we know the instruments are accurate and 
reliable?
•  How long can we use a test kit without compromising 
our test results?
Central Tendencies 
Mean: the sum of all numbers 
number of items
Frequency distribution: examination of all the different in­
dividual counts
Normal distribution: resembles a bell-shaped curve, where 
the majority of counts are clustered in the middle
Median: middle point
Mode: most frequent occurring value
M easure of Dispersion
Range: difference between largest minus the smallest
Standard deviation:
,(y7)2
n-1
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Fitting the Standard Curve
The standard curve is estimating point value samples of 
known concentration of the material under study. Then 
under conditions identical to those used by patient samples 
from known results, curves can be constructed that allow 
estimateion of patient values. The patient values are called 
interpolated into the actual known standards.
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The Use of the Normal Distribution
Example of its u se  in statistics:
Number of Cts (1SD)68% Range Percent Error
100 + 10 90-110 10%
1.000 + 32 968-1,032 + 3.2%
10.000 +100 9,900-10,100 1.0%
100.000 +317 99,683-100,317 + 0.3%
In routine N.M., the decision must be made how many cts. be 
accumulated to have reasonable confidence that cts. within 
acceptable degree of error.
95% confident - within + 2% error
10,000 cts. - represent 68% chance of 1% error
2SD = 95% 3SD = 99%
2SD range percent error
+ 200 9,800-10,200 +"235
Regardless of time required, 10,000 cts. should always be 
accumulated.
Relationship between number of cts, recent errors, and 
desired confidence level:
V = % error 68% confidence N = 10,000 N = #  of cts.
V*
95% confidence N = 40,000 V 2  
99% confidence N = 90,000 V 2  
68% - preliminary studies 
95% - routine studies 
99% - research studies
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Suppose: We wanted to know + 1% error or 99% confidence. 
How many cts. would be needed?
(n) =  90,000 X (1)2 =  90,000 cts.
95%, 2% error
(n) =  40,000 x(2)2 =  10,000 Cts
As the number of cts. (n) collected increases , the relative 
percent error decreases.
Error: The deviation of an observed value from the from 
absolute or true value:
•  Determinate errors - equipment malfunction
•  Indeterminate or random errors - operator has no 
control
(See lab exercises on normal distributant percent error)
Quality Control and Normal Ranges
The results obtained in any type of lab must be valid. Proved 
Q.C. measures should be routinely used in order to ensure 
valid results.
Q.C.: Any and all measures taken to ensure a valid result. 
Precision, accuracy, reproducibility, standard 
controls, sensitivity, specificity
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REVIEW
Section 1
Based on the following set of count rates, find the mean, 
median, mode, 1SD, 2SD, 3SD
1. 10,352
2. 9,681
3. 10,945
4. 11,842
5. 10,369
6. 9,677
7. 10,001
8. 10,356
9. 10,945
10. 10,258
Section 2
Multiple Choice
1. TTie minimum number of counts for any sample testing 
in nuclear medicine is
a. 5,000 cts./min
b. 10,000 cts./min
c. 10,000 cts. regardless of the time required
d. depends upon the amount of efficiency one desires
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d. depends upon the amount of efficiency one desires
2. The number of counts needed in routine studies can be 
derived from
a. N = 10,000/V squared
b. N =  40,000/V squared
c. N = 90,000/V squared
d. depends upon type of scan one is performing
3. If a technologist is receiving 900/ct./sec on a patient for 
a spleen scan, how long must he count to be + or - 2% 
error: _____ .
4. As the number of counts in any test increases,
a. the relative percent error increases
b. the relative percent error decreases
c. percent error will not change
5. If a test is performed in nuclear medicine department 
with 5,000 ct./sec., how long must the test take in order to 
be 95% confident and + or - 2% error:
a. 20 seconds
b. 2 minutes
c. 2 seconds
d. 5,000 of x 200 seconds
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Chapter 5
BASIC IN VITRO EQUIPMENT AND 
DETECTION INSTRUMENTATION
Objectives
•  Have a working knowledge of pipettes, vortexers, 
centrifuges, refrigerator, timers, test tubes, and 
incubators in a RIA laboratory setting.
•  Know the basic principles and concepts of a gamma 
well counter and a liquid scintillator, including their 
applications and purposes.
•  Understand the counting of iodine 1-125 and its many 
inherent problems.
•  Demonstrate knowledge and understanding of the 
various components of gamma scintillation detection 
and liquid scintillation.
Basic In Vitro Equipment
•SK3S8383&KS3SSS83
Pipettes
A device which no RIA laboratory can do without is the 
pipette. Pipettes are used to withdraw specific quantities of 
solution, as a sample or ingredient of an RIA kit. Pipettes are 
available in various sizes and volumes or they may be 
equipped with a control which can be set to control the 
amount of solution to be collected. The tips of the pipettes 
also vary in size and are usually made of glass or plastic, and
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most are disposable. Most of these devices are semi­
automatic; that is, they are operated by pushing a (button) at 
the top of the pipette while in solution and releasing to 
remove the pipette. The tip is then placed into the desired 
tube and the (button) pushed again to release the solution. 
Pipettes are also available which have rubber suction devices 
or designed so that the user must use mouth suction, but this 
kind is not appropriate for collecting samples or radioactive 
materials due to the inherent danger of swallowing or trans­
ferring contaminated solutions. Automatic pipettes are also 
used in those laboratories which do large quantities of tests.
Vortexers
Since most tests require the mixing of samples and reagents, 
electronic instruments called vortexers have become indis­
pensable. The test tubes can be placed in the vortexer for a 
predetermined time (some require that the tube be held at 
the top until the mixing is done) to assure adequate agitation 
and to increase the chances of component interaction.
Centrifuges
The centrifuge is used for the separation of elements, namely 
the supernate and precipitate. The tubes are placed in the 
centrifuge, being careful to balance the weight from side to 
side so as not to cause uncontrolled vibration of the instru­
ment. Care must also be taken to control the time, tempera­
ture (if possible; some centrifuges do not have this capability), 
and speed inside. Its principle is based on that of centrifugal 
force, with the heavier elements ultimately ending up at the 
bottom and the lighter elements on top. Most will have 
controls which the operator can set to a desired number of 
revolutions per second or minute.
Refrigerators
Refrigeration is essential for the storage of certain kits which 
require temperatures below normal room environment in 
order to maintain their stability. Certain samples, such as 
blood, also require refrigeration to keep them fresh and 
usable for a longer period of time. These refrigerators must 
be lead-lined (due to the radioactive materials being stored 
inside) and should have the capability of being locked for
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safety and protection. Thermometers should also be easily 
accessible and monitored to avoid the costly destruction of 
samples and kits.
mmmsssm
Timers
The use of timers may be necessary in some laboratories 
should some instruments not contain one. Devices such as 
vortexers and centrifuges may already have timers; but should 
they not or this component is malfunctioning, a timer would 
be essential.
Test Tubes
Test tubes come in various sizes and materials. Plastic tubes 
are lighter in weight, basically non-destructible, and are less 
expensive than glass since disposability can be important. 
Test tube holders and racks are also available in various sizes, 
materials, and capacities. Tubes and racks should be able to 
be identified easily and/or labeled appropriate (by using an 
easily removable maker if nondisposable, for example).
mmzsimmmss
Incubators
An incubator is used should the test tube require a constant 
temperature.
|In Vitro Detection Instrumentation
•  Gamma well counters
•  Liquid scintillation
Primary strength of RIA is its ability to measure extremely 
small quantities of material because of the presence of 
radioactivity. Radiation means spontaneous decomposition 
of a nucleus that is accompanied by emission of radiation 
types common in RIA, gamma rays, x-ray, beta emissions.
Gamma ( y ) is most desirable, as contrasting with beta radia­
tion 1-125,1-131, Co-57 are the most commonly used gamma 
radionuclides. Solid scintillation detector (well counter) can 
be used.
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For some applications the counting of beta particles must be 
performed. The beta emitting radionuclides commonly used 
tritium 3H and 14C - liquid scintillation counting is most 
frequently used.
Detection of Radiation by NAI System 
sample
crystal
Output
Device Height Tube
Analyzer
Preamp
This type of detection is considered two (2) jz . It relates the 
positioning of the sample within the NAI counter.
NAI Crystal (TL) Thalium Impurities
Gamma Detection System
Iodine is an element of high (Z) number the properties of an 
absorption event by photoelectric absorption is greatly en­
hanced.
Thalium impurities—When a ( y ) or (x-ray) photon is ab­
sorbed, visible light is emitted by the crystal. The amount of 
light emitted is proportional to the energy given up to the 
photoelectron or the recoil by the incident photon.
The technologist must select the proper window in the pulse 
height analyzer for the specific energy range of the 
radioisotope one wishes to count. If PHA accepts a pulse, this 
pulse is then passed to the output device—commonly scaler. 
Simply sums the cts. which have been passed by the PHAs. 
The output of the scaler with modem instruments usually 
prints the results on some form of hard copy output-coupled
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by computer that will give both total cts. and ct. rate accumu­
lated.
If more than one isotope is counted, two PHA are needs.
Example: B-12, folates (C 057,1125)
Instrument should be calibrated separately for each 
radionuclide measured. 1251,1311,57CO
Counting of 1-125
Counting iodine 125 has many inherent problems. First, be­
cause of its very low energy, it has many self-absorption 
problems, which stem from the fact that the energy may be 
absorbed in the sample if the sample is too large, if the 
container holding the sample is too thick, if its position within 
the well is improper. All of these situation may drastically 
reduce the count rate. Second, setting up the spectrum has a 
unique problem.
When the spectrum of 1251 from a sodium iodide detector is 
plotted, the spectrum shows two basic energy peaks. One 
peak is at approximately 28 KeV, and the second peak is at 
approximately 60 KeV. The first primary energy peak is com­
posed of basic characteristic X-rays and the primary 35 KeV 
energy peak. Because of the inherent resolving problem of a 
sodium iodide detector, the individual peaks from the X-ray 
and the primary gamma ray cannot be resolved. Thus a 
resulting peak of 28 KeV is observed. The second peak, which 
is sometimes called the sum-peak, is the sum of the charac­
teristic x-ray from 1251 and radiation from the daughter 
product of 1251 (tellurium 125). The resulting sum is ap­
proximately 60 KeV. When 1251 is counted, the spectral 
settings either can be set to count just the primary peak, which 
is a larger peak, or it can be set up to count both peaks.
The Decay Schem e of 1-125 Looks Like:
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The Decay Schem e of 1-125 Looks Like: 
Electron Capture: e + p n + + energy
electron capture
1251
125Tb
52Te
ENERGY PEAKS:
Primary peak (larger)
28KeV 60 KeV
Liquid Scintillation Counters
Used for low energy beta emitters, sample is actually dis­
solved in the scintillation itself.
Advantage—Excellent geometry. Literally surrounded by 
scintillator (4IT) geometry.
Disadvantage—Problem of solubility of material to be 
counted. Sample cannot be brought into solution. Counting 
by liquid scintillation becomes more difficult.
Four Components:
•  Solvent: tolvene and diozane. This is an aromatic 
solvent.
•  Solubilizer: protosol, hydroxide. This requires 
treatment with relatively strong agents. It functions to 
dissolve the sample for biological liquid counting.
e Fluor: a primary and secondary. Primary: (PPO) 2.5 
diphenyloxazole. Light emitted by primary fluor is a 
wavelength not detected by some types of P.M. tubes. 
Secondary: (POPOP) 2.5 phenoyloxade benzene. 
The second fluor is used to shift the wavelength to emit 
light.
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•  Radioactive sample: usually H-3 or C-14 Quenching 
Problems—Anything that interferes with the 
visualization by P.M. tubes of the emitted light. 
Chemical Quenching—Scintillation solution absorbs 
the energy of radiation without the emission of 
detectable light (inorganic adds, organic compounds).
Color Quenching—Samples that are red or yellow, such as 
blood or urine, may cause problems. Red color absorbs the 
bluish light emitted by fluor, causing reduction in amount of 
light reaching P.M. tubes and reducing count rates.
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REVIEW
Section 1
1. List and describe the major components of a gamma 
well counter
2. List and describe the 4 components of liquid scintilla­
tion counters, including their functions.
3. Compare gamma well counters and liquid scintillation 
in terms of geometry, uses, advantages and disadvantages.
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Section 2
1. The principal gamma energy and half-life of 1-125 is
a. 159 KeV, 13 hours
b. 364 KeV, 8 days
c. 173 KeV, 2.8 days
d. 35 KeV, 60 days
2. 1-125 shows two basic energy peaks, 28 KeV and 60 
KeV. 28 KeV is based on
a. characteristic X-ray and primary energy peak
b. inherent resolving problem
c. 1-131 interference
d. all of the above
e. a and b only
3. The most common causes for counting failure include
a. high voltage drift
b. cracked Nal crystal
c. preamp to scaler malfunction
d. loss of control of window setting
e. none of the above
4. Geometric factors do not include
a. volume of sample solution
b. type of Nal arrangement (side window)
c. position of sample in counter
d. none of the above
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Section 3
T/F Section
_  1. A  gamma counter works in this sequence:
Nal -* pre-amp -* P.M. tubes -* PHA -* scaler
  2. The primary peak (larger) for 1-125 is approximate­
ly 60 KeV and decays by electron capture.
  3. 1-125 window settings are 25-60 KeV.
  4. Liquid scintillation counters are used to count beta
emitting radionuclides such as 1-125,1-131, and C-14.
  5. 1-125 has a sum-peak of approximately 35 KeV and
decays by position emission.
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It: can be predicted that RIA and related techniques 
will be applied increasingly to the detection of active 
infectious disease. Straus, et al (1981), have reported an 
RIA for a tuberculoprotein that can make the diagnosis of 
active tuberculosis more rapidly and in a much less 
expensive, simpler, and far safer fashion than with the use 
of classic microbacteriologic methodology (p. 3214.) . Even 
were this technology applicable only to the diagnosis of 
tuberculosis, it would remain a major breakthrough.
However, it should serve as a model for the development of 
assays for proteins associated with other slow-growing 
organisms, the diagnosis of which may be difficult with 
standard microbiologic methodology.
Future of RIA
This review of the development of a small sampling of 
applications of RIA emphasizes the fact that in science new 
truths become evident when new tools become available. For 
more than a quarter century, RIA has been an important tool, 
fruitfully employed in diverse areas of biomedical 
investigation and clinical medicine. Can we predict what 
the relative usage of radioactive and non-radioactive labels 
in immunologic methods for diagnosis (immunodiagnostics) 
will be in the future? A Wall Street investment concern has 
attempted such a prediction (Dunne, 1981) . They have 
estimated that in 1980 the market segment for RIA in
immunodiagnostics was $332 million, for non-radioisotopic 
therapeutic drug monitoring $43 million, and for all other 
non-radioisotopic immunoassays $28 million? in 1990, they 
predict markets of $785 million, $625 million, and $838 
million respectively for these three methodologies. Thus, 
from a commercial point of view RIA usage is expected to 
more than double during the decade of the 1980s, but its 
fraction of the total immunodiagnostics market is expected 
to drop from over 80 percent to about 35 percent. Why?
First of all, many of the new applications simply do not 
require the exquisite sensitivity of RIA. For instance, in 
therapeutic drug monitoring the concentrations being 
determined are generally a million-fold higher than the 
concentrations of peptide hormones. Furthermore, assays for 
drugs generally need not be quantitative over a multiple 
hundredfold range. It is often necessary only to determine 
whether the concentration is high enough to be efficacious 
and not so high as to be toxic. In the field of infectious 
diseases, where immunodiagnosis will play a major role, the 
choice between radioisotopic and non-radioisotopic 
methodology again would depend on the sensitivity required; 
in the presence of massive infection, the massive infection 
the sensitivity of RIA is not likely to be necessary. 
However, in a number of instances, those promoting non- 
radioisotopic labels are not necessarily suggesting that 
these have any technical advantage, but rather that
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regulatory procedures and fear of radiation at any level 
would make radioisotopic label less desirable. Nonetheless, 
RIA is likely to remain the method of choice for what has 
been its first application, the measurement of peptide 
hormones in plasma and other body fluids, since their 
concentrations are well below 10"10M, and the sensitivity of 
RIA is essential (Dunne, 1981).
RIA and related methodologies have opened new vistas in 
science and medicine. RIA is now used in thousands of 
laboratories around the world to measure hundreds of 
substances of biologic interest. Even now, a quarter 
century after the introduction of RIA, there remain many 
additional fields that can be explored with its help.
Review of In Vitro Literature
A selective review of the nuclear medicine In Vitro 
literature was performed on over 300 articles, text books, 
and manuals. This researcher examined the literature and 
categorized the materials into a content analysis chart.
The five areas were: Level of Material, Type of Material, 
Possibility of Providing Laboratory Exercises, General 
Principles, Concepts Discussed, and Specific Testing 
Procedures Mentioned.
The following is presented as a content analysis chart 
and a summary of resultant values obtained.
Content.Analysis of In Vitro Nuclear Medicine 
Literature. Column indexes and abbreviation conventions 
Column 1, Bibliography 
Column 2, Level of Material 
under = undergraduate 
grad = graduate 
tech a technical 
Column 3, Form of Material 
Column 4, Laboratory Exercises Provided 
Column 5, Concepts Discussed 
Column 6, Specific Testing Procedures
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Chapter 6
EQUIPMENT QUALITY CONTROL
Objectives
•  Know the three basic parameters of equipment 
performance evaluation:
° Counting efficiency
° Statistical bias
° Background cts.
•  Be able to demonstrate an understanding of the 
purpose of these 3 testing procedures.
•  Be able to quantitively analyze and set up these 3 
testing procedures.
•  Demonstrate a knowledge of normal ranges and their 
functions.
° Be able to set up a data reduction system for:
° point-to-point analysis 
° log-logit assays 
° single-point assays
•  Know the different kinds of RIA testing procedures 
that match up to the appropriate data reduction 
methods.
•  Understand how to assess antibodies, labeled ligands, 
standards and different RIA testing kits.
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Equipment Performance Evaluation.
Three parameters can affect overall accuracy and/or 
reproducibility of test results:
•  Counting efficiency (accuracy)
•  Statistical bias (reproducibility) 
e  Background cts.
Ct. Efficiency: Number of cts. registered compared to the 
number of potentially effective emissions from the source.
The ratio should be near­
ly constant for a given 
detector, nuclide, sample 
size, base and window 
setting, gain and high 
voltage.
Ct: A  standard having a similar decay scheme. A long half- 
life and record the results (see lab exercise).
Statistical Bias: The most critical performance test of any 
counting equipment is when large number of samples are to 
be counted and compared to some standard value.
Test is performed to ensure that variation in a series of in­
dividual cts. are likely to be due to random nature of radioac­
tive decay and not by other influences.
Using a single source (long - many weeks)
T 1/2 - ct. a series of 1 min. cts.
This set of cts. is compared to theoretical variation that one 
would expect from random sampling:
Chi-Square Test
JU. = g(X-X) —Compare result to tabulated P values 
X
P values should fall between. 10-.90 if outside these limits, the 
most common causes for non-reproducible counting failure:
•  High volt, drift
•  Cracked Nal crystal
CPM = a .  Per Min.
Disintegrations 
Per Min.
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•  Loss of optical coupling between P.M. tubes and crystal
•  Loss of control of window setting
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Background Checks
Observed background to quickly alert for contamination or 
other radioactive sources in area.
Sam ple Collection
Most assays are performed on the blood components (plasma 
or serum).
Collection must be reviewed by specific assay protocol. 
Proper attention to timing of collection of samples TSH and 
cortisol is necessary to account for nature of the secretion of 
these hormones.
Posture may affect serum secretion, such as plasma renin.
Food intake may affect certain test results. Human growth 
hormone is markedly affected by stress.
Collection involves immediate clotting and centifigation and 
possible freezing -20C for some specimens.
Normal Ranges
For any assay, should be established in each laboratory.
N.R. usually refers to healthy persons. It has become rather 
difficult to relate to natural phenomenon, such as aging, ac­
tives.
Statistical principles use 95% confidence limits to define 
normal population or test results.
Expected measurement for 1 individual in 20 to fall outside 
of the normal range.
Fairly large population must be sampled. Population should 
be illness-free (by as many criteria as possible) when defining 
the normal population.
Other factors: race, age, sex, etc.
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Setting up Your Equipment Parameters
Background
In all cases background is subtracted automatically prior to 
print-out of counts or any calculations.
Window Settings
There are two preprogrammed isotope values which can be 
used to set the window, 1-125 and Co-57. Ranges for these 
isotope values can be entered in one or two ways. The ap­
propriate keys representing the isotope can be entered. Or 
the range can be entered by pressing the appropriate numeric 
keys. For example, the range for 1-125 equals 15 to 70 KeV. 
By pressing the numeric keys then pressing the decimal point, 
the range is entered.
These isotopes have these equivalent ranges:
1-125 = 15 to 70 KeV
CO-57 = 45 to 235 KeV
When unknowns are run, the standard deviation and coeffi­
cient of variation are calculated as a function of dosage.
Standard Deviation (SD)
Coefficient of Variation (%CV) =
X x 100
Sum of Individual Counts
Mean =
#  Replicates
X2 =  £ (X-X)2
Chi-square = ~=r
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Methods of Data Reduction
Protocol: Point To Point
Point to Point assays are entered similarly to log-logit assays:
•  Total count tubes (if any).
•  Non specific binding (NSB) tubes (if any).
•  Zero standard (Bo) tubes (if any).
•  Lowest standard
•  Highest standard. Point to Point assays can be run 
without:
° Total count tubes
° NSBs
° Bos
Standard values for concentrations other than 0 (zero) must 
be entered in ascending order (from lowest to highest).
Respective counts for those standards can be entered in either 
a consistently ascending order or descending order. If the 
counts are not entered in consistently ascending or descend­
ing order, an error message will be printed: RECHECK 
STNDS. The assay calculations will revert to the counter 
mode and only counts will be printed.
The method of data reduction for Point to Point assays uses 
the respective averages from each set of adjacent standards to 
plot a series of straight lines.
Average counts from a givenset of unknowns will then be read 
from a series of straight lines and the corresponding con­
centration is determined.
If an individual unknown tube has a count rate corresponding 
to a concentration that is less than the lowest concentration 
or higher than the highest concentration, it will be deleted. If 
replicates are being run and one or more tubes of a given 
sample are deleted, the calculation will continue based only
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on the undeleted tubes. When this occurs the operator should 
validate the data.
Protocol: Log-logit (curve Fit) A ssays
Log-Logit assays must include:
•  Either a total count tube)s) and/or Bo tube(s) (zero 
standard tubes).
® At least three standards other than zero.
Standard values (concentrations other than zero) must be 
entered in ascending order (lowest to highest concentrations). 
Assays must be loaded and run in the following sequence:
° Total count tubes (if any).
° Non specific binding (NSB) tubes (if any).
° Bo (zero standard) tubes (if any).
° Lowest standard
° Highest standard 
DATA REDUCTION
The following formulas are used in the data reduction 
process:
Total counts = Free counts +  Bound counts +  NSB 
Bo = Bound counts at zero - NSB 
Logit = In -1— where y =  B/Bo or B/T
1-y
Pipetting Error = \ y  (sd^-t
whore (SD)2!  = Variance of total count tubes
The curve fitting procedure is a log-logit transformation using 
all data points other than the zero standard.
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Each concentration is converted to its logio. Each standard 
count ratio (B/Bo or B/T) is converted to a logit.* A least 
squares linear regression is then performed. The unknowns 
are determined by converting each ratio to a logit. If more 
than one ratio exists per patient, a mean of the patient’s logits 
is calculated. The unkinown can be read off the regression 
line. The following will be printed:
Concentration of the unknown 
SD
% CV If more than one reading/patient
Special checks of the data are performed during data reduc­
tion.
•  All standards and unknowns must be:
° >NSB  
° < Total 
° < B o
If standards do not meet these criteria, the assay must be 
re-run. When unknowns do not meet these criteria, they are 
deleted.
•  When counting bound counts, or when free counts are 
converted to bound counts, the counts must decrease 
as the standards increase.
Each standard count is compared to the mean of the previous 
standard value. If it is not less than the previous mean, an 
error message RECHECK STNDS will be printed, identifying 
the standards as questionable and the assay will continue.
•  Unknowns and controls which are not within the range 
of standards enteredare either extrapolated to zero or 
reported higher than the highest standard. Such 
controls appear as zeros in Q.C. data.
Protocol: Single Point A ssays
A Single Point assay must be loaded and run in the following 
sequence:
•  Reference control tubes (standards)
o Controls (knowns, unknowns, Q.C. tubes)
•  Unknowns
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Single Point assays, such as Triobead, have only one standard 
value. If more than one replicate is used of the standard value, 
the average count of the replicates is used and a straight line 
is plotted through that data point (counts vs. dosage or % 
bound, etc.) and the zero concentrations point.
If more than one tube is included for each patient, a mean is 
calculated.
Controls and unknowns are read from that line and reported 
in the same units as the standard. For example, if the standard 
is entered as 100%, each unknown is reported as a percentage 
of the standard.
The patient‘s T3 value is then calculated using this equation: 
Unknown % = Unknown 00001 Mean X  Reference Value in %
Control Count Mean
If multiple replicates of either or both standards and un­
knowns are run, the standard deviation and coefficient of 
variation are calculated and printed.
Q.C. data stored for each assay includes:
•  Date
•  Lot Tech. No.
•  Reference Control Counts
•  Reference Value in %
•  Control Counts
If a T3 test, such as Triobead, is being run and T7 values are 
desired, the respective T4 value for each patient must be 
manually entered. The patient’s T3 value, when derived, is 
multiplied by the T4 value. The units of T7 value are the same 
as T4 value.
If T7 values are desired for some but not all patients, a zero 
should be entered in response to the operator prompt asking 
for T4 values for those patients whose T7 value is not neces­
sary.
A ssessm ent
Binding Agents—Antibodies requirement are specificity of 
reaction and sensitivity.
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Actual specificity is determined by comparing known substan­
ces that might cross-react with the binder substance that show 
identical dose-response curves can be assumed to be im- 
munologically similar, but actually may not be identical com­
pounds.
Specificity of a system is usually estimated by adding known 
interfering substances and comparing the dose-response cur­
ves.
Labeled Ligand—Assessment is concerned with:
•  specific act of the substance
•  purity of the substance
® identity of the labeled ligand with its corresponding 
unlabeled substance (use of chromatography)
Standards—Purposes of standards are:
•  establish a curve of dilution on known amounts of 
substances to which the unknown may be compared
« ensure a stable interassay comparison
•  compare the results obtained with other lab or 
established quantities
Kit Evaluation
Some tests are requested by MDs so infrequently that it may 
be advantageous to send samples to large commercial labs.
Isotope needed—important consideration:
liquid scint. 3H, 14C and gamma counters - 1251,1311,
57Co
Stability of the reagents (components) will determine the 
shelf life of an individual kit. Lyophilized (freeze dried) 
agents generally provide the longest shelf life. Frequency and 
the number of tests performed influence kit selection.
Reliability of delivery, cost, policy of replacement, ease of 
instructions, provisions for free kits.
Type of equipment needed, separation techniques, pipetting, 
cting, temperature requirements, time requirement.
Kit should be chosen based on:
•  clinical needs
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•  equipment, personnel, and time available
•  component characteristic of kit
•  cost
e  manufacturer’s consideration, reliability, availability 
Kit evaluation should include:
•  specificity of assay
•  sensitivity of assay dose-response curve (shape of 
curve)
•  inclusion of controls to judge interassay variation and 
clarity
•  protocol itself, separation technique, equipment, time 
required
•  components of kit: shelf life, storage, replacement
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REVIEW
Section 1
1. Name at least three (3) quality control measures used 
in gamma well counter equipment and their specific func­
tions. Please show all work:
2. Calculate efficiency of a given gamma counter based on
the fo lowing data:
CPM of counter = 31,501
CS-137 = Tl/2 30 years - calibrated 9/71-1 uci
2.22 x 104 DPM = lu ci
3. Very briefly, describe these data reduction methods 
used in RIA testing.
a. Point to point:
b. Log-Logit:
c. Single Point:
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Section 2
Which d o es not belong?
1. Important components of kit evaluation include:
a. cost
b. clinical needs
c. equipment, personnel, and time available
d. manufacturer’s availability
e. a and b only
f. none of the above
2. The kit itself should include:
a. protocol
b. spedfity of assay
c. components of kit
d. inclusion of control to judge interassay variation
e. none of the above
3. The three parameters that can affect overall accuracy 
and/or reproducibility of test results include:
a. counting efficiency
b. gamma absorption test
c. statistical biases
d. background counts
Tirue/False
_  4. The results obtained in any type of lab must be
valid. Proven quality control measures should be 
routinely used in order to ensure valid results.
_  5. One of the aspects of assessment of labeled ligand
is concerned with the purity of the substance.
_  6. Counting efficiency is the number of counts
registered compared to potential number of effective 
emissions.
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7. A test to measure the variation of a series of counts 
from one source is the background check.
8. Point to point data reduction method allows for the 
development of a nicely uniformed curve.
9. Chi-square test is used to check accuracy of a 
gamma well counter.
10. A  coefficient of variance value within assay runs 
must be greater than 10% to be acceptable.
11. Point to point assays can be run without total 
count tubes, NSBs and Bo.
12. Log-Logit data reduction method is used for one 
standard only. Example: HCG-B testing.
13. In single point assays:
Unknown % = Unknown Ct-Mean x Reference value in %
Control Ct. Mean
14. Coefficient of variance — ________
Chi-Square
15. Point to point data reduction utilizes a least 
square linear regression.
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CHAPTER?
HEMATOLOGY
Objectives
•  Be able to provide a definition, including function and 
purpose, of the following terms:
° erythocytes
° leukocytes
° thrombocytes
° specific gravity
° hematocrit
° plasma
•  Understand the basic principles and methodology 
needed for blood sample collection.
•  Be able to demonstrate a basic understanding of blood 
fluid precautions.
•  Be able to demonstrate how to perform a blood volume 
determination.
•  Know the principle of dilution and its purpose.
o Understand the uses and basic procedure for plasma 
volume and RBC volume determination.
•  Know the basic procedure and purpose of red cell 
survival testing and iron metabolism studies.
Blood is a part of the main transport system that delivers O2, 
nutrients, hormones, and antibodies to the tissues.
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Blood makes up approximately 7-8% total body weight. 
Fluid fraction—
•  plasma 
Formed elements —
•  red cells (erythocytes) (RBC)
•  white cells (leukocytes) (WBC)
•  platelets (thrombocytes)
Specific gravity—Formed element which values are greater 
than 1, the plasma cells tend to settle if allowed to stand.
•  Because of abundance of red calls 5,000,000/mm3
•  in relation to leukocytes 8,000/mm3
•  Relative small size of the platelets
Volume of packed erythocytes expressed as percentage of 
blood sample—hematocrit
•  Normally averages 45%
•  Supernatant plasma (plasmacrit) 55%
Plasma—Complex, watery fluid contain various ions as well 
as inorganic and organic molecules.
Solid constitent by plasma proteins 7.5ym/100 ml
Plasma protein helps maintain the constancy of the blood 
reactors.
Albumin factor together with the proteins concerned in blood 
clotting are manufactured in the liver.
Globulins, the fibrogens, are formed by reticuloendothelial 
systems, plasma cells, lymphid nodules.
RBC—Circular, non-nucleated, biconcave manufactured — 
RB marrow—vertebrae, sternum, ribs. Hemoglobin con­
tent —red cells carries 02. Red cells usually survive for about 
120 days.
WBC —Leukocytes, are nucleated (50-70%).
•  Granulocytes — formed in RB marrow - survive for less 
than 2 weeks.
•  Lymphoid tissue (lymphocytes) —20-40%, survive 
2-200 days, essential for the development of immunity
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•  Monocytes—2-8% phagocytic, play major role in 
production of Abs.
Platelets—Small, non-nucleated, granulated bodies formed 
in RB marrow, survive 10 days, provide support for en­
dothelium of injured vessels and formation of hemostatis 
plugs, particulaiy in blood coagulation and clot retraction.
| Blood Sample Collection
Quality control involves not only actual assay consideration, 
but also the sample itself should be subjected to a similar 
scrutiny. Because most assays are performed on blood com­
ponents (plasma or serum), these samples are the most im­
portant to consider. It should be emphasized, however, that 
many other body fluids and organ structures may be analyzed 
by the principles of radioimmunoassay and related techni­
ques. For example, urine may be analyzed for its content of 
insulin, thyroxine, etc. We will confine this discussion to 
blood samples, bot other samples should have similar atten­
tion when they are analyzed.
Patient Factors
Collection of samples must be preceded by a review of the 
specific assay protocol. Several assays require special proce­
dures for collection. For example, proper attention to timing 
of collection of samples for HTSH and cortisol is necessary to 
account for the circadian nature of the secretion of these 
hormones. Posture may affect serum secretions, such as plas­
ma renin, and food intake will obviously affect insulin levels. 
Human growth hormone is markedly affected by the presence 
of stress. These factors must be either known or controlled at 
the time of specimen collection.
Sam ple Factors
Prompt handling of the specimen is desirable, and thorough 
mixing of any anticoagulant material should prevent un­
desirable clotting. Since many assays require serum, clotting 
of the collected blood ollowed by centrifugation and freezing 
(-20°C optimal) of the serum specimen should be expedited. 
Some substances may be rapidly destroyed in whole blood 
(such as ACTH), while others (such as angiotensin) may be
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inactivated by enzymes and require the addition of enzyme 
inhibitors. Hemolysis causes increased enzyme release and 
may accentuate enzymatic destmction of specific substances 
being measured. Anticoagulant effects on the assay should be 
evaluated prior to sample collection. The total amount of 
sample available should be adequate for the specific assay.
zzmmmmmmmmss
Normal Range
The statement has already been made that the normal range 
for any assay should be established in each laboratory. This 
section will review the concept of a normal range and how the 
laboratory can approach its determination.
The normal range in medical terms usually refers to healthy 
persons. It becomes rather difficult to relate a state of health 
(or ill health) to natural phenomena such as aging, activity, 
etc. Often the characteristics of healthy and ill persons over­
lap, further complicating matters. Thus the simple estab­
lishment of a “normal range” may entail serious arbitrary 
decisions on the part of the laboratory, which may directly 
affect the usefulness of the determination.
Many factors affect levels of assayable substances besides ill 
health. Age has been mentioned. Other factors include al­
terations by conditions unrelated to the substance being 
measured, as occurs in unrelated diseases in the same in­
dividual; lack of longitudinal study of the individuals; cir­
cadian variations (as with ACIH); and effects of posture. To 
establish a true “normal” population, these factors need to be 
determined and standardized.
A typical application of statistical principles is to use the 95% 
confidence limits to define the “normal” population or test 
results in that population. Using these limits, the operator 
would expect the measurement for one individual in 20 to fall 
outside of the normal range ( one in 40 would exceed the upper 
limit, and one in 40 would be below the lower limit). This 
technique of looking at a population of values in a “normal” 
population and forming a mean value and its standard devia­
tion is the most frequently used method for deriving a normal 
range for the determination.
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Blood and Body Fluid Precautions
Health care workers need to consider ALL patients as poten­
tially infective and to adhere rigorously to infection control 
precautions for minimizing the risk of exposure to blook or 
body fluids of ALL patients. Body fluids include: urine, feces, 
oral secretions, sputum, vomitus, saliva, semen, wound 
drainage and all other moist body substances.
The Centers for Disease Control recommend using the fol­
lowing precautions when caring for ALL patients:
1. Gloves should be worn when:
a. touching blood, body fluids, mucous membranes or 
non-intact skin of all patients.
b. handling items or surfaces soiled with blood or other 
body fluids.
c. performing venipuncture or other vascular access 
procedures.
Gloves should be changed after contact with each patient and 
hands should be washed, with particular attention to the area 
around the nails and in between the fingers, immediately after 
gloves are removed.
If a glove is tom or a needlestick injury occurs, the glove 
should be removed, hands washed, and a new glove used as 
promptly as patient safety allows.
2. Masks/protective eyewear or face shields should be 
worn to prevent exposure to mucous membranes of the 
mouth, nose or eyes during all procedures that are likely to 
generate droplets of blood or other body fluids.
3. Gown or apron made of materials that provide an effec­
tive barrier should be worn during procedures that are like­
ly to generate blood or body fluid splashes.
4. Needles should not be recapped, bent or broken or 
otherwise manipulated. Puncture-resistent containers 
should be located as close as practical to the use area.
Special care should be taken to avoid needlestick injuries 
when discontinuing IVs, IV meds or giving injections. Get 
help when giving injections to uncooperative patients.
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5. Ventilation devices should be available for use in areas 
in which the need for resusitation is predicted.
6. Health care workers with exudative lesions or weeping 
dermatitis should refrain from all direct patient care and 
from handling patient care equipment until the condition 
resolves.
7. For all invasive procedures (surgical entry into tissues, 
cavities, organs or repair of major traumatic injuries), car­
diac caths and angios, vaginal and C-section delivery gloves, 
surgical masks, protective eyewear or face shields and 
aprons or gowns should be worn.
8. All specimens of blood and body fluids should be put in 
well-constructed containers with a secure lid to prevent 
leaking during transportation to the lab. Care should be 
taken when collecting specimens to avoid contamination of 
the outside of the container.
9. Soiled linen should be handled as little as possible with 
minimum agitation to prevent gross microbial contamina­
tion of the air and of the person handling the linen. All 
soiled linen should be bagged at the location where it was 
used.
10. Chemical germicides that are approved for use as a 
hospital disinfectant can be used to clean up spills of blood 
or body fluids.
11. Hands and other skin surfaces should be washed im­
mediately and thoroughly if contamination with blood or 
body fluids occurs.
Besides following the usual routine of completing an occur­
rence report and seeking medical attention, the employee 
that has had a blood or body fluid exposure should contact the 
employee health nurse as soon as possible after the occur­
rence.
Blood Volume Determination
Radioactive tracers used for volume measurements must be 
non-toxic and completely safe for parenteral administration, 
should mix rapidly and uniformly with the diluting fluid, and 
remain for a reasonable time interval.
TVacer—easily detected and quantitated in high dilutions. 
Ideally, accurate measurement of circulating blood volume 
should be performed by simultaneous determination of the 
volume of both plasma and blood cells. Two radioactive
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tracers of different energy are used to enable their differences 
by means of PHA.
I - Human serum albumin - used measure plasma
51Cr - Tagged erythrocytes - used measure red cell volume
Problem s with m easuring both together:
•  time consuming
•  tedious calculations to correct for I measuring from 
51Cr
® use of dual isotopes
•  specific equipment
Single tracer can be used for determination of volume of 
either plasma or red cells using principle of dilution!
V1C1 = V2C2 Q = V x C V = diluting volume
C = tracer concentration 
V = Q in diluting fluid
C Q = total quantity of tracer
Serum differs from plasma in that it contains no fibrinogen 
plasma. Since of the volume of one component is determined, 
the total blood volume can be calculated with the aid of 
hematocrit.
Total blood = Plasma volume — R.G volume 
Volume Plasma crit Hematocrit ~ 45%
Average whole-body hematocrit is roughly 92% of venous 
blood hematocrit.
Problems: different size vessels, different organs 
Discrepancy exists: plasma trapped within cells 
Hematocrit is multiplied by correction factor 0.90 (.92 x .98)
Plasma Volume Determination
1311 human serum  albumin (RISA or IHSA)
•  Venous blood sample is obtained to estimate 
background radioacivity.
•  Test dose of 5-30 uci RISA transferred into volumetric 
container and diluted up to 1,000 ml to act as stand.
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•  Exactly equal amount of tracer is injected in patient 
(antecubital vein).
•  After 15 minutes, a blood sample is withdrawn from 
patient’s other arm in a heparinized syringe.
•  Hematocrit is determined and plasma separated by 
centrifugation.
•  Radioactivity in equal volumes of stand, and plasma are 
measured in canter.
•  Background is subtracted.
Plasma volume (liters) = count rate of standard
net count rate of plasma
Normally 43 ml/kilogram of body weight
1 2 5 I — human serum albumin: main disadvantage is lower 
cting efficiency
51Cr—tagged chromic chloride trivalent: 98% labels the
plasma protein
Remainder attached RBC 
Red Cell Volume Determination
Depends on labeled erythrocytes as the tracer. Sodium 
chromate (5 lCr) radiochromate is most commonly utilized - 
hexavalent compound - easily penetrated RC membrane and 
establish firm tag with hemoglobin - tagged is done (invitro).
•  Anticoagulated blood sample (10 ml) is obtained from 
patient and mixed with 50 uci of radiochromate.
•  Mixture left at room temperature 15 minutes (ACD 
solution added) (stops tagging process). 
Radiochromate should not be added to ACD solution 
before use. ACD is going to hinder the chromate and 
hinder tagging process.
•  Aid 100 mg (ascorbin acid) (vitamin C) to mixture to 
reduce radiochromate and thus prevent it from tagging 
any other erythrocrytes.
•  Accurate measured volume (0) of tagged mixture is 
kept as a standard.
•  Exact equal amount is injected back into patient.
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•  After 15-30 minutes, blood sample is withdrawn from 
patient’s other arm.
•  Hematocrit of blood sample and standard one 
determined
•  1 ml of standard, 1 ml of blood sample - counted in well 
counter
RBC Volume =  Cts of Standard V =  O
Net Cts of RBC C
Problem s with this m ethod
•  Errors encountered by the occurrence of extravasation 
during intravenous injection of tagged cells
•  Lack of tagging due to reducing agents
•  Formation of clots in standard
•  Hemolysis of tagged cells
Clinical Indications for Blood Volume Determination
•  After acute blood loss
•  After extensive burns
•  Preoperatively in patients of extreme ages —children 
and elderly—before major surgery
•  Measure for degree of anemia of a patient
•  Postoperatively - need for transfusion therapy
Red Cell Survival
Is measured by following a given group of erythrocytes to 
determine the time required for their elimination from circul- 
tion. Specific erythrocytes easily identified from remainder 
of RBC by a label or tag.
IWo m ethods
Selective labeling—uses glycine C-14, glycine N-15, glycine 
H-3, Fe-59, Se-75. The RBC are tagged and followed for the 
full life span which can extend over 4 months.
•  Normal life span = 120 days
•  Normal disappearance T 1/2 = 25-35 days
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Difficulties of this method include: radionuclide expense, 
special preparation, specific equipment is required for count­
ing (liquid scintillation).
Random labeling—uses Cr-51 sodium chromate tagged to 
TBCs. This method is easier. The RBC survival time is 
calculated from the percent of surviving tagged erythrocytes 
as determined at period time intervals.
Procedure: Inject Cr-51, wait 24 hours, take sample, then take 
sample every other day for 3 weeks.
It is preferable to rely on the results of the first 3 weeks and 
express the survival in terms of time required for elimination 
of 50% of the tagged erythrocytes. Since survival is computed 
from % of surviving tagged cells as determine/volume, a wide 
fluctuation in blood volume can invalidate results.
Disadvantage: inability to differentiate a short life span from 
random destruction.
Clinical application: study cases of unexplained anemia and 
helps determine the nature of defect causing shortened R.C. 
survival.
Determine site of R.C. sequestration - choice of proper treat­
ment
Iron metabolism studies - uses 10 uci of Fe-59 ferrous citrate. 
After injection of Fe-59, external counting is performed peri­
odically and simultaneously over the precardium, sacrum, 
spleen and liver over a period of 2 weeks. Normally within 
the first few hours, after injection. The tracer dose —ct rates 
over the precardium—representing blood diminishes. Ct. 
rates over spleen and liver decrease. Ct. rates over sacrum 
increase - represent bone marrow - and peak for about two 
days before rapidly decreasing.
Significant increases in spleenic cts.—denotes spleenic se­
questration of red cells.
If radioactivity over liver/spleen behave similar to that over 
sacrum  —extram edullary ( form ation o f RBC) — 
erythropoiesis is suggested.
The main indication of ferrokenetic studies is the investiga­
tion of obscure hematologic disorders.
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REVIEW
Section 1
1. What is
a. Plasma
b. Specific gravity
c. Hematocrit
d. Plasmacrit
2. Explain the different functions of RBC, WBC, platelets.
ViCi = V2C2 
Initial volume = 15 ml 
Initial concentration = .6 uCi
ml
New concentration = .007 uCi
ml
What is the new volume?
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Section 2
Multiple choice
1. The fluid portion of the blood is called____ .
a. serum
b. plasma
c. fibrogen
d. hematocrit
2. The three types of cellular elements present in the 
blood are_____
a. fibrogen, semm and plasma
b. granulocytes, albumin, and monocytes
c. eoslinophils, globulin, and albumin
d. erythrocytes, leukocytes, and thrombocytes
3. The term used to describe the production of blood 
cells is  .
a. nuclear maturation
b. hematopoieis
c. polyphyletic
d. Unitarian
4. The volume of packed erythrocytes expressed as a per­
centage of the blood sample is defined as_____
a. plasmacrit
b. hematocrit
c. albumin ffactia
d. all of the above
5. The normal hematocrit is approximately what percent­
age of a given blood volume?
a. 10%
b. 25%
c. 45%
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d. 85%
6. Hematocrit obtained from blood sample is multiplied 
by .91. This is done:
a. because 91% of the blood cells are erythrocytes
b. because 91% of blood is usually plasma
c. to correct for large vein sampling
d. all of the above
7. The following equation:
Q = V xC  where V = volume of diluent,
Q =  amount of tracer, C = concentration of tracer
— explains the relationship between volume and con­
centration. This equation is based upon:
a. Starting’s Law
b. the dilution principle
c. law of concentration
d. none of the above
8. In blood volume measurements, the plasma portion of 
the blood is most commonly labeled with_____
a. 51Na chromate
b. 125IHSA
c. m I HSA
d. 32p
9. The RBC survival test can be performed .
a. by randomly labeling RBCs in the circulation with 
sodium chromate
b. to estimate the RBC life span
c. to diagnose hemolytic anemia
d. all of the above
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10. Selective labeling of erythrocytes for RBC survival can 
be achieved with .
a. 75Se
b. 59Fe
c. 3H glycine
d. all of the above
11. In a red cell survival determination, samples are taken 
from the patient:
a. every day for 1 week
b. every other day for 3 weeks
c. every other week for 1 month
d. every week for 1 month
12. If the specific gravity is less than 1, cells will
a. tend to settle if allowed to stand
b. recombine after a while
c. tend to remain in solution
d. form particles that will fragment into alpha, beta, 
and gamma emitters.
13. Leukocytes are in abundance approximately ____
mm3 in the body while erythrocytes are mm .
a. 8,000; 5,000,000
b. 8,000,000; 5,000,000
c. 5,000; 8,000,000
d. 7,000; 16,000,000
14. The supernatant is
a. the volume of packed erythrocytes expressed as per­
centage of whole blood
b. approximately 55% of whole blood normally
c. approximately 45% of whole blood normally
d. a and b
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15. RBCsare
a. small, non-nucleated granulated bodies formed in 
red bone marrow
b. granulocytes, nucleated formed in red or yellow mar­
row
c. circular, non-nucleated, biconcave, manufactured in 
red bone marrow
d. could b any of the above
16. The hematocrit value of a given blood sample repre­
sents
a. the ratio between the plasma compartment and the 
cellular compartment
b. the ratio between the serum compartment and the 
cellular compartment
c. the percentage of the cellular components to the 
whole blood
d. the ratio of the RBCs to WBCs
17. The dilution principle can be expressed as
a. QSVXC
b. V = QXC
c. V = QXC2
d. V = QXC2
18. Radionuclides used for blood volume determination 
may either be tagged to plasma proteins or to the
a. serum
b. WBCs
c. platelets
d. erythrocytes
19. The form of Cr-51 which can permeate the red cell 
membrane is
a. trivalent form
b. bivalent form
c. hexavalent form
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d. all of the above
20. All of the following are types of WBCs except
a. thrombocytes
b. granulocytes
c. lymphocytes
d. monocytes
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Chapter 8
SIGNIFICANT IN VITRO TESTING 
PROCEDURES IN NUCLEAR 
MEDICINE
Objectives
® Understand the functioning and metabolic effects of 
the hypothalamus-pituitary-thyroid axiom.
•  Be able to describe the function, clinical applications, 
normal ranges and testing procedures for: TSH, T-3, 
T-4, T-3 binding capacity.
•  Understand the importance of Vitamin B-12 to the 
human body.
•  Demonstrate a knowledge of Vitamin B-12 absorption 
testing methodology, including blood testing, hepatic 
uptake testing, and Schilling test.
•  Understand the function and methodology of folic acid.
•  Demonstrate an overall understanding of tumor 
testing, including HCG, CEA, and AFP.
•  Understand the basic feedback system for 
pituitary-gonadal axis and the hormones that are 
involved.
•  Demonstrate a knowledge of Indium-III WBC 
labeling, including the basic tagging procedure.
•  Develop an appreciation for the functional uses of 
various other RIA tests.
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Thyroid Functioning and Testing
These tests are often used as a screening device for patients 
suspected on clinical grounds of having thyroid dysfunction.
Do before radioactive iodine-uptake and invivo thyroid tests.
TSH - thyroid stimulating hormone
T4 - thyroxine
T3 - triothyronine
Uptake T3 - binding capacity
Hypothalamus-Pituitary-Thyroid Homeostasis
Normal thyroid function depends on effective function at 5 
levels:
® Hypothalamus and its release of thyrotropin-releasing 
hormone (TRH) or (TRF) - thyrotropin-releasing 
factor
® Pituitary release of (TSH)
•  Thyroid’s secretion of active hormone T4, T3
® Plasma space with its specific thyroid-binding plasma 
protein
•  Target organs and specific cell receptors
TRH is transported from hypothalamus via the portal system 
of the pituitary region of adenohypophysis where it stimulates 
basophilic cells to produce and release TSH.
TSH stimulates thyroid gland to increase production and 
release of active thyroid hormones T3 and T4; therefore, 
plasma T4 and T3 are increased. If plasma levels of T4 and T3 
fall, TSH is secreted.
Thus, TSH is the prime regulator of the rate of function of the 
thyroid gland and hence of thyroid hormone production and 
secretion.
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’ituitaryHypothalamus
T3T4 TSH
Thyroid
T4,T3
TSH—Thyroid Stimulating Hormone
TSH is a glycoprotein — molecule weight approximately 
28,000. Protein contains one alpha and one beta polypeptide 
subunit. Possible cross-reactivity (same alpha species as 
HCG, LH, FSH).
It is the beta subunit of TSH that determines the specific 
physiology of the hormone.
TSH is essential to normal thyroid function. Absence of TSH: 
thyroid gland undergoes involution. It is involved in all levels 
of thyroid function.
•  Production of hormone is stimulated by increasing the 
amount of thyroid iodide transported into gland and by 
increasing organic binding of iodide— 12 (I- = Iodine)
•  Increase T4,T3 storage—iodotyrosines—into 
thyroglobulin
•  Release of T4/I3
TSH is part of a sensitive control system that keeps the semm 
concentration of thyroid hormones within fairly narrow limits.
TSH under direct control by TRH—via portal system.
TRH stimulates basophilic cells in the adenohypophysis to 
produce TSH, TSH stimulating thyroid gland to release T4T3.
Increased blood levels inhibit release of TSH.
1/2 time of TSH turnover in plasma is approximately 1 hour. 
Daily secretion rate is about 170 mU.
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Test is performed in 24 hours or less—long incubation. 
Double-Ab precipitation and solid phase tech.—separation 
tech. HCG is usually added to absorb out alpha chain.
Clinical Applications
Hypersecretion of TSH occurs when hypofunction of thyroid 
due to decreased plasma levels of thyroid hormones.
Suspicion of hypothyroid disorders is a main clinical reason 
for TSH assaying.
Primary TSH overproduction—pituitary tumors and in­
creased TRH secretion.
Secondary TSH (pituitary level)
Hyposecretion of TSH
Secondary (pituitary level)—destruction in pituitary is the 
cause — postpartum patient necrosis, pituitary tumors
Usually TSH deficiencies are associated with other trophic 
hormones: gonadotropins, ADH.
Frozen samples —stable for years.
Samples of TSH — does not undergo marked diurnal variation
Pregnancy—TSH is unchanged
TRH stimulation test for hyposecretion of TSH
I.V. dose 200 ug TRH—normal patient prompt increase peak 
in 30 minutes
Average increase: lOuU/ml 
Normal levels: 0-10uU/ml 
15 uU/ml
Interpretation of Results
Elevated TSH level—greatly elevated in primary hypothyroid 
myxedema. Levels up to 100 uU/ml are frequently seen in 
untreated hypothyroid.
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Decreased TSH Levels
TSH levels are not measurable in hyperthyroid or 
hypopituitarism and secondary myxedema. Most assays do 
not permit difference between normal and decreased TSH 
levels.
In hypothyroid, response of serumTSH to TRH infusion (I.V.) 
is greatly increased.
Circulation of increased concentrations of T4,T3
Response of TSH to TRH (I.V.) is markedly reduced. Patient 
with thyrotoxicosis: no effect is observed.
Thus, TRH may be used different diagnosis of thyrotoxicosis 
(excessive activity of thyroid gland).
Normal response to TRH—good evidence of absence of hy­
perthyroidism.
Thyroxine (T4)
Tetraiodothyronine
T4 is produced by the actinar epithelium of the thyroid gland. 
A large reserve of T4 is stored in the thyroid gland within 
thyroid follicle—sufficient supply for body’s needs for 2 
weeks.
In bloodstream T4 is bound to plasma protein.
99.9% of plasma T4 is bound to TBG.
Protein-bound thyroid hormone is metabolically inactive— 
free (T4) that exerts metabolic effects.
T4 -1/2 life = 8 days
60 ug T4 - extracted daily from blood by target tissues
Performance of Test
Serum absorbed with charcoal to remove thyroid (T4-free 
serum) is frequently added to standard curve samples.
APPENDIX C-94 IN VITRO NUCLEAR MEDICINE LABORATORY MANUAL
Separation Technique (Absorption Technique)
Absorption of unbound thyroxine to activated charcoal 
predominates—also may use double-Ab method.
Time needed for test usually 2 hours.
Clinical Application
Hyperfunction of thyroid gland—thyroxicosis: excessive 
amount of thyroid hormone is present in peripheral tissues. 
Denominates in every organ system—accelerated metabo- - 
lism.
Disease states cause hyperthyroid: diffuse toxic goiter.
Most common: toxic multinodules (Graves disease), goiter 
(Plummer’s disease) and toxic adenoma (epithelial tumor). 
In these disorders, thyroid loses its normal responsiveness to 
inhibition of falling TSH level.
Its automous or “nonresponsive” (independent of TSH).
Thyrotoxicosis Factitin
Excessive ingestion of T4 or T3.
Hypofunction—thyroid tissue fails to provide enough thyroid 
hormone to peripheral tissues—reduction on metabolism to 
activity.
Absence of thyroid hormone—ultimately leads to coma, 
progressive falling body temperature of organ systems and 
death.
Not commonly—idiopathic (self-originated, spontaneous) — 
last manifestation of autoimmune thyroiditis.
Hypothy—end stage of treating hyperthyroid may occur at 
birth leading to cretinism from low levels of circulating TSH.
T4 sample—stable in serum for several days at room tempera­
ture little diurnal variation unaffected by fasting acute febrile 
illness (pertain to fever).
•  Reference Values
normal - 45 to 120 ng/ml 
hypo - 5 to 50 ng/ml
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hyper -120-460 ng/ml
Interpretation of Results
Elevated levels — patient has hyperthyroidism.
Decreased levels—hypothyroidism of both primary and 
secondary types different diagnosis of these disorders is best 
made using TSH.
Elevated TSH - Decreased T4 - primary hypothyroidism
Decreased TSH - Decreased T4 - secondary hypothyroidism
Increase T4 concentration in blood may be wrongly thought 
to be due to thyroid overactivity when real cause is increase 
in binding protein concentration (TBG).
T4 - along with T3 binding capacity may be affected by the 
following conditions:
Increased
TBG—estrogen, pregnancy
hypothyroidism
hepatitis
cirrhosis
Com petes with T4 for binding
•  Phenytoin (Dilantin)
•  T3
•  Dicumanol
T3 Tridothyronine
13 Tridothyronine—like T4, T3 is produced with thyroid 
gland by the Acinar epithelium. Thyroid secretes T3 in mass 
amounts that are less than 10% of T4 secreted.
Thyroid secretion of T3 is only a minor source of T3 produced. 
The majority is produced by monodeiodination of T4 in the 
peripheral tissues.
Decreased
hyperthyroidism 
acromegaly 
Down’s syndrome 
major illness 
androgens 
corticosteroid
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T3 concentration is influenced by TBG concentration - same 
as T4. T3 -1/2 life in plasma 2.0 days.
Daily turnover: 30ug/day.
Performance of T est
Charcoal absorption is most frequently used separation 
method. Also solid phase method.
Highly specific antiserum is required for T3. T4 concentra­
tion in serum 80 - lOQx. T3 serum close structure - makes for 
some degree of cross-reactivity.
Clinical Applications
Hypersecretion of 13 is always found in hypothyroidism as far 
as is now known.
Frequently T3 levels are much more elevated thanT4, indicat­
ing T3 is being produced directly from the thyroid in greater 
abundance than T4. Some patients’ hyperthyroidism may be 
manifested only by T3 elevation. T3 Thyrotoxicosis—before 
T4 begins to elevate T3 thyrotoxicosis is very common hyper­
thyroidism patients are in iodine deficient areas.
Hyposecretion of T3—accompanies hypothyroidism, may 
occur in euthyroid patient with acute febrile illness.
Reference Values —normal 1.5 +1-1 ng/ml
hyper 3.0 ng/ml
Interpretation of Results
Elevated T3 - single best indicator of hyperthyroidism. If T3 
is normal, what seems to be hyperthyroid state should be 
carefully scrutinized.
D ecreased Values T3 —do not necessarily  imply 
hypothyroidism. May be low euthyroid or acute illness. Tend 
to decrease in hypothyroidism. Normal T3 - is not infrequent 
in hypothyroid state, therefore, T3-RIA is not particularly 
usefiil for diagnosis of hypothyroidism.
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T3 Binding Capacity or T3 Uptake
Since most thyroid hormone circulates bound to protein in 
plasma, changes in concentration markedly influence thyroid 
hormone concentration.
An indirect estimate of capacity of plasma protein to bind 
thyroid hormone is the T3 uptake test. It measures the ability 
of patient’s plasma proteins to compete with a secondary 
binder such as a resin bed, red cells or rubber sponge matrix.
Technique gives an estimate of unoccupied binding sites of 
transporting proteins, chiefly TBG.
Adding I-125-T3 to free binding sites of TBG and by the resin.
If free binding sites TBG decrease because of TBG deficiency 
or because sites are occupied by increase T4 production, 
I-125-T3 will be greater degree take-up by resin. If free 
binding capacity TBG increases, example is extremely lowT4 
levels, or increase (example pregnancy).
Resin will bind less to I-125-T3. Resin uptake should be 
interpreted in light of total T4 serum concentration.
Free T4 Index—estimate of the amount of free thyroxine 
hormone present in plasma.
Value from T3 uptake x total T4 have been combined into a 
free T4 index.
Free T4 index has been shown to be closely related to the 
actual concentration of free T4 in serum.
Since resin T3 uptake reflects the number of TBG binding 
sites present and since total T4 concentration indicates total 
hormone, the product should be proportional to free T4.
Vitamin B-12
Vitamin B-12 is a very potent, cobalt-containing, dietary fac­
tor available in many foods such as liver, kidney, muscle, milk, 
and eggs. It plays a major role in the synthesis of nucleic acids 
and therefore, is particularly important in the process of cell 
maturation. The first cells to suffer from its deficiency are 
the rapidly dividing cells such as bone marrow and 
gastrointestinal tract cells.
Proper absorption of vitamin B-12 depends upon adequate 
secretion of intrinsic factor by glands in the stomach. Vitamin
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B-12 intrinsic factor complex mainly absorbs in the termal 
ileum. After absorption vitamin B-12 is carried in blood by 
plasma protein. Then goes to liver as a storage depot. It stays 
in the liver for months to even years and is slowly released, 
carried out by normal cellular metabolism. Vitamin B-12 is 
excreted through urine.
The presence if cobalt atom in each molecule of vitamin B-12 
makes it possible to synthesize a radioactive cobalt labeled 
vitamin B-12 using 57Co, 58Co, 6OC0 . 57Co is preferred 
because of its efficiency and absence of beta radiation.
This is called cyanocobalamin. It is essential to a variety of 
enzymatic reactions, normal growth, hematopoiesis, func­
tional states of nervous system.
Intrinsic factor is produced by gastric parietal cells found in 
the stomach. .1 ug of vitamin B-12 daily, recommended in­
take 2 ug/day.
Radioisotope of cobalt (57Co,58Co) are easily substituted for 
natural cobalt, used for highly specific receptors in RIA.
The binding of cyanocobalamin to exogenous binders must 
not disrupt vitamin B-12 reactivity.
In the lower normal and lower levels substitution may cross- 
react giving falsely high levels of measure for vitamin B-12. 
Most assay give sensitivity in the order of 10-30 pg/ml.
Clinical Applications
Vitamin B-12 deficiency—A characteristic defect develops in 
cells of many different tissues. The nucleus is unable to 
mature normally and does not divide appropriately. Affects 
organ systems with rapidly dividing cells such as hemopoietic 
cells. Prolong deficiency causes central nervous system 
problems. Most deficiencies are due to malabsorption of 
vitamin B-12.
Possible Causes
•  Inability of gastric parietal cells to secrete intrinsic 
factor.
•  Gastric resection.
•  Inflammatory disease of ileum.
•  Bacterial growth in stomach.
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•  Diet deficiency such as seen in strict vegetarian dieters 
and their breast fed infants.
The normal ranges in blood serum is 200-900 pg/ml. 
Interpretation of Results
Values less than 100 pg/ml are almost always associated with 
vitamin B-12 deficiency.
Falsely low levels have been reported in patients taking very 
large doses of ascorbic acid and high concentrations of 
fluoride in serum.
Elevated values are values greater than 1,000 pg/ml which can 
be found in hepatic disorders such as hepatitis and leukemia 
patients in which there is a release of cyanocobalamin.
Folates—Generic term used to describe folic acid. In adults 
the dietary requirement is about 50 ug/day. The requirement 
in children is considerably greater at about 100 ug/day. 
During pregnancy the requirement is 400 ug/day and during 
lactation (period of secretion of milk) 300 ug/day.
Folates are found in all foodstuffs. Examples are liver, yeast, 
vegetables and fruits. Folates in food are in the form of 
polyglutamate. They are broken down within the stomach 
into monoglutamate form and is rapidly absorbed primarily 
through the proximal small intestine. Folic acid is rapidly 
absorbed into the blood and converted into a variety of active 
folate forms and stored in the liver.
Two isotopes have been utilized to evaluate levels;
•  3H—triton was first used
•  1251 - is now more common.
Clinical Applications — Malabsorption of folate may occur in 
intestinal disorders.
Most common is folate deficiency in diet. In certain disease 
states, hyperutilization of folate may occur and result in 
deficiencies found in pregnant patients, hemolytic anemia, 
malignancies, and lactation. Some drugs such as oral con­
traceptives, phenytoin, and ethanol impair absorption of fo­
late.
Like vitamin B-12, folate is essential in rapidly dividing cel­
lular systems.
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Sampling Blood — fasting serum should be used, folate levels 
vary significantly after eating.
The normal ranges 3-20 ng/ml.
Interpretation of Results
Elevated levels are not uncommon in patients with vitamin 
B-12 deficiency. Ranges less than 3 ng/ml is common in 
malabsorption states, pregnancy, alcoholism and a malignan­
cy
Other Methods to Measure Vitamin B-12 
Absorption_______________________
Fecal Excretion Method —Stools collected at least 72 hours 
after the administered dose of radiation, the net amount of 
radiation in stools is expressed as % of administered dose. 
This represents the amount of vitamin B-12 not absorbed. 
Remainder is absorbed normally in stools at 30%-70% of 
administered dose with defective absorption, stool % is 
higher.
Hepatic Uptake Test—days after oral ingestion subject is 
given a laxative to clear alimentary tract. Two days later, 
radiation accumulates in four different areas over the liver, 
left iliac fossa, and thighs (considered background). The ratio 
between hepatic count rate and that over iliac fossa is then 
calculated. Normal patient’s count over liver and over left 
iliac fossa is at least 2.5 to 1.
Urine Radioactivity Collection—Schilling Test—most com­
monly used. The patient is given an oral dose of .5 uci of 
vitamin B-12. Patient is then given nonradioactive vitamin 
B-12 which will reach and block specific binding sites before 
absorbed radioactive vitamin B-12. This non-radioactive B- 
12 is given intramuscularly. Consequently the absorbed un­
bound radioactive vitamin B-12 is excreted in the urine. The 
1,000 ugofstable vitamin B-12 is injected within 2 hours after 
oral administration of tracer dose. Urine is collected over the 
next 24 hours. Radioactivity is estimated and expressed as a 
percentage of the administered oral dose. Percentage of dose 
that is absorbed and consequently recovered in urine by flush­
ing with stable vitamin B-12 is normally 1% or more. The 
main source of error is in the collection of urine, measure­
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ment of radiation, and results may also be affected by renal 
disease. (For preparation procedure, calculations and diag­
nostic values see Laboratory Exercises.)
In Vitro Testing for Tumors in Body
Measurement of tumor-specific products in body fluids may 
in the future offer a selective way to detect human neoplasms 
at a curable stage. Some tumors produce hormones that call 
attention to their presence, such as gynecomaastia (excessive 
development of mammary glands in males), Cushings 
Syndrome (overproduction of adrenocortisol from the 
pituitary effecting the adrenal cortex), and certain trophoblas­
tic (uterus) tumors for examples.
The ideal method for detecting tumor products would be 
extremely sensitive and specific for neoplasia. The level of 
the tumor product in the blood should correlate with the total 
mass of the tumor present.
Such methods would be useful for:
o Screening for cancer in high risk patient populations.
•  Assisting in establishing a specific diagnosis of cancer.
•  Helping to localize tumors.
•  Monitoring tumor response to therapy.
The three most common blood testing methods for tumor 
detection are:
•  CEA - carcinoembryonic antigen
•  AFP - alpha-fetoprotein
•  HCG - human chorionic gonadotropin
CEA - carcinoem bryonic antigen
CEA is a normal product of human development and occurs 
in the fetal colon. CEA may also be found as a normal 
constituent of adult tissues, such as the glycocalyx of the adult 
large intestine.
Gold and Freedman found a tumor-specific antigen (CEA) 
that was present in perchloric acid extracts of cancer of the 
colon and fetal intestine, but not the adult intestine. This 
developm ent showed great promise for diagnosis of
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gastrointestinal malignancies. CEA has become a 
widespread evaluator of patients with a variety of neoplasm.
A double-antibody measurement used to extract perchloric 
acid, CEA is located in the luminal surface of the mucosal cell.
Two factors appear to be important as a cause for increased 
serum levels of CEA in malignancies:
e Tumor cells produce a greater quantity of this antigen.
•  Rapidly growing tissue results in disruption of 
blood-tissue barriers, what is produced in tissues is 
more accessible to the blood.
A variety of malignant tumors produce CEA in abundance 
some examples include: pancreas, colon, rectum, lung, 
breast, cirrhosis and gastrointestinal.
Reference Values:
•  normal - 2.5 ng/ml
•  m a l i g n a n t . -  40 n g / m l
Modest elevation occurs in pancreatitis, cirrhosis, chronic 
bronchitis and inflammatory bowel diseases.
Increased levels - disseminated malignancies, main utilization 
of measuring CEA is evaluating patients who have already 
been documented to have tumors checking on effects of 
therapy. CEA is often utilized as an indicator of recurrence 
of tumor after surgical treatment of colon cancer.
AFP - alpha-fetoprotein
Associated with liver malignancies, hepatoma, teratocar- 
cinoma (malignant neoplasm in testes), and metastic tumors 
to liver AFP is a normal constituent of the fetus and plays a 
similar role in fetal life that serum albumin plays in adults.
The normal transition from AFP to serum albumin as the 
dominant serum protein begins at about 13 weeks of gesta­
tion, peak concentrations in AFP in fetus is 3 to 4 ng/ml. In 
pregnancy and adults it is 100 ng/ml.
AFP is found as a normal constituent of human serum but in 
diseases of the liver massive elevations may be noted.
Elevated values of AFP are seen in both benign and malignant 
liver diseases.
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Reference values:
3-25 ng/ml - normal adult 
up to 120 ng/ml - pregnant women
Values above 1,000 ng/ml in an adult are always associated 
with primary liver malignancies.
HCG—human chorionic gonadotropin
Certain trophoblastic tumors (uterus) which produce HCG 
can be detected since this hormone is not present in nonpreg­
nant individuals. Its presence in serum indicates a neoplastic 
state significant HCG levels are associated with tumors of 
1mm in size.
HCG levels are virtually always present with patients with 
choriocarcinoma and chorioadenomas.
HCG-B is a common testing method to rule out pregnancy. 
It can be either qualitative or quantitative in value.
Pituitary—Gonadal Axis
The reproductive system’s regulated by three distinct classes 
of hormones.
•  The hypothalamic releasing hormones.
•  Gonadotropins which exert no target organ effect 
except stimulate release of other hormones (anterior 
pituitary hormones).
0 follicle stimulating hormone (FSH)
° luteinizing hormone (LH)
° placental hormone 
° human chorionic gonadotropin (HCG)
•  Gonadal steroids—Hypothes. releasing hormone 
known to be of importance in reproductive physiology 
is gonadotropin releasing hormone (Gon RH) 
migrates within the portal venous system to the 
pituitary where it stimulates production of LH and 
FSH.
FSH and LH stimulate the gonads to produce a number of sex 
steroids principally estradiol and progesterone from the 
ovaries and testosterone from the testes.
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Complex interactions between the gonadotropins and the sex 
steroids that produce the cyclic changes of ovary such as 
maturation of the follicle ovulation and formation of the 
corpus luteum are only partially understood.
Estrogen and testosterone exert an inhibiting feedback on the 
secretion of FSH and LH. Increased plasma levels of sex 
steroids will inhibit release of gonadotropins and decrease 
levels stimulate release of gonadotropins and decrease levels 
stimulate release of gonadotropins.
Castration, oophorectomy (rem oval of ovaries) and 
menopause are followed by an increase of the release of 
gonadotropins.
During pregnancy HCG intervenes in this regulatory system 
and secretion of FSH and LH is suppressed.
Feedback inhibition is directed against anterior pituitary.
Pituitary—Gonadal Negative Feedback System
Hypothalamus
Feedback
System
Estradiol
Progesterone
Testosterone
Gonadotropin 
(GonRH)
Pituitary
LH, FSH
Placental hormones 
HCG
Sex Steroids
INDIUM-111 LEUKOCYTES TESTING 
PROCEDURE AND TECHNIQUE
Introduction:
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The clinical use of Indium-111 oxine labeled white blood cells 
for detection and localization of abscesses and other inflam­
matory disease is a valuable diagnostic tool.
Physiological Principle:
Leukocytes function primarily in the localization, destruction, 
and removal of micro-organisms and damaged cells. The 
leukocytes chemotactic, phagocytic, and microbial destruc­
tion functions all play a role in the body defense mechanisms. 
With the introduction of Indium-111 oxine as a radiolabel for 
cellular blood elements, it became possible to image the 
distribution of leukocytes. The lipid soluble oxine carries the 
Indium-111 across the cell membrane where the Indium 
separates from the oxine and preferentially binds to 
cytosolular proteins. The labeled cells retain viability and 
function. When labeled cells are intravenously administered 
to the patient they will normally distribute to the liver, spleen 
and functioning bone marrow, but some will continue to 
circulate in the blood. Any collection of labeled white cells 
outside of these areas indicates an area of abnormality to 
which the patient’s blood cells are being attracted.
Description of Technique:
Forty cc’s of patient blood are collected with five cc’s of 
acid-citrate-dextrose (ACD) as an anticoagulant. Donor 
blood may also be used. The blood components are separated 
by centrifugation. The white blood cell layer is removed, 
suspended in saline and incubated at room temperature with 
Indium-111 oxine for 15 minutes. All white blood cells will 
be labeled unless more sophisticated procedures (generally 
not available) are used to separate the granulocyte from 
mononuclear and lymphoid cells. The cells are washed to 
remove non-incorporated Indium and oxine from the labeled 
white blood cells which are resuspended in the patient’s plas­
ma and returned to the patient via intravenous injection.
Imaging may be started as early as four hours after injection; 
however, the quality and diagnostic value of the images will 
be superior in the day after (18-24 hours) the labeling and 
injection of the white blood cells. Anterior and posterior 
whole body images along with spot views of the anterior upper
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and lower abdomen are routinely obtained along with addi­
tional images as indicated. Occasionally, delayed imaging at 
48 hours is useful.
m m m m m m m m m m m m m m m m m ssm m m ii
Indium-111 oxine - dose 500 uci
•  Energy levels 171 kev (primary)
•  252 kev
® T 1/2 67.2 hours
Basic Invitro Labeling Technique
© 40 cc of patient blood is collected with 5 cc’s of 
acid-citrate-dextrose (ACD) anticoagulant
© blood components are separated by centrifugation
•  WBC layer is removed - suspended in saline (1% 
albumin)
•  incubate at room temperature for 15 minutes
•  WBC’s are labeled
•  cells are washed
•  labeled In-111 WBC are reinjected into patients (for 
step by step procedure see lab exercise)
Indications for In-111
Useful for spectrum of inflammatory diseases. Abscess 
localization, acute and chronic osteomyelitis. Activity in in­
flammatory bowel disease, Crohn’s disease, ulcerative colitis, 
fever of unknown origin, study of choice.
CT and ultrasound has better resolution in abdominal absces­
ses. When one does not know specific area of abscess, use 
In-111.
m m m m m m sm
Limitations
Technically demanding, false negatives if chemostatic func­
tion has been altered, long-term antibiotic therapy may fail to 
attract WBC’s, gallium scan is preferred, false positives, 
gastrointestinal bleeding, upper respiratory infection.
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Hepatitis
RIA TEST Antibody to Hepatitis B Surface Antigen 1-125 
Ausria 1-125
Introduction
Three forms of viral hepatitis are currently recognized. 
Hepatitis A, Hepatitis B which can be differentiated by 
Serologic Tests. A third form called non A, non B is diagnosed 
by exclusion.
Hepatitis B causes greatest concern in terms of it spreading 
from patient specimens to laboratory personnel. As little as
0.0004 ml of blood contaminated with hepatitis B can transmit 
the disease. Transmission can also occur by oral route, 
mucous membrane and through minor cuts or scratches in the 
skin.
Clinical Differences
T^ pe A
Incubation 15-45 days Avg. 28 days
Symptoms 2040% (in patients)
Onset of Symptoms
usually abrupt 
Duration 1-3weeks
Jaundice 3035% (of patients)
TypeB
28-120 days Avg. 45 days 
4060%
usually insidious 
1-4 weeks sporadic 
3040%
Major Difference —Type Bhas a tendency to evolve to chronic 
carrier state in 5 to 10% of cases.
Structural Components & Physiology
Electron Microscopy has shown that in the serum Hepatitis B 
Surface Antigen (HBsAg) is constantly associated with 
spherical particles, ubular forms, and the Dane particle 
(larger). Hepatitis B virus (HBV) production in the body is 
characterized by the disproportionate manufacture if HBsAg 
as compared with the production of whole virus particles. The 
complete HBV (Dane particle) consists of a core component 
enveloped by a lipoprotein Surface matrix (HBsAg). HBsAg 
is produced in vast unassembled amounts in tubular and 
spherical forms. The number of such incomplete virus par-
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tides in the circulation of a typical H BsA g carriers is immense 
and may range up to 100 billion to a trillion particles per 
milliliter of blood.
Principle
The Ausria 11-125 system uses the “Sandwich principle”. It is 
a solid phase radioimmunoassay technique to measure 
HBsAg levels in serum. Plastic beads coated with guinea pig 
antibody are supplied. Patient semm or plasma is added and 
during incubation Hepatitis B Antigen, if present is fixed to 
the antibody. When antibody tagged with Iodine-125 is added 
if binds to any Hepatitis B Antigen on the bead creating an 
antibody-antigen-antibody sandwich.
Indications
•  Testing should be done on a routine basis particularly 
on patients admitted to the hospital.
•  Medical and health care staff that have a high risk of 
exposure.
•  Determine the type of viral hepatitis and type of 
prevention and prognosis.
•  For studies of epidemics.
•  Diagnosing of liver disease.
•  Screening of blood donors.
Implications: H BsAg presence is the earliest indicator of the 
presence of acute infection. Also indicative of chronic infec­
tion.
Interpretation of Results
The presence or absence of HBsAg is determined by relating 
net cpm of the unknown to the “cut off value”. The cut off 
value is the net cpm of negative control mean (NCX) times a 
correlation factor.
Specimens with net cpm equal to or greater than the cut off 
value established with NCX are to be considered reactive for 
H BsA g which should be evaluated further.
For the run to be valid, the mean value for the positive 
controls (PCX) specimens should be at 4 times the NCX.
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Disease States and Patient Problems
•  The chances of detecting H BsA g in patients with 
hepatitis B relate directly to the time of testing, 
frequency of testing, sensitivity of the method.
•  The detection of H B sA g in a patient with acute viral 
hepatitis is strong presumptive evidence that the 
patient has hepatitis B.
•  The persistence of H B sA g for 3 or more months 
following the onset of acute viral hepatitis suggests that 
the patient is becoming a chronic carrier or is 
developing chronic active hepatitis.
•  Positive results may be first evidence that the patient 
has underlying liver disease.
Infrequently Utilized Nuclear Medicine—In Vitro 
RBA Tests
Cortisol Levels—useful in the diagnosis of Cushing’s 
syndrome (hyperadenocorticolism) and Addison’s disease 
primary adrenal insufficiency.
Secreted by adrenal cortex called zona fasciculata.
Pituitary secretion of ACTH stimulates adrenal cortex to 
secrete cortisol.
Diurnal variation—diff. am and pm values.
Dexamethasone used to suppress overactive ACTH stimula­
tion.
Hepatitis Testing—used to evaluate viral hepatitis, type A and 
B at different stages.
•  Hepatitis A —transmitted by oral-fecal rates.
•  Hepatitis B —spread by contaminated blood or blood 
products.
•  Hepatitis A —positive for acute and recovery period. 
A-AB, A-B-M.
•  Hepatitis B —known as Australia Antigen (positive for 
forms of Hep-B complex). BS-Ag, Bc-Ab, BS-Ab, 
Be-Ag.
RIA tests for hepatitis will give qualitative results - not quan­
titative.
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Calcitonin—useful for differential diagnosis of medullary 
thyroid carcinoma and to monitor therapy.
Produced in parafollicular or C-cells of thyroid gland.
Important in calcium metabolism.
HGH Levels (Human Growth Hormone) — Important in diag­
nosis of growth retardation.
Pituitary insufficiency—lack of hypothalamic stimulation. 
Hypersection in adults (acromegaly).
Hypersection in children (giantism).
PTH (Parathyroid Hormone)—Useful in differential diag­
nosis and management of hypercalcemia and hypocalcemia, 
tumors of parathyroid gland.
Regulation of calcium—by regulating the calcium—ion con­
centration in body fluids.
Gastrin—useful in diagnosis of peptic ulcers, pernicious 
anemia, Zollinger-Ellison syndrome (extreme gastric hyper­
activity).
Functions in body and stimulate gastric acid secretion. 
Collected sample should be fasting.
Digoxin—useful in treatment of congestive heart failure, 
atrial fibrillation, atrial flutter and supraventricular tachycar­
dias.
Blood drawn 8 hours after last dose.
Must be monitored closely—proper therapeutic range .5-2 
ng/ml.
Ck-B (Creatinine-Kinase-B Isoenzyme)—Is most specific 
and sensitive for acute myocardial infarctions.
Test should be done with N.M. scan evaluating heart infarct.
Myoglobin—elevated levels following myocardial infarction 
and usually peaks 5-18 hours after onset of chest pain.
Found in skeletal and cardiac striated muscles.
HCG-B Levels (Human Chorionic Gonadotropin - Beta) —
Useful in detection of choriocarcinoma, ectopic pregnancy 
and threatened abortion. Can be detected within first 10 days 
of pregnancy.
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Useful in diagnosis of tumors of ovaries, testes, breast, pros­
tate.
Maximum levels of HCG-B during second-third month.
Can be used for quantitative or qualitative results.
Renin Levels (Plasma PRA) — Useful in diagnosis of primary 
and secondary aldosteronism in hypertensive and renin-an- 
giotensin system disease states.
Usually measuring angiotensin 1—rate of angiotensin form- 
directly related to renin level.
Collected in EDTA—coated tubes (usually purple tops) and 
early morning draw, and after letting patient walk around.
Gentamicin - used as a aminoglycosole antibiotic with narrow 
therapeutic range.
IgE—immunaglobin class responsible for allergic reactions 
and is elevated in most patients with asthma, hay fever, ec­
zema, and other allergies.
Phenytoin or Dilantin—Is an anticonvulsant drug used to 
treat epilepsy.
Theophylline—Bronchodilator useful in the treatment of 
asthma. Must be drawn two hours after dose.
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REVIEW
Section 1
Draw and explain the feedback system of the hypothalamus- 
pituitary-thyroid axiom including the process, function, and 
type of hormones released at each level.
Thyroid Functioning
Match the organ with the substance it releases. 
_  1. pituitary a. T3, T4
_  2. thyroid b. TSH
_  3. hypothalamus c. TRH
d. thyroglobulin
e. barium
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Section 2
1. Secondary hyperthyroidism refers to disorders of the
a. thyroid
b. pituitary
c. hypothalamus
d. adrenal gland
2. T4 (thyroxine) is stored in the .
a. acinar epithelium
b. thyroid follicles
c. adenophysis
d. colon
3. Hyperfunction of T4 or thyroid gland is called 
thyrotoxicosis this is when  __ .
a. there is accelerated metabolism throughout the body
b. decreased metabolism
c. unknown etiology
d. too much TBG in system
4. When there is an increase in TSH levels and a decrease 
in T4 levels it is probably_________ .
a. primary hyperthyroidism
b. primary hypothyroidism
c. secondary hyperthyroidism
d. secondary hypothyroidism
5. Elevated T3 testing is _____
a. the single best indication of hyperthyroidism „
b. doesn’t necessarily imply hyperthyroidism
c. must be elevated with TRF stimulation test
d. none of the above
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6. In T3 uptake testing, the greater the number of binding 
sites, the (lower) or (higher) the uptake on the resin of I- 
125-T3.
7. The pituitary release of TSH is influenced by___
a. amount of TRH
b. amount of thyroid hormone in plasma
c. amount of cortisol simultaneously stimulated
d. all of the above
e. a. and b. only
8. TSH help stimulate thyroid to  .
a. increase the amount of thyroid iodide transported 
into the gland
b. increase T4, T3 storage
c. release T4, T3
d. a. and b. only
e. all of the above
9. The hormones which the thyroid gland produces in­
clude all of the following except .
a. calcitonin
b. thyroxine
c. triiodothyronine
d. TSH
10. After synthesis, the thyroid hormones T3 and T4 are 
stored in the until needed for use in the body.
a. acinar epithelium of the thyroid
b. parathyroid glands
c. adenohypophysis
d. colloidal thyroid follicles
11. The thyroid hormone which is in the greatest abun­
dance in the bloodstream is___
a. triiodothyronine
b. thyroxine
c. calcitonin
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d. TSH
12. The more metabolically active of the thyroid hor­
mones T3 and T4 is  .
a. triiodothyronine
b. thyroxine
13. The bulk of circulating thyroid hormone is  .
a. free, unbound
b. TBG bound
c. TBPA bound
d. albumin bound
14. TSH is secreted by the___
a. hypothalamus
b. pituitary gland
c. parathyroid glands
d. thyroid glands
15. The element which is essential for normal thyroid 
function is  .
a. iron
b. iodine
c. chlorine
d. fluorine
16. Isotopes of iodine which have been used to evaluate 
thyroid function include all the following except .
a. 1-127
b. 1-123
c. 1-131
d. 1-132
17. Euthyroidism refers to the condition of the thyroid as 
being .
a. overactive
b. normal
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c. underactive
d. oversecreting
18. Which of the following conditions occurs as a result of 
thyroid deficiency in infancy?
a. Down’s syndrome
b. mongolism
c. cretinism
d. myxedens
19. Primary hypothyroidism is due to  .
a. failure of the pituitary to secret TSH
b. failure of the hypothalamus to secrete TSH
c. failure of the gland itself
d. all of the above
20. Secondary hypothyroidism is due to ___
a. failure of the pituitary to secret TSH
b. failure of the hypothalamus to secret TRH
c. failure of the gland itself
d. none of the above
21. T3 by RIA is most helpful in the diagnosis o f___
a. hypothyroidism
b. hyperthyroidism
c. thyroiditis
d. thyroid carcinoma
22. The greatest clinical utility of measuring TSH by RIA 
is in differentiating .
a. primary from secondary hypothyroidism
b. Graves from Plummers disease
c. Hashimoto’s thyroiditis from Reidel’s struma
d. thyroid adenoma from cyst
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23. Serum TSH levels are Generally in the
hypothyroidism and in hyperthyroidism.
a. decreased, elevated
b. decreased, normal
c. normal, elevated
d. elevated, decreased
24. Calcitonin, a hormone involved in calcium metabo­
lism, is produced in the___
a. parathyroid glands
b. thyroid gland
c. pancreas
d. anterior pituitary
25. A person with clinical features of acromegaly is likely 
to be tested for which hormonal aberration?
a. elevated TSH levels
b. depressed TSH levels
c. elevated HGH levels
d. depressed HGH levels
26. PTH, which is produced by the parathyroid glands, is 
important in the regulation o f___
a. iodine
b. calcium
c. tyrosine
d. thyrotropin
27. Plummer’s disease is another name for .
a. toxic diffuse goiter
b. toxic nodular goiter
c. hypothyroid goiter
d. Grave’s disease
28. Free thyroxine index (H I) was developed to ade­
quately reflect thyroid status; the formula used is  .
a. 1-131 uptake
1
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T4
b. T4
T3 uptake
c. T3 uptake x T4
d. T3 uptake xTBG
29. If a patient is tested for vitamin B-12 deficiency and 
received a value less than 7% in phase I and phase II, but 
urine values above 7% after antibiotics are given, then the 
most probable disease state is  .
a. pernicious anemia
b. gastrectomy
c. blind loop
d. disease of the ileum
30. Cyanocobalamin is  .
a. important in cell maturation
b. absorbed in stomach with intrinsic factor
c. same as folates
d. both a. and b.
e. all of the above
31. Which is not needed for a Schillings test?
a. blood sample
b. urine sample
c. standard
d. cyanocobalamin injection
32. If a phase I Schillings test provided a 17% uptake on a 
patient, one should .
a. begin phase II using intrinsic factor
b. consider patient normal and end testing
c. administer antibiotics to make sure patient does not 
have sprue or gastro-colic fistula
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33. The first procedure performed dining Schillings test is
a. inject 1 cc (1000 micrograms) of non-radioactive 
vitamin B-12 (flushing dose)
b. administer cobalt-labeled cyanocobalamin capsule 
to patient
c. instruct patient to remain fasting for four hours
d. collect blood sample of patient
34. Which does not belong when evaluating vitamin B-12 
deficiency?
a. inability of gastric parietal cells to secrete intrinsic 
factor
b. gastrointestinal reflux and esophagal pain
c. gastric resection
d. inflammatory disease of ileum
e. all need to be evaluated
35. When evaluating B-12 by RIA, the isotope used is  ,
whereas folic acid utilizes__
a. cobalt, Tc-99m
b. 1-125, cobalt
c. cobalt, 1-125
d. 1-125, cobalt
36. Normal ranges for vitamin B-12 are while values
less than are almost always associated with vitamin B-12
deficiency.
a. 200-900 pg/ml, 100 pg/ml
b. 200-800 pg/ml, 200 pg/ml
c. 3-20 ng/ml, 3 ng/ml
d. 100-500 ng/ml, 100 pg/ml
37. The most common test utilized for vitamin B-12 ab­
sorption after blood testing is__
a. hepatic uptake test
b. fecal excretion method
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c. Schillings test
d. depends upon the type of absorption one desires
38. CEA testing is most commonly associated with what 
type of carcinoma?
a. liver
b. uterus
c. fetal intestine
d. colon
39. Elevated levels of AFP between 25-100 pg/ml are as­
sociated with___
a. primary liver malignancies
b. an indeterminate range that no diagnostic value is as­
sessable
c. either benign or malignant liver diseases
40. Vitamin B12, which is not stored in the body, is ex­
creted primarily via the .
a. feces
b. urine
c. bile
d. all of the above
41. Intrinsic factor is a glycoprotein secreted by the .
a. jejunum
b. stomach
c. duodenum
d. ileum
42. Absorption of vitamin B12 can be studied by one 
more of the following tests .
a. fecal excretion
b. hepatic uptake
c. urinary excretion
d. all of the above
e. b. and d. only
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43. The dose of Co-57 vitamin B12 given for a Schilling 
test is generally .
a. 0.5 uci
b. 5.0 uci
c. 50 uci
d. 500 uci
44. The most common cause of vitamin B12 malabsorp­
tion is  .
a. drug therapy
b. small bowel blind loop
c. pancreatic insufficiency
d. deficiency in intrinsic factor
45. Failure to absorb dietary vitamin B12 will eventually 
lead to  .
a. pernicious anemia
b. microcytic anemia
c. leukemia
d. hyperchromic anemia
46. Choose one that does not belong—Possible causes of 
malabsorption of Vitamin B12 include___
a. inability of stomach to secrete intrinsic factor
b. gastric resection
c. inflammatoiy disease of ileum
d. Down’s syndrome
e. bacterial growth in stomach
47. High levels of HCG-B hormone in the blood cor­
responds highly with .
a. patient with abdomen cancer
b. patient is pregnant
c. patient has fever of unknown origin
d. impossible to diagnose without correlation to bone 
or liver scan
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48. Rtuitaiy-Gonadal negative feedback system means 
that___
a. low levels of estradiol or testosterone stimulate 
hypothalamus to release gonadotropin
b. high levels of estradiol or testosterone stimulate 
hypothalamus to release gonadotropin
c. L H  and F SH  (low levels) stimulate sex hormone 
production
d. pituitary stimulates hypothalamic release of hor­
mones at certain time intervals
49. L H  and FSH  are released by the .
a. gonads
b. anterior pituitary
c. hypothalamus
d. a. and b. only
50. The Australia antigen, discovered in 1963 by Blum- 
berg is also known as the antigen o f___
a. hepatitis A
b. hepatitis B
c. hepatitis C
d. hepatitis D
51. The effect of the hormone gastrin, secreted by the 
gastric antrum, is to  .
a. stimulate gastric acid secretion
b. suppress gastric acid secretion
c. increase gastric motility
d. decrease gastric motility
52. The standard time when blood for digoxin concentra­
tion measurements should be drawn is approximately__
hours after the last digoxin dose was taken.
a. 2 hours
b. 4 hours
c. 6 hours
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d. 8 hours
53. The serum Ck-B is elevated in cases o f___
a. acute myocardial infarctions
b. chronic liver disease
c. ischemic heart disease
d. digoxin toxicity
54. The radiolabel used in Vitamin B12 RIA testing is___
a. 1-125
b. Se-75
c. Co-57
d. 1-131
55. The subunit which is immunologically identical for the 
glycoprotein hormones FSH, LH, TSH, and HCG is the
a. Alpha subunit
b. Beta subunit
c. Gamma subunit
d. Delta subunit
56. Theophylline, which may be measured RIA, belongs 
to the class of drugs known as___
a. anticonvulsants
b. bronchodilators
c. antibiotics
d. vasodilators
Section 3
True or False
_  1. Acid-citrate-dextrose (ACD) is used to clot blood
when making up Indium-111 labeled WBC’s.
_  2  Lipid soluble oxine carries the In-111 across the
cell membrane where In-111 separates from oxine.
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3. Labeled WBC will not distribute to liver, spleen, 
and functioning bone marrow in normal patients.
4. In-111 is the isotope and technique o f choice 
(WBC labeling) when investigating abdominal absces­
ses.
5. As little as .0004 ml of blood contaminated with 
hepatitis B can transmit the disease.
6. Incubation of hepatitis B is approximately 3-4 days.
7. Digoxin is used to treat congestive heart failure.
8. IgE is an immunoglobulin class responsible for al­
lergic reactions.
9. The normal range is 3-250 nglml in adults for CEA 
testing.
10. Alpha-fetoprotein plays a similar role in fetal life 
that serum albumin plays in adults.
11. One reason for high levels of CEA is the rapid 
growth of tissue resulting in disruption of blood tissue 
barriers.
12. Pancreas, colon, rectum, and lung carcinomas are 
associated with AFP.
13. Blood testing of carcinoma are useful in evaluating 
response to tumor therapy.
14. Liver disease and Cushing syndrome are as­
sociated with high levels ofHCG.
15. The recommended intake of vitamin B12 is 2 
ug/day.
16. Folates is a generic term for vitamin B12.
17. Folic acid is found in liver, yeast, and vegetables.
18. Vitamin B12 and folates are stored in small intes­
tines until needed by the body.
19. Decreased levels of TSH with decreased levels of 
T4 is indicative of secondary hypothyroidism.
20. T3 uptake is an indirect estimate of capacity of 
plasma protein to bind thyroid hormone.
21. CEA levels become increased in pancreas, rectum 
and lung malignant cancers.
22. Alpha-fetoprotein is most commonly associated 
with liver malignancies such as hepatomas.
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Chapter 9
ALTERNATIVE METHODS TO RIA 
TESTING
Objectives
•  Understand the basic differences between
heterogenous and homogeneous immunoassay testing.
© Be able to distinguish the advantages and 
disadvantages of heterogeneous and homogeneous 
testing.
•  Demonstrate an overall understanding of EIA, FLA, 
FPIA and monoclonal antibody testing including their 
function and methodology.
Alternative Methods to RIA Testing
All of the discussion within this manual thus far has centered 
on radioimmunoassay testing. This type of testing is called 
heterogeneous immunoassay. That is when there is no dif­
ference between the signals produced by bound or free 
labeled substances, therefore it is necessary to separate the 
two before measurement.
Hom ogeneous Immunoassay
In these types of testing procedures there is a difference 
between the signals generated by the free and the bound 
labeled substances. Separation is therefore unnecessary.
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Example: EIA, FIA (optical) testing, FPIA testing. Dif­
ference between signals arise because the signal is either 
produced or altered upon binding.
Heterogeneous Homogeneous
more sensitive no separation technique
Advantages more specific easier, faster to perform
less matrix interference
Three common homogeneous immunoassay testing proce­
dures will be briefly discussed:
© Enzyme immunoassay (EIA)
•  (FIA or LIA) fluorescence and luminescence 
immunoassays
•  Fluorescence polarization immunoassay (FPIA)
•  Monoclonal antibodies
Enzyme Immunoassay (EIA)
Substance is labelled with an enzyme rather than I . This 
enzyme catalyzes another reaction within reaction matrix. 
This other reaction produces an optical signal.
EMIT (Enzyme Multiplied Immunoassay Test)
Enzyme GGPDH (Glucose-G-Phosphate Dehydrogenase)
Catalyzes NAD NADH Nicotinam ide Adenine 
Dinucleotide
But GGPDH is deactivated when bound to antibody 
measures change of absorbance at 340 nm produced by con­
version of NAD to NADH.
When large amount of natural Ag, little Ab remaining to 
deactivate enzyme. Rate of conversion of NAD to NADH 
high as measured by increase of absorbance at 340 nm. Con­
versely low natural Ag high Ab to deactive enzyme, rate NAD 
NADH low.
Direct Relationship
Advantages
•  Less expensive to run, can be automated.
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© No separation.
•  Not labor intensive like heterogeneous.
Disadvantages
•  Not as specific as RIA.
•  Reaction medium critical.
•  pH, ionic, temperature, other enzyme like lysozyme 
interfere 95 % confidence level false negatives and false 
positives.
FIA or LIA Luminescence Immunoassays
Ag labeled with fluorophore but not active and an enzyme that 
release fluorophore - active but enzyme is ineffective when 
Ag is bound to Ab.
Ag +  Ag* +  Ab < — > AgAb + Ag Ab
What happens to fluorescence when large Ag - goes up direct­
ly proportional.
Fluorescein - fluoresces when light added to system luminol 
produces light on own - no light to system.
Fluorescence Polarization Immunoassay (FPIA)
Ag + Ag* +  Ab < — > AgAb +  Ag* Ab
Ag* fluorescent labeled with a fluorophore when light at 485 
nm (blue) hits fluorophore - raises it to an excited state (e- 
outer shell) when returning to ground level (e- come back), a 
different is emitted 525 - 550 hm (green).
How does it tell difference? B/W Ag* and Ag*Ab
Polarize the 485 nm blue light, THerefore absorption of the 
blue light takes place on a single plane. But during emission 
of green light, a rotation occurs or a depolarization and the 
525 - 550 nm light is emitted on different plane.
But Ag* Ab hinders rotation B/W absorption and emission 
preventing depolarization of green light. Green light emits 
on the polarized plane so higher natural Ag, Lower the Ag* 
Ab and lower the degree of polarized (green) light (inversely 
proportional) degree of polarized light akin to radioactivity.
Advantages
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•  Specificity, stability like RIA
•  Can be automated, not labor intensive
Disadvantages
•  Cost
Monoclonal Antibodies
Generally when inject antigen, animal immune system ac­
tivates broad range of antibody secreting cells each cell 
releases one molecular configuration antibody against an­
tigen. Wind up with a mixed population of antibodies that 
bind with differing affinities—call polyclonal antibodies. 
Binding is also at different locations. This increases possible 
cross reactions to substances with similar configurations to a 
particular locations. To produce monoclonal antibodies, an­
tibody secreting cells are fused with myeloma cells purpose: 
faster division genetic material of myeloma cells—provides 
the rapid division. Resulting “hybridomas” are separated 
with special techniques into separate cell colonies which 
produce only one antibody population.
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REVIEW
Section 1
1. List and describe the four types of homogeneous test­
ing methodologies described in the chapter.
2. List and describe the advantages and disadvantages of 
heterogeneous and homogeneous tests.
Section 2
1. Which blood testing technique os considered 
heterogeneous?
a. florescence
b. enzyme
c. sandwich
d. RIA
APPENDIX C-130 IN VITRO NUCLEAR MEDICINE LABORATORY MANUAL
2. Enzyme immnno testing is the most common form of 
blood sample testing because .
a. it’s cheap and not labor intense
b. of it’s sensitivity
c. of it’s reliability
d. it produces the fewest false negative results
e. all of the above
3. Enzyme testing and . RIA testing and .
a. results are a direct relationship between counts and 
Ag
b. results are presented an indirect between counts and 
Ag
c. high sensitivity, high specificity
d. not labor intensive
4. Two substances that may interfere with analysis of drug 
testing are___
a. opiates, free T4
b. chlorine, salts
c. iodine and morphine
d. any of the two above
5. Which is not true of florescence blood sample testing?
a. absorbed florescence is polarized in blue light, 
emitted in green light
b. emission of light is due to rotation of plane or 
depolarization
c. high specificity, sensitivity and high cost
d. all of the above are true
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Laboratory #1
Lab Safety & Pipetting Laboratory
SELECTING RADIOISOTOPE COUNTERS
In equipping a radioimmunoassay laboratory probably the most important piece 
of equipment is the auto-gamma scintillation spectrometer. All of the assays per­
formed will depend upon the reliability and efficiency of this instrument. Con­
siderations involving the selection of a gamma counter include: (1) the number 
of assays to be performed, (2) availability of service for the instrument, (3) 
capability of the instrument (e.g., does it have a single pulse height analyzer or 
more than one; does it have a rapid, clear printing system, etc.), and (4) the finan­
cial resources of the laboratory. If beta counting is to be performed, a high 
quality liquid scintillation system is mandatory.
THE LABORATORY FACILITY
As in any good laboratory, the RIA facility includes many components: adequate 
lighting and counter space, abundant cabinet storage for chemicals and 
glassware, convenient electrical outlets, a hood with an outside air escape (espe­
cially working with volatile chemicals or pathogenic antigens), vacuum, air, and 
gas sources, and a place for disposing of all radioactive waste.
General Laboratory Equipment
An assortment of glassware consisting of beakers, graduated cylinders, and Erlen- 
meyer flasks, should be on hand. Additional equipment includes graduated 
serologic pipettes (1,5, and 10 ml); Pasteur pipettes; test tubes, both glass and 
plastic (polypropylene or polystyrene); and test tube racks.
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A triple beam balance is necessary for weighing chemicals and balancing tubes 
for centrifugation. An analytical balance is occasionally required for certain as­
says for more accurate weight determination. Three or four timers capable of 
timing up to two hours are also useful. Magnetic stirrers and magnetic stirring 
bars are necessary for complete mixing of the many different solutions in the as­
says. A vortex mixer for test tube or vial mixing should also be available.
Many assays require careful regulation of the temperature; consequently, a water 
bath capable of maintaining temperatures from 37° to 100°C should be available. 
In addition to heat, ice is needed for a number of applications. Distilled water in 
plentiful supply represents an integral part of preparing any buffer or solutions 
needed in the assays.
A pH meter should be used to check the pH of many assay solutions. We recom­
mend a pH meter with an expanded scale and single electrode.
A refrigerated centrifuge equipped with a horizontal head is the centrifuge of 
choice.
A refrigerator and freezer must also be available for storage of reagents, sera, etc.
Specific RIA Equipment
Automatic pipettes with disposable tips capable of delivering accurate volumes 
are required for all procedures (including commercial kits). The pipettes should 
be available in the following sizes: 5,10,20,50,100,200,500,1,00 ul. Also 
needed is an automatic jar type pipette that can deliver volumes of 1 to 10 ml. 
This device allows the rapid delivery of known volumes of solutions used in the 
assays. A relatively new type pipette is the automatic pipetting station. This in­
strument was designed for high volume laboratories that perform very large num­
bers of studies. While expensive, this type of instrument promotes a greater 
degree of efficiency and reliability for the larger laboratory than is possible with 
conventional pipettes.
A calculator is needed to compute the results of the different assays. Also, a 
good bookkeeping system is critical. The receipt of the sample, the date of the 
assay, and the result must be carefully recorded and available for immediate 
retrieval.
Laboratory Safety and Pipetting problems with radiation safety include:
Personnel, monitoring, loss of data validity, and environmental pollution Of 
these factors, the most prominent is lab contamination with radioactivity.
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Lab Facility & Selection of Equipment in R.I.A.
1. Gamma scintillation spectrometer (counter). All of the assays per­
formed will depend upon the reliability and efficiency of this instru­
ment.
2. Adequate lighting and counter space.
3. Adequate cabinet storage for chemicals and glassware.
4. Beakers, graduated cylinders and flasks.
5. Graduated serologic pipettes (1,5,10 ml), tubes, test racks.
6. Triple beam balance for weighing and balancing tubes in centrifuge.
7. Magnetic stirrers, vortex mixers.
8. Temperature controls — water baths, distilled H2O.
9. pH meter — check pH of many assay solutions.
10. Refrigerated centrifuge, refrigerator, and freezer to store reagents.
Specific R.I.A. Equipment
•  Pipettes — 5 — 1,000 ul size.
•  Automatic pipettes with huge volumes.
•  Calculator to compute the results of different assays.
Contamination Control
1. Limit amount of radioactive material to just amount needed.
2. Surfacing materials should be chosen with contamination control in 
mind.
3. Areas designated for opening, transferring and handling radioactive 
materials.
4. Removable absorbent material or non-absorbent easy to clean 
material.
5.* Wear lab coats.
6. No eating or drinking.
Personnel Monitoring—film badge or TLD may be required depending upon 
type and amount of radioactive used.
Radioactive Material—Inventory, Storage, Disposal — all radioactive materials 
require legal documentation of each isotope - received and disposed - monitor­
ing of expiration date.
Storage of radioactive expired kits may become prohibitive due to long half lifes.
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The amount of activity that may be discharged into the sewage is restricted by the 
amount per unit volume and by the total amount of activity per year. Each 
isotope has its own specific limit.
Pipetting Laboratory
The purpose of this laboratory exercise is to allow students the opportunity to 
practice with a variety of different pipettes. Students will be able to demonstrate 
competence in their pipetting technique by the end of this lab.
1. Have students set-up racks of test tubes and number them 1-10.
2. Using various pipette sizes 10 ul - 200 ul students will practice pipet­
ting H2O into various test tubes 1-10.
3. Students will visually inspect the test tubes to see if the amounts dis­
pensed were similar from tube to tube.
4. Using tracer 1-125 from any R.I.A. test kit, have students set-up at 
least 2 different sets of test tubes and number them 1-10 and 11-20 
respectively.
5. Students will choose any two pipettes from the variety available size 10 
ul - 200 ul and attempt to pipette equal amounts into each set of ten 
then change pipette and dispense into next tubes 11-20.
6. Calculate C.V. for tubes 1-10.
7. Calculate C.V. for tubes 11-20.
8. Repeat until C.V. values are less than +/-10%.
Ex: Using pipettes 20 ul and 1-125 tracer and counting tubes in Gamma well 
counter the follows counts are recorded;
1. 10,551
• —  ~  — ----- —  —  -------- - ' " - ' - 7
coefficient of variance
2. 10,392 %C.V. = SD x 100
3. 11,001 X
4. 10,845 S.D. = (Xi- X)2
5. 10,782 n - 1
6. 10,615 n = total number of tubes used
7. 10,432
8. 10,444 X = X = 106,275 = 10,627.5 round to 10,628
9. 10,681 n 10
10. 10,532
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( X i - X )2 
10,551 - 10,628 = { - l l )2 = 5929 
10,392- 10,628 = (-236)2 = 55,696 
11,001 - 10,628 = (373)2 = 138,384 
10,845 - 10,628 = (217)2 = 47,084 
10,782-10,628 = (154)2 = 23,716 
10,615 - 10,628 = (-13)2 = 169 
10,432-10,628 = (-196)2 = 38,416 
10,444 - 10,628 = (-184)2 = 33,856 
10,681 - 10,628 = (53)2 = 2,809 
10,532-10,628 = (-96)2 = 9216
355,275
S.D. = 355,275 = 198.6 
9
Calculate C.V. % = 198.6 x 100 = 1.86%
10,628
This is the percent variance or deviation for all ten test tubes that were pipetted.
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Student Worksheet
1. After pipetting a known volume into the first ten tubes 1-10, count in 
gamma counter and record results.
1. 
2.
3.
4.
5.
6.
7.
8.
9.
10.
2. Calculate X =e X
n
3. Calculate e (Xi - X)2
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4. Calculate S.D. = /J 2 & i2 Or
v  n - 1
5. Calculate % C.V. = _SyD. x 100
X
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Laboratory 2
Normal Distribution, Confidence 
Intervals and Percent Error Laboratory
Data Given: 20 individual counts
1. 15,505 11. 17,981
2. 14,90112. 18,002
3. 13,876 13. 16,544
4. 19,351 14. 16,994
5. 18,41115. 15,456
6. 18,302 16. 17,893
7. 16,451 17. 16,543
8. 17,339 18. 15,988
9. 16,272 19. 16,901
10. 14,98120. 17,042
1. Calculate X = e X =
n
2. Calculate +1-1 S.D. =
What is the range in counts for 68% confidence
3. Calculate +/-2S .D . =
What is the range in counts for 95% confidence
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4. Calculate+ /-3  S.D. = ______
What Is the range in counts for 99% confidence_____
5. Is ct. number (3) 13.876 outside 3 S.D. = _______
6. Is ct. number (4) 19,351 outside 3 S.D. = ______
Why or why not?__________________________________
7. How many cts. would be needed to be 99% confident and + /- 2% 
error?
Show work_______________________________________
8. If a source is counted provides 100 ct/sec, how long will you need to 
count this source to be within 95% confidence and +/- 8% error?
Show work_____________________________________
9. A source is counted in a nuclear medicine department during a 
routine liver scan gives us 17,500 counts what is the % error?
Show all work_______________________________
10. What percent confidence is necessary for research?
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Laboratory 3
Examining Principles and Procedures 
for Reagents
The purpose of this laboratory exercise is to have students become familiar with 
the component parts of a typical R.I.A booklet used in Nuclear Medicine.
In this laboratory, the student will use a booklet on an R.I.A. procedure common­
ly performed in your lab (ex.: T4, T3, digoxin, Haa, Cortisol, etc.).
1. What is the intended use of this kit?
2. Why is it important to know the level (quantity) in samples?
3. How does this blood level (T4, Digoxin, CEA, FSH, etc.) function in 
the body?
4. What is the basic principle of this assay? Competitive or non-competi­
tive?
5. List and describe each component in this test.
6. What supplies and materials are needed?
7. How do you prepare reagents?
8. Explain and describe the protocol used in this test?
9. What precautions (if any) need to be noted?
10. What are the quality control measures?
11. Limitations of test?
12. What is the (Ag), (Ab), standards, sample in test?
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Laboratory 4
Typical R.I.A. Testing
Competitive Protein Binding in most R.I.A. analysis testing is 
considered to be competitive because the antigen (Ag), which is 
either the patient unknown, standards, or controls, compete for 
binding sites on the antibodies (Ab). This reaction takes place 
in each test tube.
Let’s give an example of a typical R.I.A. test, outlining each 
step and then, upon gaining an understanding of the process, the 
student will attempt to develop a typical test and plot the 
results obtained.
ffismsmsmss&ixsmimsi
Procedure 1
Using the appropriate test tubes for a given test, label each tube 1 through 20 
with a dark magic marker and place tubes into a test tube rack sets of two.
Tubes are set up in sets of two because each component is run in duplicate.
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Procedure 2
Set up a worksheet explaining which tubes correspond to which item or com­
ponent, allowing space for values obtained after running the test.
For example:
Test tube # ’s Component
*
I,2 total counts (Ag only)
3,4 NSB (non-specific binder from
manufacturer plus standard “0")
5,6 standard - “0" concentration
7,8 standard - 2.5 concentration
9,10 standard - 5.0 concentration
II,12 standard - 10.0 concentration
13,14 standard - 15.0 concentration
15,16 standard - 30.0 concentration
17,18 patient unknown (Mary Smith)
19,20 control A (high count rates)
21,22 control B - (low count rates)
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Resultant values:
The purpose of any R.I. A. test is to ascertain the value of the unknown or 
patient, or Mary Smith in this case.
Procedure 3
Adding appropriate reagents: assume we are testing Mary Smith 
for a T4 blood concentration level.
Pipette into test tubes 1 and 2 the appropriate amount of total counts from the 
kit, let’s say 20ul.
Follow your worksheet and add the specified amounts of each standard (20ul) to 
their corresponding tubes.
Add patient serum (20ul) to the appropriate tubes (15 and 16).
Add control A to tubes 17 and 18, and add control B to tubes 19 and 20.
*
Pipette Ag (radioactive antigen) to each test tube (1-20) in a given amount (100 
ul for our purposes).
Now, pipette the Ab into each test tube (1-20) in a given amount (let’s say 
200ul).
At this point, competition for binding sites on the Ab begins between either non- 
radioactive Ag, the NSB, standards, patient unknown, control and the radioactive 
(usually 1-125), labeled ligand (Ag).
♦
Ag Ag Ab
Ab
(either standard, 
patient or control) Ag AgAb
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The higher the concentration of NSB, standards, patient or
control, the less the binding of 1-125 to the Ab binding sites.
Thus, when counting the radioactivity, there is an inverse
relationship between counts and concentration, which will be demonstrated 
shortly.
Procedure 4
Incubation of reagents: allow the reaction to reach a state of 
equilibrium (Ki - K2). Depending on the type of test performed, 
this incubation may be at room temperature or may require heating 
in water baths from, typically, 10 minutes to 2 hours.
Procedure 5
Centrifugation: this allows for binding to be completed and aids 
in separation.
Procedure 6
Separation of bound from free: the results of the test are 
obtained from counting the bound portion only. This is typically 
done by decanting the reagents nor bound into a sink or toilet.
m^mmmmssssmsssm
Procedure 7
Count tubes in gamma well counter.
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Procedure 8
Analyze resultant values: refer back to Mary Smith’s T4 test.
The manufacturer has sent known concentrations on components 
refered to as the standards at various values and have also 
supplied us with controls of known values.
If the normal values for a T4 patient is known, let’s say 5-20ug/dl, we can analyze 
the results. After running the test,
assume the following data were obtained:
TEST TUBE COUNTS COMPONENTS
1 25,404 total counts
2 24,355 rr
3 21,456 NSB
4 20,596 it
5 19,347 "0" concentration
6 19,562 tt
7 16,322 2.5 concentration
8 16,848 It
9 13,471 5.0 concentration
10 13,484 it
11 10,958 10.0 concentration
12 11,651 II
13 8,945 15.0 concentration
14 8,886 It
15 6,842 30.0 concentration
16 6,731 it
17 1,785 patient-Mary Smith
18 1,698 II
19 15,421 Control A (low)
20 15,822 tt
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21 7,345 Control B (high)
22 7,269
Plot the standard curve for the above:
concentration
counts
Interpolate the values for Mary Smith and controls A and B.
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Laboratory 5
R.LA. LABORATORY
Running and Analyzing Resultant Values for 
Common R.LA. Tests
This lab should be run at least 2 different times by stu­
dents.
1. Set up worksheet including all components in assay listed in packet in­
sert, such as: (see typical R.I.A. testing LAB for example)
total counts, NSB, B0, all standards, controls and patient unknowns
Do all test tubes in duplicates. For example:
COMPONENT TEST TUBE #
total counts
NSB
Bo
standard 1
1,2
3,4
5,6
7,8
etc ...
2. Perform test as described in packet insert in test kit.
3. Count tubes in gamma well counter.
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4. Plot counts received vs. known concentration of standard on graph 
paper.
counts 
received 
in test
concentration of assay
5. Interpolate resultant values for controls and patient unknowns in 
graph on original worksheet.
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WORKSHEET
TUBE #  COMPONENT COUNTS INTERPOLATED RESULTS
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
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A Typical R.I.A. Procedure Protocol
THC used as an example
Details of th e  Procedure
A standard curve must be constructed for each set of unknowns assayed. Follow 
the order of the steps exactly.
1. Label and arrange the assay tubes according to the assay protocol 
shown in Table 2.
2. Dilute the 125I-THC derivative with BSA buffer (1:50) according to the 
instructions for dilution of tracer. Add 200ul working tracer to the 
total count tubes, stopper and set them aside for counting at the com­
pletion of the assay.
3. Add 50ul cannabinoid standard to the correspondingly numbered 
tubes. Note that the Ong/ml standard is dispensed into the NSB and 
zero standard tubes.
4. Add 50ul of the urine low control and high control to the correspond­
ingly numbered tubes.
5. Add 50ul of the urine samples to their correspondingly numbered 
tubes.
6. Add lOOul of the BSA buffer to the NSB tubes.
7. Add lOOul of the THC antibody to all assay tubes (do not add antibody
to NSB tubes).
8. To each assay tube add 200ul of the working tracer solution.
9. Add 200ul of second antibody complex to all tubes (mix the second an­
tibody well before use).
10. Gently vortex mix all tubes and incubate the entire assay for 15 
minutes at room temperature (25°C). The assay rack may be covered 
with Parafilm (optional). Avoid incubating in direct sunlight.
11. Centrifuge the assay tubes at 2500g for 15 minutes.
12. Replace the assay tubes in their rack. Aspirate the supernatant fluid 
taking care not to disturb the pellet (See Note 3). Count all assay 
tubes in a gamma counter for at least one minute per tube.
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Laboratory 6
Equipment Performance Evaluation 
Laboratory
There are three basic ways of analyzing your gamma counter’s effectiveness and 
unbiasness of results.
1. Chi-square test (checks for reliability of counter)
2. Efficiency (checks for sensitivity of instrument)
3. Background check (rules out contamination)
A test that is performed to ensure that variation from a series of individual 
counts are likely to be due to random nature of radioactive decay and not by 
other influences.
Parti
Using a single source (T-l/2 many wks) 1-125
1. count a series of 1 min cts
2. count this same sample 20X
3. Place values in appropriate spaces
4. Calculate Chi-square value
5. Compare to tabulated results
Is instrument reliable?
Why or why not?
This set of data of different counts are compared to the theoretical variation that 
one would expect from random sampling.
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Chi-square test*2 = e  (X-X )2
X
compared calculated result to tabulated (P) values 
(P) value should be around (.5) must fell between .1-.9 or equipment is considered faulty.
DATA FROM COUNTING 1-123 SOURCE 20 TIMES
1. 11.
2. 12.
3. 13.
4. 14.
5. 15.
6. 16.
7. 17.
8. 18.
9. 19.
10. 20.
Part 2
Another way to analyze equipment is by calculating the efficiency.
This is performed by comparing the number of counts registered to the number 
of potentially effective emissions from the source.
CPM = Counts per/min 
DPM disintegrations per/min
1. Take a known NBS standard source CS-137,50-60, calculate the DPM 
based on its decay.
1 curie = 3.7 x 101°dps 
1 curie = 22 x 1012dpm
show all work
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2. Count the source in the well-counter 10 times for 1 min each and 
record data.
1. 6.
2. 7.
3. 8.
4. 9.
5. 10,
3. Based on the average X of these count rates/min calculate:
CPM for this gamma well counter 
DPM
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Laboratory 7
Laboratory Worksheet for Indium-111 
Labeled for Leukocytes
I.
Patient information: (Patient should not be dehydrated)
Date:___________________
Hospital:_____________________
Patient Name:_________________
Indium Rx #:
WBC Count:
n.
Radiopharmaceutical preparation: Check off each step as completed.
  1. Time blood was drawn:_____ Volume of blood drawn:_____mis 50ml.
  2. Plasma volume after separation: ____ mis (Approx. 251m, Need at
least 15ml)(10cc HESPAN if needed after 30min, Doctors Cons.)
  3. Centrifugation for 5 minutes at 400-450g (setting 70
WBC button from supemate.
  4. Draw off platelet-rich plasma (PRP) and save.
  5. Saline wash: Wash button with 3mls of saline. Centrifuge for ap­
proximately 5 minutes at 400-45Og. Draw off wash and discard.
) and separate
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6. Reconstitute the WBC button using approximately 3mls of saline. 
Break up button with needle.
7. Activity added to button:  uci Assay time__
8. Total incubation time:______
9. Centrifuge PRP for 10 minutes at lOOOg (setting_____90 ) Yielding
PPP top layer.
10. Plasma wash 2-5mis of PPP from top layer. Let stand for 5 minutes.
11. Centrifugation at 400-450g for five minutes. Draw off hot supemate 
and save.
12. Resuspend button with 4mls of plasma (PPP top).
13. Assay of hot supemate and discard:_____uci.
14. Assay of WBC button:_____uci.
15. Labeling efficiency of In-111 labeled WBC:
(14)________ / (7)________ x 100 = ________
____________ time
____________uci
ml
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Laboratory 8
Linearity Testing in R.I.A. Procedures
RIA/THC LAB
* note this lab exercise utilizes a THC kit, which is commonly used in RIA labs, 
but any other kit can be substituted.
sm&m&mmsmm
Introduction
The basic purpose of this lab is to study serial dilution linearity of natural human 
urine containing cannabinoid metabolites (primarily 11-NOR-D -THC-9-CAR- 
BOXYLIC ACID). There is evidence showing that some urine specimens con­
taining cannabinoid metabolites do not maintain a linear response to RIA 
activity upon serial dilution, while others do. The reason for this is unclear. Pos­
sible explanations include solubility changes influenced by the amount of protein 
present, or the presence of an interfering substance which becomes more 
pronounced with decreasing concentrations of antigen. As this lab develops, 
depending on results, these, and other possible influences, will be explored.
mmmmmmmmztmm
Basic Procedure
Dilute a urine specimen containing between 100 and 200 ng/ml THC metabolite:
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URINE DILUTANT TOTAL VOLUME
1:2 200ul 200ul 400ul
1:4 lOOul 300ul 400ul
1:6 lOOul 500ul 600ul
1:9 50ul 400ul 450ul
1:11 50ul 500ul 550ul
1:16 20ul 300ul 320ul
1:21 20ul 400ul 420ul
Using (1) water, (2) negative natural urine, (3) negative synthetic urine. Com­
pare results. This needs to be preformed on several different urine samples.
For values between 200 and 400 ng/ml
URINE DILUTANT TOTAL VOLUME
4
6
9
11
16
21
31 20ul
For values between 400 and 800 ng/ml
9
11
16
21
31
42 dilute 
62 dilute
600ul 620ul
1:21, 1:2 
1:31, 1:2
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Construct curves to determine linearity. In particular, point where linearity 
begins to deviate should be noted. In addition, any consistency in holding to, or 
deviating from linearity should be recorded.
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Laboratory 9
Effects of Time on R.I A . Testing
Procedures
RIA/THC LAB II
Introduction
It is well known in RIA testing that time is a critical parameter in the outcome of 
the analysis. This fact becomes crucial when considering the workup itself involv­
ing adding reagents in a sequential fashion. The purpose of this lab is to deter­
mine the total effect of time difference between the front and end of the assay 
on the final results. Only the calibrators and controls contained in the THC kit 
are needed.
Basic Procedure
The high and low controls are to be compared by running two sets (everything in 
duplicate including calibrators, therefore one set of high and low controls equals 
4 tubes) per assay - one before and one after the calibrators. Since there are 
seven calibrators, each assay will have 18 tubes (19 with total tube). One high 
and low control set will assume the positions for unknown samples during count­
ing.
Following package insert, add all reagents as readily as possible recording time. 
Repeat, but doubling the time for adding reagents. Repeat again doubling once 
more. Compare values calculated for the high and low controls at the beginning 
and end of the assay.
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Repeat the above procedure adding isotope first, 2nd antibody second, and 1st 
antibody last. Compare.
IN VITRO NUCLEAR MEDICINE LABORATORY MANUAL APPENDIX C-161
Laboratory 10
Altering the Standard Curve
RIA/THC LAB III
Introduction
The proportions of reagents added in the THC assay according to the package in­
sert are calculated to provide the most beneficial curve between the highest 
(100) and lowest (0) calibrators. It is possible, however, to alter the curve by 
changing reagent and sample ratios. Occasionally, it is desirable to make such an 
alteration. For instance, when assaying a sample containing THC metabolite 
above the range of the curve, you could dilute the sample to fit the curve, or you 
could alter the curve to fit the sample.
msmmmmmsmststmsmsst
Basic Procedure
Using calibrators only, using the package insert proportions as a base, run the fol­
lowing assays with the indicated changes in reagents or calibrators. You should 
have already ran a normal curve for comparison. Everything in duplicate. P = 
package insert.
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CALIBRATOR 1ST ANTIBODY ISOTOPE 2ND ANTIBODY
X2 P P P
X4 P P P
P X2 P P
P X2 X2 P
P P X2 P
P X4 X4 P
P P P X2
P X4 X4 X4
Additional changes may be tried as stimulated by above results.
Compare and explain variations of curves. Which assay could be used to deter­
mine a higher level which normally would have to be diluted? Which assay 
would be more sensitive to low levels?
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Laboratory 11
Plasma Volume
S -S S S S 5 3& 8 38 S 8 K S 8
Purpose
Plasma volume studies are a great asset in treating patients suffering from con­
gestive heart failure, nephrosis, cirrhosis, polycythemia, and the anemias. It is 
especially useful when doing serial studies on patients in whom large blood los­
ses and blood replacements are apt to occur.
Rationale
The radioiodinated human serum albumin being a protein, travels solely with the 
proteins in the plasma.
D osage and Radiation
The dosage of 10 c of ratioiodinated human serum albumin is so small that the 
total radiation dose is approximately 0.2 rads. In the case of a daily serial study, 
the doses run 10 uc on the first day, with 20 uc on the second day, and 40 uc on 
the third day. The increased dosage is necessary because it is essential that the 
patient’s sample count be at least twice background. This dosage increase in­
sures adequate counting statistics.
Patient Preparation
None.
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Material and Equipment
I'll1. Human semm albumin I (IHSA) — 15 microcuries
2. Syringes
a. = 20ml. (1)
b. 10ml. (3)
3. Needles - 20 gauge
4. Timer
5. Microhematocrit and capillary tubes
6. Centrifuge - capable of spinning 10 ml. samples at 2000 rpm.
7. Pipettes - 3 ml. (3)
8. Test Tubes
a. glass (3) 13 mm
b. plastic (3) 13 mm
9. Scintillation well counter
PROCEDURE
1. Obtain patient’s weight and height.
2. Dilute 15 uc ^ I  IHSA in a 30 ml. saline vial to which has been added 
1 ml. or 0.5 mg. human semm albumin.
3. Withdraw 20 ml. and count the activity in the syringe at a fixed dis­
tance above the well with the analyzer set at 150 Kev to infinity.
4. If the patient had any previous isotope procedure, draw 10 ml. of 
whole blood in a heparinized tube as a control. Inject 20 ml. of diluted 
IHSA into the patient.
5. Withdraw 10 ml. of venous blood at 10 and 15 minutes post injection 
from opposite arm not receiving transfusion.
6. Count the empty m I IHSA syringe.
7. Do hematocrit on both patient samples.
8. Centrifuge the samples for 15 minutes at 2000 rpm.
.9. Pipette 3 ml. of plasma from both 10 and 15 minute samples and count
the radioactivity in the well using setting in step. Record the back­
ground.
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CALCULATIONS
Total plasma activity is equal to counts before injection minus counts after injec­
tion times the distance factor. NOTE: (Distance factor utilizes the inverse 
square law whereby the syringe is counted a certain distance from the crystal and 
the counts are decreased by a fixed and known amount). If a distance factor is 
not extablished, simply dilute 1 ml. of the remaining 10 ml. saline solution mix­
ture to 100 ml. Pipette 1 ml. of the dilution and count in the well.
Plasma volume = Net Standard Count x Dilution
Net Sample Count/ml
Whole Blood volume = Plasma Volume
l-(Hct x 0.91)
Red cell mass - Whole Blood volume - Plasma volume 
Express all values as cc per wt. in kg.
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Laboratory 11
51Cr RED CELL MASS
PURPOSE
Blood volume studies are a great asset in treating patients suffering from conges­
tive heart failure, nephrosis, cirrhosis, polycythemia and anemias. It is also used 
to follow the status of the patient who has had open heart surgery and other 
major surgery with associated large blood loss and replacement.
RATIONALE
51Cr as sodium chromate is present in the hexavalent ( + 6) state and readily 
penetrates the red cell to attach to the hemoglobin where it is reduced to the 
trivalent (+ 3 ) state.
MATERIAL AND EQUIPMENT
1. A-C-D (Strumia formula) solution
2. Socium chromate (51Cr) - 60 microcuries
3. Syringes - 50 cc (2), 10 cc (2)
4. Needles - 18 gauge, 20 gauge
5. Hematocrit tubes
6. Test tubes (8)
7. Volumetric flasks - 100 cc (2)
8. Heparin solution - 1000 USP units per cc
9. Timer
10. Centrifuge
11. Tourniquet
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12. Scintillation well counter
PROCEDURE
1. Obtain patient’s weight and height.
2. Withdraw the 10 ml. of Strumia formula ACD solution into a 50 ml. 
syringe.
3. Into the same syringe, draw 40 ml. of whole blood to make a total 
volume of 50 ml.
4. Expel the entire syringe contents back into the tagging vial. Use an 18 
gauge needle to avoid hemolysis and have a 20 guage needle for an air­
way.
5. Add 60 uc Na2 51Cr 04  to the vial and let stand at room temperature 
for 15 minutes with occasional mixing every 2-3 minutes.
6. Withdraw 40 ml. from the mixture and weigh the capped syringe. The 
remaining 10 ml. will be used as the standard.
7. If the patient had any previous isotope procedure, withdraw 15 ml. of 
whole blood as a background control.
8. Have physician inject the tagged blood back into the patient.
9. At 10 and 15 minutes post injection, withdraw 15 ml. whole blood from 
the contralateral arm into a heparinized syringe.
10. Do hematocrit on both patient and sample and on standard.
11. Pipette 3 ml. whole blood from each patient sample.
12. Pipette 1 ml. of whole blood standard and dilute to 100 ml. with dis­
tilled water. Pipette 3 ml. of this dilution for counting.
13. Centrifuge standard and both patient’s samples for 15 minutes at 2000 
rpm.
14. Pipette 3 ml. plasma from each patient sample.
15. Pipette 1 ml. of plasma standard and dilute to 100 ml. with distilled 
water. Pipette 3 ml. of this dilution for counting.
16. Count all samples in a scintillation well-type counter and record the 
background.
CALCULATIONS
Red Cell Mass =
Where:
a. Standard whole blood count
b. Standard plasma count
c. Hematocrit of the standard
d. Patient’s whole blood count
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e. Patient’s plasma count
f. Patient’s hematocrit
Vwbi. Volume of whole blood injected 
Whole Blood Volume = Red Cell Mass
Pt. hct x 0.9.18
Plasma volume = Whole Blood volume - Red Cell Mass.
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Laboratory 11
Principle of Dilution Laboratory Exercise
Formulas
Q = VxC_or V = Q/C 
Q = total quantity of tracer 
C = tracer concentration in diluting fluid 
V = diluting volume 
V1C1 = V2C2
In calculating blood volumes if either plasma volume or red cell volume is deter­
mined, the total blood volume can be calculated with the aid of hematocrit.
PLASMA VOLUME = Net standard counts x dilution
Net sample counts/ml
WHOLE BLOOD VOLUME = Plasma volume
(1-HcL x 0.91)
OR
Red blood cell volume 
(hematocrit x 0.01)
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EXAMPLE: 15uCi of 1-125 HSA in a 10ml syringe = 15uCi
10ml
This material is then tagged to patient’s plasma and reinjected into the 
individual’s arm. Fifteen minutes later, 10ml of blood is withdrawn from patient. 
Activity is calculated as:
So, patient’s plasma volume = 6521ml (this is V2)
Normal plasma volum = 43 ml/kilogram of body weight 
Calculated hematocrit = 49%
Whole blood volume = 6.5 liters = 11.81 liters of blood
(1 - .49 x 0.91)
Students will calculate blood volumes on the following patients:
1. patient’s weight = 92kg 
VI = 15ml
C l = lOuCi (use 1-131 HSA for plasma determination)
0.023uCi
10ml
Substitute known values into dilution equation:
V1C1 = V2C2
15uCi 
(10ml)( 10ml)
0.023uCi 
V2( 10ml )
15uCi = 0.0023V2
15ml 
C2 = 0.035uCi 
15ml 
hematocrit = 0.41
PATIENT’S BLOOD VOLUME________Is patient normal?
Why or why not? SHOW ALL WORK...
2. patient’s weight = 117kg 
VI = 10ml
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Cl = lOuCi 
10ml 
C2 = 0.078uCi 
10ml 
hematocrit = 0.56 
PATIENT’S BLOOD VOLUME 
Why or why not? SHOW ALL WORK.
Is patient normal?
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Laboratory 12
SCHILLING
Purpose
To determine the ability to absorb Vitamin B12.
Rationale
Oral Vitamin B12 combines with a small polypeptide in the gastric juice. This 
polypeptide is secreted by the parietal cells of the gastric mucosa, and usually is 
referred to as Intrinsic Factor. The Intrinsic Factor combines with Vitamin B12, 
the complex is later absorbed as it passes into the ileum portion of the small in­
testine. Diseases such as Pernicious Anemia, total Gastrectomy, and even some 
subtotal gastrectomized patients have a deficient Intrinsic Factor secretion and 
will fail to absorb Vitamin B12 in the ileum. Other gastrointestinal disease such 
as spme, tuberculosis of the ileum, regional ileitis, lymphomatous infiltration of 
the ileum, may also show failure to absorb Vitamin B12. Blind loops caused by 
Billroth I procedure or multiple small intestinal diverticuli absorb Vitamin B12 
because of preutilization by resident blind loop bacteria. Administration of 
broad spectrum antibiotics will kill the bacteria and correct this condition there­
by causing normal Vitamin B12 absorption. Short circuiting procedures or fistula 
formation causing bypassing of the ileum as well as severe diarrheal states will 
also have defective Vitamin B12 absorption.
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Oral Vitamin B12 Absorption
B12 with After 
 State_______ B12 alone_________ Int. Factor Antibiotics
Normal +
P.A.; Gastrectomy - +
Blind Loop - - +
Disease of Ileum -
Sprue + /-
Gastro-colic Fistula
Patient Preparation
The patient is to be in an overnight fasting state from solid food, liquids are al­
lowable. He is then instructed to abstain from solid foods for the next four 
hours, coffee and water are permissible. In the case of diabetics, coffee, toast, 
and jelly are allowable one hour after the onset of the procedure.
Material and Equipment
1. Cyanocobalamin Injection (Vitamin B12) — 1000 ugm/cc
2. Cyanocobalamin (5 Co or Co) — 0.5 microcuries
3. Reference Standard (57Co or ^ Co) — 1:50 dilution of 0.5 microcuries.
4. Gallon jug
Procedure
1. Administer the cobalt-labeled cyanocobalamin capsule to the fasting 
patient with water.
2. Inject 1 cc. (1000 micrograms) of non-radioactive Vitamin B12 in­
tramuscularly immediately following the ingestion of the capsule.
3. Instruct the patient to remain fasting for four hours and to collect all 
of the urine excreted during the following 24 hours.
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Urine Calculations
1. Measure the 24-hour urine volume and pipette a 20 cc. aliquot for 
counting.
2. Pipette 1 cc. of standard and dilute to 20 cc. This is equal to 2% of the 
administered dose, or 1/50 of the standard.
3. Count the urine aliquot and standard in the well for three minutes. 
Determine a background count.
Total volume
% = (cpm in patient’s  sample - Bkgd) x 20 x 100 
(cpm in standard sample - Bkgd) x 50
SCHILLINGS TEST FOR VITAMIN B-12 
EXCRETION
Using the formula:
total vol.
Vitamin B-12 % uptake =  CPM in pt. - bkgd. x 20
CPM in standard 
sample
bkgd.x 50
x 100
Normal value = greater than 7%
Example:
CPM in pt. = 65,360
Bkgd. = 9,520
Total volume = 1600 cc.
CPM in standard
sample = 62,335
CPM in
pt. 65,360
CPM in 
std.
% Excretion = 14.5% 
Pt. is normal for B-12
total volume 
bkgd. 9,521 x 1600 cc.
20 X100
62,335 - bkgd. 9,526 X 50
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LABORATORY EXERCISE FOR SCHILLING 
TEST EVALUATION
1. Each student will properly calculate the % of Vitamin B-12 from the 
two (2) sets of data given.
2. Each student will then provide a diagnosis based on values obtained 
from each pt’s data.
P t #1 Phase II
Data collected using Intrinsic Factor
total vol.
Vitamin B-12 % uptake = CPM in pt - bkgd. x 20 x 100
CPM in standard - bkgd. x 50 
sample
CPM in pt. 1 = 10,351 
Bkgd. = 105
Total volume = 1200 cc. 
CPMinstd. = 140052
% ofvitaminB-12is = 
Diagnosis =
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Pt. #2
Data collected in Phase I using Intrinsic Factor 
CPM in pt. 2 = 1,005 
Total volume = 1800 cc.
CPM in std. = 37,562 cc. 
Bkgd. = 501
% of vitamin B-12 is = 
Diagnosis =
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Answer Key to Questions
Chapter 1
Section 1 
1. J
Section 3 
1. C
2.
3.
4.
5.
6.
7.
8.
9.
10.
F
H
I
E
G
B
C
D
A
2.
3.
4.
5.
6.
7.
8.
9.
10. 
11.
D
C
D
D
C
C
D
D
C
D
Section^
1. F
2. F
3. T
4. T
5. F
6. T
7. F
12. A
13. A
14. A
15. B
16. C
17. C
Chapter 2 
Section l  Section 2
Chapter 3 
Section 2 SSCCtionJl
1. B 1. F 8. T 1. T 1. C
2. D 2. T 9. F 2. T 2. D
3. A 3. T 10. T 3. F 3. C
4. A 4. F 11. F 4. F 4. E
5. D 5. F 12. F 5. F 5. D
6. T 13. F 6. D
7. F 14. F 7. B
Chapter 4 
Section 2
Chapter 5 
Section 2 Section 3
1. C 1. D 1. F
2. B 2. E 2. F
3. 11.1 Sec 3. C 3. T
4. B 4. D 4. F
5. C 5. F
Chapter 6 Chapter 7
1. F 7. F 12. F 1. B 6. C 11. B 16.C
2. E 8. F 13. T 2. D 7. B 12. C 17A.
3. B 9. F 14. F ' 3. B 8. C 13. A 18.D
4. T 10. F 15. T 4. B 9. D 14. B 19.C
5. T 11. T 5. C 10. D 15. C 20.A
6. T
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Chapter 8
Section 1 Section.2
1. B 1. B 11. B 21. B 31. A 41. B S1.A
2. A 2. B 12. A 22. A 32. B 42. D 52.D
3. C 3. A 13. B 23. D 33. B 43. A 53.A
4. B 14. B 24. B 34. B 44. D 54.C
5. A 15. B 25. C 35. C 45. A 55-A
6. A 16. A 26. B 36. A 46. D 56.B
7. E 17. B 27. B 37. C 47. B
8. E 18. C 28. C 38. D 48. A
9. D 19. C 29. C 39. C 49. A
10. A 20. A 30. D 40. B 50. B
Section-2
1. F 11. T 21. T
2. T 12. F 22. T
3. T 13. T
4. F 14. F
5. T 15. T
6. F 16. F
7. T 17. T
8. T 18. F
9. F 19. T
10. T 20. T
Chatper 9
1. D
2. A
3. A,B
4. B
5. D
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BASIC RIA VOCABULARY LIST
ACCURACY 
AFFINITY 
ANALYTE 
ANTIGEN (Ab)
ANTIGEN (Ag)
ANTISERUM
AVIDITY
CONTROLS
CROSS
REACTIVITY
EQUILIBRIUM
SATURATION
FREUD’S
ADJUVANT
HAPTEN
HEMATOCRIT
IMMUNOGEN
H Closeness to true or real value.
H Strength (energy) of binding to the receptor.
a The patient sample.
a A protein formed as part of an immunologic 
response to foreign substance.
h A substance capable of including formation of 
antibodies.
H Serum form an immune animal (contains various 
antibodies).
n Measure of the strength of the bound Ag.
** May be a standard or any known concentration 
of testing material that serves as a comparison 
between successive test runs.
53 Similar structured Ag that interfere with analysis 
of a given assay.
H Competition between labeled and unlabeled 
ligand is allowed to occur simultaneously until 
equilibrium is reached between the ligand and 
the binder.
** An emulsifier that enhances the immune
response and allows for slow absorption into an 
animals system when producing antiserum.
a A substance that is not immunogenic in itself, 
but becomes immunogenic when complexed 
with another compound.
b formed elements 
whole blood
H A substance capable of inducing an immune 
response.
IMMUNO­
GLOBULINS
H A group of serum proteins (antibodies) that 
specifically bind the antigens (Ag).
Page 180 IN VITRO NUCLEAR MEDICINE LABORATORY MANUAL
LIGAND a
NON-SPECIFIC a 
BINDING
PRECISION a
QUALITY a
CONTROL
RADIO- a
IMMUNOASSAY
RECEPTOR «
SENSITIVITY a
SPECIFIC ACTIVITY «
SPECIFIC GRAVITY «
SPECIFICITY a
STANDARD a
STANDARD CURVE a 
TITER a
The substance that is bound.
When labeled Ag and Ag free serum (without 
Ab’s) are put into the same test tubes.
Degree of agreement of repeated measurement 
of a quantity (usually expressed as coefficient of 
variance).
Ensure that the results of assays are reliable and 
representative of true concentrations.
Radioligand assay in which the receptor is an an­
tibody.
A substance (protein) that specifically binds a 
certain compound (ligand).
Minimum quantity detectable.
Activity, usually expressed as uci 
mass g
Materials whose weights are being compared to 
that of water.
Capacity to discriminate antigens of similar struc­
ture.
A substance that is added to certain reference 
tubes to serve as a yardstick for quantitation of 
the contents.
A curve of dilutions of known amounts of sub­
stances to which the unknown may be compared.
Measurement of antibody concentration - the 
dilution of antiserum that will bind 50% of 
added radioligand.
